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ABSTRACT 
Immunisation is considered as one of the most cost-effective and successful disease 
prevention strategies. Immunisation during the adolescent period requires additional 
evaluation because of lower uptake of recommended vaccines compared with childhood 
immunisation, and the important role of adolescents in indirect protection and 
transmission of infection to others. This may be particularly pertinent for invasive 
meningococcal disease (IMD), where adolescents have high rates of IMD, attributed in 
part due to their higher pharyngeal carriage rates of the bacteria compared to others in 
the community. The inclusion of a new meningococcal B vaccine on the national 
immunisation program for direct protection of adolescents has been rejected in Australia 
due to uncertainty in cost-effectiveness analysis.  
 
By focusing on the above issues, this PhD thesis comprises four peer-reviewed published 
papers and two manuscripts, that have contributed to a better understanding of 
adolescent views and preferences for vaccination and the burden of IMD as a case study. 
This PhD project aims to answer four research questions: 
1. What are adolescent views about immunisation and how do they differ from adult 
views? 
2. What are adolescent preferences for vaccination programs and what are the most 
important factors influencing their decisions? 
3. What is known about the disease burden and consequences of IMD, a severe 
infection with adolescence a peak risk period? 
4. What is the mean lifetime cost of IMD per patient taking healthcare system and 
societal perspectives? 
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To evaluate adolescent views and perception about vaccines, a national online survey 
was conducted in adolescents and adults to assess and compare their views on vaccine 
benefits, community protection, risks, side effects, sources of information, and decision-
making preferences. By using the first three survey questions to predict participants’ 
vaccine hesitancy, a higher level of vaccine hesitancy was demonstrated in adolescents 
in comparison with adults (Odds Ratio=1.44, 95%CI: 1.01, 2.04, p=0.043). Adolescents 
were more concerned about vaccine side effects than adults for potential side effects 
including pain (p<0.001), redness or swelling (p<0.001), and fever (p=0.006). To make a 
vaccine decision, adolescents were more likely to prefer a joint decision with parents 
(Relative Risk Ratio=1.78, 95%CI: 1.41, 2.25, p<0.001) or make the decision themselves 
(Relative Risk Ratio=2.24, 95%CI: 1.25, 4.03, p=0.007) than adults.  
 
A discrete choice experiment design was used in a second online survey to evaluate 
adolescent preferences for vaccination. Stronger preferences were observed for 
vaccination in the case of a life-threatening illness (p<0.001), lower price vaccinations 
(p<0.001), mild but common side effects (p=0.004), delivery via a skin patch (p<0.001) 
and vaccination administered by a family practitioner (p<0.001). Participants indicated 
that they and their families would be willing to pay AU$394.28 (95%CI: AU$348.40, 
AU$446.92) more for a vaccine targeting a life-threatening illness than a mild-moderate 
illness, AU$37.94 (95%CI: AU$19.22, AU$57.39) more for being vaccinated at a family 
practitioner clinic than a council immunisation clinic, AU$23.01 (95%CI: AU$7.12, 
AU$39.24) more for common but mild and resolving side effects compared to rare but 
serious side effects, and AU$51.80 (95%CI: AU $30.42, AU$73.70) more for delivery via 
a skin patch than injection. 
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Published literature that reported the clinical and financial burden of IMD was reviewed. 
Meta-analyses were performed to assess the effect of age and serogroup on case fatality 
rates (CFRs) of IMD. All costs associated with IMD were converted into international 
dollars (I$) to compare costing data across studies. The pooled overall CFR was 8.3% 
with the highest pooled CFR in serogroup W cases. The predicted CFR was higher in 
adolescents compared with young children. Presence of sequelae (complications) was 
associated with significantly higher hospitalisation costs. Most commonly reported 
sequelae were arthritis, neurocognitive sequelae, hearing loss, seizures, 
speech/communication problems, and amputation. The mean costs of acute admission 
ranged from I$1,629 to I$50,796.  
 
To estimate the lifetime costs of IMD, a cohort-based state-transition model (Markov) was 
developed. A comprehensive clinical and health economic literature review and expert 
panel discussion were used to develop the model structure. Selections of model 
parameters including age-specific mortality rates, and probabilities of IMD-related 
sequelae were based on a systematic review or best available evidence. The 
undiscounted lifetime societal cost per IMD case is US$319,897 including the direct 
healthcare cost of US$65,035. Given a 5% discount rate, the costs are USD$54,279 and 
USD$13,968 respectively. Chronic renal failure and limb amputation result in the highest 
direct healthcare costs per patient. Patients aged <5 years incur the higher healthcare 
expenditure compared with other age groups. The costing results are extremely sensitive 
to the discount rate and disease incidence. 
 
In this doctoral study, adolescents demonstrated lower levels of vaccine confidence than 
adults, but preferred vaccine strategies for a life-threatening disease. The vaccine 
preventable disease, IMD, although uncommon and occurring primarily in young children 
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and adolescents, imposes a substantial clinical and financial burden on patients, their 
families and society. Improving vaccine confidence and providing publicly funded 
vaccines are important factors that may positively affect vaccine uptake in adolescents. 
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CHAPTER 1 THESIS OVERVIEW 
1.1 BACKGROUND 
Suboptimal vaccine uptake in adolescents has been increasingly recognised as an 
important public health issue [1]. Strategies to achieve optimal uptake in this age group 
have become a priority in the public health sector [1-3]. Engaging adolescents in 
decisions affecting their health is vital to build a safe and healthy passage from 
adolescence into adulthood and parenthood [4]. The prevalence of health risk behaviours 
rises markedly during adolescence as individuals become gradually responsible for their 
own health [5]. The views and values of adolescents in immunisation are seldom 
investigated [3,6-12] and yet their opinions may impact the success of adolescent health 
programs [13]. The systematic incorporation of adolescent views will improve their health 
by developing disease prevention programs tailored to their needs [14]. Evaluating 
vaccine perception and preferences in adolescents, can inform strategies to improve 
vaccine uptake in this age group. Given the importance of vaccine uptake and research 
gap identified in the literature, this PhD project aims to investigate adolescent views and 
preferences towards vaccination. 
 
Prior research has found disease severity was one of the key drivers influencing vaccine 
decisions in parents and adults [15-17]. In one qualitative study that included a youth jury, 
adolescents listed life-threatening diseases as a key priority for determining vaccine 
funding decisions [13]. Since Invasive meningococcal disease (IMD) is a serious infection 
and meningococcal serogroup B (MenB) vaccines have not been nationally funded yet 
mainly because of lack of strong economic evidence, the burden of IMD has been further 
investigated as a case study.  
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IMD is a life-threatening disease due to its rapid onset and potentially severe outcomes. 
Although IMD is uncommon, the disease is a significant public health concern. Secondary 
to infants and young children, adolescents are at increased risk of IMD with a high case 
fatality rate (CFR) compared to other age groups [18,19]. IMD is caused by a Gram-
negative bacterium Neisseria meningitidis. The bacteria can cause meningitis, 
septicaemia or a combination of both. Around 10% of the healthy population carry and 
spread the bacteria asymptomatically [20]. People who develop IMD often have non-
specific symptoms including sudden onset of fever, general malaise, cold hands, thirst, 
joint pain, aching muscles, headache, neck stiffness, photophobia, nausea, vomiting, 
drowsiness and coma. The development of the typical rash usually occurs late in the 
illness. Despite timely antibiotic therapy, the overall CFR in Australia is approximately 5% 
[21]. IMD can cause sequelae in up to 58% of children who survived the infection [22]. 
Thirteen serogroups are characterised and serologically defined: A, B, C, D, E, H, I, K, L, 
W, X, Y, and Z. Five primary serogroups (A, B, C, W and Y) and more recently X cause 
almost all cases of IMD globally [23,24]. IMD is a vaccine preventable disease. 
Adolescent immunisation can provide direct protection and generate potential herd 
immunity. Vaccines are available to protect against five major serogroups: A, B, C, W and 
Y. Three types of meningococcal vaccines are available in Australia [25]. The 
meningococcal serogroups ACWY (MenACWY) vaccine is listed on the National 
Immunisation Program (NIP) for adolescents aged 15-19 years from 01 June 2019 due 
to a recent rise in serogroup W (MenW) disease. 
 
• recombinant MenB vaccines - for protection against serogroup B disease: 
Bexsero®, Trumenba® 
• quadrivalent (A, C, W, Y) meningococcal conjugate vaccines - for protection 
against four serogroups of IMD: Menactra®, Menveo®, Nimenrix®  
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• meningococcal C (MenC) conjugate vaccine vaccines - for protection against 
serogroup C disease: Menitorix® (combination formulation with the Haemophilus 
influenzae type b (Hib-MenC) vaccine), NeisVac-C® (monovalent meningococcal 
C vaccine)  
 
This research has been undertaken in the Australian context, where meningococcal 
vaccine funding in adolescents as part of the NIP is being considered (MenB vaccine) or 
has been decided (MenACWY vaccine). Adolescent views and preferences towards 
vaccination can assist in developing new strategies to improve vaccine uptake after the 
roll-out of a new vaccine program in adolescents. The results of online surveys in Chapter 
2 can also assist in determining vaccine coverage estimates which are important 
parameters in health economic models. For example, the predicted high coverage rate of 
vaccination against a life-threatening illness, may positively affect outcomes of health 
economic evaluation. Assessing the disease burden (both clinical and financial) of IMD, 
for which a new MenB vaccine program is being considered at a national level, can inform 
future cost-effectiveness analyses and public funding decisions. 
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1.2 RESEARCH QUESTIONS AND HYPOTHESES  
The overall aim of this PhD thesis is to provide useful information and valuable insights 
into vaccine attitudes and the burden of a vaccine-preventable disease to improve 
adolescent health through immunisation. This PhD project aims to address the following 
research questions: 
 
1. What are adolescent views about immunisation and how do they differ from adult 
views? (Paper 1 in Section 2.2) 
 
The World Health Organization (WHO) defines adolescents as those people between 
10 and 19 years of age [26]. Adolescents aged between 15 - 17 covering year 10 to 
year 12 of high school in Australia were enrolled in the online survey. Since vaccine 
attitudes were compared between adolescents and adults, this online survey did not 
focus on a specific vaccine for adolescents (e.g. meningococcal or HPV vaccines). 
General views about immunisation were investigated.   
 
Three specific hypotheses were investigated in Paper 1, namely: 
H1: Higher concerns about vaccine safety and lack of vaccine confidence in 
adolescents lead to low vaccine uptake. 
H2: Social media is used as a main source of information in adolescents.   
H3: Parents make vaccine decisions for their children. Adolescent involvement in the 
decision-making process is minimal. 
 
2. What are adolescent preferences for vaccination programs and what are the most 
important factors influencing their decisions? (Paper 2 in Section 2.3) 
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As the research objective was to assess their preferences for vaccination including 
locations such as schools or universities, 15-19 year olds were enrolled to cover 
students in years 10 through 12 of high school or in the first year of university.  
 
Two hypotheses were considered as part of this research question: 
H4: Adolescents prefer vaccines against serious (life-threatening) infections or 
sexually transmitted infections with individual and community protection, common but 
mild side effects, delivery via oral dose/skin patch and being administered at 
school/university. 
H5: Vaccine prices influence their vaccine decisions, although for most adolescents 
their living and medical expenses would be paid by parents. 
 
3. What is known about the disease burden and consequences of IMD? (Paper 3 in 
Section 3.1.1, Section 3.1.2, and Paper 4 in Section 3.1.3) 
 
The overarching hypothesis investigated in these sections was: 
H6: IMD is associated with high mortality and morbidity rates. 
 
4. What is the mean lifetime cost of IMD per patient taking healthcare system and 
societal perspectives? (Paper 6 in Section 3.2) 
 
The hypothesis investigated in this paper was: 
H7: The societal and healthcare costs associated with long-term sequelae are 
substantial.  
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1.3 THESIS OUTLINE 
Chapter 2 focuses on research gaps in adolescent immunisation. Results including 
preferences for vaccines against life-threatening diseases were obtained from two online 
surveys evaluating adolescent views and preferences towards vaccination in general 
(Papers 1 and 2). The first online survey assessed and compared vaccine attitudes in 
adolescents with adults. Adolescents showed a higher level of vaccine hesitancy than 
adults, as reflected by low vaccine uptake in adolescents. It was also found that 
adolescents were eager to engage in the vaccine decision-making process. Vaccine 
preferences were further investigated in the second online survey using a discrete choice 
experiment (DCE) design. Adolescents expressed strong preferences for vaccination 
against a life-threatening illness. The vaccine price would affect their decision too. 
Chapter 2 provides information on how to improve vaccine uptake. The results can be 
potentially used to determine important parameters (e.g. vaccine coverage) in health 
economic models and support the results of health economic evaluations. Strategies to 
improve vaccine uptake are also important for cost effectiveness evidence. 
 
As IMD is a serious infection with high mortality and morbidity rates, it is a perfect example 
to use for evaluation of the disease severity from clinical and financial perspectives. In 
Chapter 3, the burden of IMD and development of meningococcal vaccines were 
investigated and reviewed. A systematic review was conducted to comprehensively 
estimate the clinical and financial burden of IMD. Meta-analyses were performed to 
investigate the effects of age and serogroup on CFRs. The results are presented in Paper 
3. The sequelae and complications associated with IMD were also included in the 
systemic review and summarised in Section 3.1.2. The review results in regard to the 
financial burden of IMD (Paper 4) were published in a highly ranked international health 
economic journal. The development and current status of vaccines that provide protection 
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against five major serogroups of IMD (A, B, C, W and Y) were reviewed and published 
(Paper 5). Paper 6 describes lifetime costs derived from a decision analytic model. Given 
its severity, IMD has been selected to generate evidence to better inform future cost-
effectiveness evaluations. The MenB vaccine programs for infants and adolescents have 
not been included on the NIP in Australia. Evidence of the considerable burden of IMD 
can assist in informing government funding decisions. The MenB vaccine programs for 
adolescents are publicly funded in South Australia. The results regarding outcomes of 
IMD can be used to reduce vaccine hesitancy in adolescents. 
 
Chapter 4 discusses the possible contribution to the scientific literature, potential 
implications and translation of study results, and the directions of future work. Chapter 5 
summarises the main findings of this PhD project.  
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CHAPTER 2: ADOLESCENT IMMUNISATION 
2.1 LITERATURE REVIEW 
It is often stated that immunisation is one of the most cost-effective public health 
strategies which enormously contribute to global health [27]. A major success story is the 
eradication of smallpox with massive mortality in the pre-vaccination period. In Australia, 
the first publicly funded vaccine (diphtheria-tetanus-pertussis) was introduced in 1953. 
The first national immunisation schedule was implemented in 1975 [28]. Immunisation 
has become a major public health strategy funded by state and federal governments. 
Since the introduction of immunisation in Australia, the incidence of vaccine preventable 
diseases, such as tetanus, diphtheria, haemophilus influenzae type B and measles, has 
fallen dramatically [29]. After the implementation of the national MenC vaccine program 
in 2003, the incidence of MenC disease has declined considerably, with the number of 
cases decreasing from 162 in 2002 [30] to 14 in 2017 [31]. The current NIP (Figure 1) 
consists of a schedule of recommended vaccines in different age groups, which covers 
16 diseases, including hepatitis B, diphtheria, tetanus, pertussis, Haemophilus influenzae 
type b disease, poliomyelitis, pneumococcal, rotavirus, measles, mumps, rubella, MenC 
disease, chickenpox, hepatitis A, human papillomavirus (HPV) and influenza. Infants and 
young children remain the main target population for vaccination programs. However, 
adolescents have received increasing attention because of 1) new vaccines being 
available targeting the adolescent age group, 2) low vaccine uptake of vaccines for 
adolescents compared to children [4]. Improving vaccination uptake in this age group is 
important to boost immunity, and provide direct protection against diseases in 
adolescents and the potential for indirect community protection [1].  
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Figure 1 National Immunisation Program Schedule [32] 
(From 1 July 2018) 
Age Disease Vaccine Brand 
 Childhood vaccination (also see influenza vaccine) 
Birth • Hepatitis B (usually offered in 
hospital)a 
H-B-Vax® II Paediatric or 
Engerix B® Paediatric 
2 months 
Can be given from 6 weeks of age 
• Diphtheria, tetanus, pertussis 
(whooping cough), hepatitis 
B, polio, Haemophilus 







Prevenar 13®  
Rotarix® 
4 months • Diphtheria, tetanus, pertussis 
(whooping cough), hepatitis 
B, polio, Haemophilus 







Prevenar 13®  
Rotarix® 
6 months • Diphtheria, tetanus, pertussis 
(whooping cough), hepatitis 
B, polio, Haemophilus 
influenzae type b (Hib) 
Infanrix® hexa 
Additional vaccines for Aboriginal 
and Torres Strait Islander children 
(QLD, NT, WA and SA) and 
medically at-risk childrenc 
• Pneumococcal Prevenar 13® 
12 months • Meningococcal ACWY 
• Measles, mumps, rubella 
• Pneumococcal 
Nimenrix® 
M-M-R® II or Priorix®  
Prevenar 13® 
Additional vaccines for Aboriginal 
and Torres Strait Islander children 
(QLD, NT, WA and SA) 
• Hepatitis A Vaqta® Paediatric 
18 months • Haemophilus influenzae type 
b (Hib) 
• Measles, mumps, rubella, 
varicella (chickenpox) 




Priorix-Tetra® or ProQuad®  
 
Infanrix® or Tripacel® 
Additional vaccines for Aboriginal 
and Torres Strait Islander children 
(QLD, NT, WA and SA) 
• Hepatitis A Vaqta® Paediatric 
4 years • Diphtheria, tetanus, pertussis 
(whooping cough), polio 
Infanrix® IPV or 
Quadracel® 
Additional vaccines for medically at-
risk childrenc 
• Pneumococcal Pneumovax 23® 
 Adolescent vaccination (also see influenza vaccine) 
• 10-<15 years 
• (School programsd) 
• Human papillomavirus (HPV)e 
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Age Disease Vaccine Brand 
Adult vaccination (also see influenza vaccine) 
15 – 49 years  
Aboriginal and Torres Strait Islander 





50 years and over Aboriginal and 





65 years and over • Pneumococcal Pneumovax 23® 
70–79 yearsf • Shingles (herpes zoster) Zostavax® 
Pregnant women • Pertussis (whooping cough)g 
• Influenzah Boostrix
® or Adacel® 
 
a Hepatitis B vaccine: Should be given to all infants as soon as practicable after birth. The greatest benefit 
is if given within 24 hours, and must be given within 7 days. 
b Rotavirus vaccine: First dose must be given by 14 weeks of age, the second dose by 24 weeks of age. 
c Refer to the current edition of The Australian Immunisation Handbook for all medical risk factors. 
d Contact your state or territory health service for school grades eligible for vaccination. 
e Observe Gardasil®9 dosing schedules by age and at-risk conditions. 2 doses: 9 to <15 years - 6 months 
mininimum interval. 3 doses: ≥15 years and/or have certain medical conditions - 0, 2 and 6 month schedule. 
Only 2 doses funded on the NIP unless 12-13 year old has certain medical risk factors. 
f All people aged 70 years old, with a five year catch-up program for people aged 71-79 years old until 31 
October 2021. 
g Single dose recommended each pregnancy, ideally between 28-32 weeks, but may be given up until 
delivery. 
h Refer to annual influenza information for recommended vaccine brand for age. 
 
Infectious diseases contribute to significant burden of disease in relation to epidemiology, 
morbidity and mortality. Global efforts are focused on improving vaccination programs 
and developing new vaccines against major and severe infectious diseases such as HIV, 
malaria, tuberculosis, Respiratory Syncytial Virus, Enterotoxigenic E. Coli, Shigella and 
Norovirus [33]. In Australia, government funding for vaccine programs has increased from 
ten million dollars per annum in the mid-1970s to almost half a billion in the early 2010s 
[29].  
Funded annual influenza vaccinationh 
6 months and over with certain medical risk factorsb 
Aboriginal and Torres Strait Islander children 6 months to less than 5 years 
Aboriginal and Torres Strait Islander people 15 years and over 
65 years and over 
Pregnant women 
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All adolescents in Australia aged 15-19 years will receive free MenACWY vaccine in 2019 
owing to a continuous increase in incidence of MenW disease [34]. Vaccines against 
MenB disease, which has been one of predominant serogroups in Australia, have recently 
been publicly funded by the state government in South Australia partly due to 
meningococcal epidemiology, serogroup distribution and community concern [35]. 
However, the publicly funded national MenB vaccine program has been rejected three 
times based on an assessment of its clinical effectiveness and cost-effectiveness [36]. 
Two MenB vaccines are currently available on the private market, 4CMenB (Bexsero®) 
and MenB-FHbp (Trumenba®). The MenB-FHbp vaccine specifically targets adolescents 
and young adults. 
 
Whilst Australia has one of the highest vaccine coverage rates in the world for its infant 
and childhood vaccination [37,38], uptake is less impressive for adolescent vaccination 
(e.g. HPV) [39] and for vaccination against illnesses such as influenza [40], which despite 
their potential severity, are often perceived as milder illnesses [41]. In Australia, three-
dose HPV vaccination coverage rates are steadily increasing, but lower than 80% (72.9% 
for boys and 78.6% for girls) [39]. The adolescent vaccination coverage rates are 
suboptimal in other developed countries such as the US and UK. In the US, the National 
Immunization Survey estimated the national vaccination coverage at 47% for girls and 
53% for boys [42]. In the UK, the two-dose HPV vaccination coverage rate is 83.1% for 
Year 9 girls who completed a course in 2016/17 [43].  
 
It has been found that adolescents prefer to be actively involved in decision making about 
their health and have an increasing role in the decision-making process, especially as 
they age and mature [3,44-46]. However, most prior research has concentrated on 
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parental perception, health workers’ preferences, and/or vaccines against specific 
illnesses such as HPV, influenza, and IMD [7,9,11,12,15,17,41,45-71]. Several qualitative 
studies have attempted to gain an understanding of adolescent vaccine attitudes, 
knowledge and decision-making roles [3,10,72,73]. Limited quantitative research has 
been conducted to investigate general vaccine preferences and identify vaccine 
hesitancy in adolescents [6,8,44].  
 
In the US, adolescents and parents were asked about general vaccine perceptions 
including vaccine safety and efficacy and alternative vaccination venues (school, 
pharmacy, public health department, hospital emergency room, teen clinic, other). The 
adolescents stated that vaccines were “very effective” (71%) or “very safe” (69%), 
representing significantly lower figures than the parental respondents (85% and 83%, 
respectively). Most adolescents preferred to receive vaccines in hospital settings [44]. In 
five European countries, face to face interviews were performed to assess knowledge 
and perception of general vaccination in adolescents. A lack of vaccine confidence was 
identified, as only 40 - 45% of adolescents strongly agreed that vaccination is the 
best/safest way to prevent diseases. The study found seriousness of diseases (individual 
protection), physician or parental recommendations and herd immunity were key 
motivations for vaccination [8], which was consistent with findings in a Belgian study [6]. 
The aim of the Belgian study was to assess general perception of vaccination and 
knowledge about vaccines. Although the Belgian study reported that most adolescents 
understood that vaccination was a good way to protect against diseases, there were 
considerable misunderstandings about existing vaccines. For example, 20 - 30 % of 
adolescents believed vaccines protecting against HIV and preventing diabetes were 
currently available. 
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The success of immunisation programs relies heavily on high coverage rates to prevent 
the spread of vaccine preventable diseases. High coverage of a vaccine with potential 
indirect population protection could impact cost-effectiveness results [74] and is also an 
important consideration in vaccine funding decision-making. The Joint Committee on 
Vaccination and Immunisation in the UK have taken account of the potential for indirect 
population protection in evaluating cost-effectiveness of a MenB vaccine [75]. 
Furthermore, policy makers are often expected to make decisions about immunisation 
programs on assumptions about vaccine acceptance with little evidence of societal 
opinions and concerns regarding such programs. Since adolescents have become a 
target group for several vaccines in the immunisation program, increasing their 
awareness and knowledge of immunisation and vaccine preventable diseases has 
become a priority. Therefore, it is fundamental to conduct research to investigate 
adolescent views, concerns and preferences towards vaccination and to actively engage 
them in the immunisation policy.  
 
This chapter aims to answer two research questions: 1) What are adolescent views about 
immunisation and how do they differ from adult views? 2)  What are adolescent 
preferences for vaccination programs and what are the most important factors influencing 
their decisions? The next two sections report the results obtained from two national online 
surveys. The first online survey (Section 2.2) assessed and compared vaccine views and 
confidence between adolescents and adults and answered the first research question. 
The second online survey (Section 2.3) quantitatively evaluated vaccine preferences and 
priorities in adolescents using a DCE design and answered the second research question. 
A literature review was also conducted specifically for each research question, and these 
are summarised in the relevant publications.  
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2.2 VACCINE CONFIDENCE 
Adolescent attitudes towards vaccine benefits, risks, sources of information and decision 
making were assessed and compared with adults in a national cross-sectional online 
survey. In 2013, 2505 participants completed the online survey including 502 adolescents 
and 2003 adults. General public perceptions of vaccination were assessed using linear, 
logistic, ordinal logistic and multinomial logistic regression models. Adolescents showed 
lower confidence in vaccines and higher concern about potential vaccine reactions than 
adults. The resulting publication entitled “Adolescent confidence in immunisation: 
Assessing and comparing attitudes of adolescents and adults”, demonstrated vaccine 
hesitancy and concerns. Adolescents showed eagerness to be part of the vaccine 
decision making process with parents or to make vaccine decisions on their own. 
 
Our results show adolescents are less likely to consult a health professional compared 
with adults for vaccine advice and rather consult their social network. This likely suggests 
that most adolescents do not have their own health professional they can engage 
independently for health advice such as a general practitioner (GP). In line with previous 
research [2,76,77], this finding may reflect a considerable downward trend in health care 
utilisation from childhood to early adulthood.  
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AdolescentsIntroduction: There is limited knowledge of adolescent views and attitudes towards immunisation. Our
study investigated adolescent attitudes to immunisation and compared differences in vaccination
attitudes between adolescents and adults.
Methods: This study was a cross-sectional, national online survey. Recruitment was stratified by state
and gender to ensure findings were nationally representative. Regression analyses were performed to
assess and compare adolescent and adult views on vaccine benefits, community protection, risks, side
effects, sources of information, and decision-making preference.
Results: In 2013, 502 adolescents and 2003 adults completed the online survey. Lower levels of vaccine
confidence were observed in adolescents with adolescents less likely to believe vaccines are beneficial
and/or safe compared to adults (p = 0.043). Compared to females, males were less confident of vaccine
benefits (p < 0.05) but less concern about vaccine side effects (p < 0.05). Adolescents were more con-
cerned about vaccine side effects than adults for pain (p < 0.001), redness or swelling (p < 0.001), and
fever (p = 0.006). Adolescents were less likely than adults to consider health professionals (p < 0.001)
and the media (e.g. internet) (p = 0.010) as important sources of information, and were more likely to
seek information from social networks (p < 0.001) including families and schools. Although 62.0% of ado-
lescents agreed that parents should make the decision about vaccination for them, adolescents were
more likely to prefer a joint decision with parents (p < 0.001) or by themselves (p = 0.007) compared with
adults.
Conclusion: Adolescents have a lesser understanding of vaccine safety and benefits than adults and have
higher concerns about potential vaccine reactions. Improving adolescent awareness and knowledge of
the benefits and risks of vaccination through school-based educational programs may improve confi-
dence in and uptake of vaccines for adolescents and increase vaccine confidence in the next generation
of parents.
 2016 Elsevier Ltd. All rights reserved.1. Introduction
Adolescent immunisation programs have expanded substan-
tially in developed countries over the last decade with inclusion
of publicly funded vaccines such as human papillomavirus (HPV),
varicella, hepatitis B, pertussis, and meningococcal vaccines. The
success of immunisation programs relies on high coverage rates
to protect vaccinated individuals and the community [1]. In coun-
tries such as the United States of America (USA) and Australia,
although ‘fully immunised’ coverage rates are high, these figures
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including adolescents with adolescent immunisation uptake con-
siderably lower for publicly funded vaccines (40–80%) than child-
hood immunisations (90–95%) [2,3]. This may be because
immunisation coverage for young children (e.g. children aged
under 10 years) is strongly correlated to parental decisions, while
evidence shows that adolescents are more likely to establish their
vaccine-related attitudes independently of their parents and hence
differ from their parent’s attitudes [4–6]. As adolescents are a tar-
get group for current and future immunisation programs, evaluat-
ing their awareness and knowledge of vaccination is an important
priority. Identifying perceived barriers can lead to the development
of more effective adolescent immunisation policies aiming to
improve uptake.
Previous research has focused on individual vaccines or paren-
tal views, showing that parental perception of disease susceptibil-
ity and severity, vaccine safety, side effects, lack of vaccine and
disease knowledge, multiple injections at a single visit or being
confused about the immunisation schedule, could influence paren-
tal decisions to accept, refuse or delay vaccination for their chil-
dren [4,7–12]. Reasons for low uptake of adolescent routine
immunisations are poorly described in the literature apart from
HPV and influenza vaccines [4,5,8,13–21]. The aim of our study
was to identify adolescent views about immunisation and how
they differed from adults’ views. We also aimed to identify the bar-
riers and facilitators which may influence receipt of recommended
vaccines in adolescents now and in the future as potential parents.2. Methods
2.1. Study design and population
We undertook a national online survey which comprised a ser-
ies of attitudinal statements relating to views about vaccination.
We aimed to enrol 500 adolescents and 2000 adults (50% with
children aged <18 years) in Australia with state and gender strati-
fication to ensure findings were nationally representative. Details
of sample size determination and stratification were reported in
a previous publication [22]. All participants were recruited through
an online panel company, Pureprofile. Parents who registered on
the Pureprofile database were contacted and study information
was provided if their child was willing to complete the survey
and parental consent and adolescent assent was obtained for them
to participate in the study. Following parental consent, the parents
were asked to turn the computer over to their adolescent child and
the adolescent was then guided through the online survey. Inde-
pendent Pureprofile account holders were approached to recruit
potential adult participants and adolescent participants separately.
Prior to survey commencement, a pilot study was completed in
March 2013 and results were reviewed to assess questionnaire
completion. Since no revisions to the questionnaire were required,
the pilot data were included in the final analysis.2.2. Survey tool
A series of survey questions relevant to vaccination (Fig. 1): (1)
vaccine benefits, (2) herd immunity/community protection, (3)
vaccine risks, (4) side effects, (5) sources of vaccination informa-
tion, and (6) vaccination decision-making preferences were
presented on-line and distributed to participants. For questions
on vaccine benefits participants could nominate highly, moder-
ately, slightly, none at all or uncertain. Concerns about vaccine side
effects were measured on an eleven point scale, where 0 was no
concern and 10 was extremely concerned. For the survey question
regarding main sources of information, although participants wereasked to rank sources in order, the top ranked source was consid-
ered as the primary source and therefore each source was re-coded
into two categories: ‘‘Yes, the most important source” or ‘‘No, not
the most important source”. The frequency of the primary source
was counted for the analysis.2.3. Predictor variables
The variables were selected on the basis of prior research find-
ings and a literature review of vaccination coverage and attitudinal
studies [23–26]. Socio-demographic variables including age, gen-
der, household size, socio-economic status and area of residence
(rural or metropolitan) were obtained from participants. For the
purpose of comparison, participant age was coded into two cate-
gories: 15–17 years (adolescents) and P18 years (adults). The
levels of socio-economic status were measured by the Socio Eco-
nomic Index for Areas (SEIFA) Index of Relative Socio-economic
Disadvantage and categorised into tertiles: low (1st–33rd per-
centile), medium (34th–66th percentile) and high (67th–100th
percentile) [27].2.4. Data analysis
Descriptive results were reported according to socio-
demographic characteristics with mean values and standard devi-
ations for continuous variables and percentages for categorical
variables. Student’s t-tests, analysis of variance (ANOVA), and v2
tests were performed to assess differences in group means and
proportions, as appropriate.
Ordinal logistic regression was used in analyses of vaccine ben-
efits, community protection and vaccine risks, as these outcome
measures were assessed on an ordinal scale (e.g. from ‘‘not at all/
uncertain” to ‘‘high”). Since lower levels of vaccine confidence have
been observed to be associated with higher levels of hesitancy
[24,28–30], the first three survey questions were used to predict
participants’ vaccine hesitancy. If participants showed lack of
vaccine confidence in at least two of three statements, for example,
describing vaccines were slightly beneficial, denying vaccine bene-
fits, believing vaccines were not important in protecting the com-
munity, reporting vaccines were moderately to highly risky or
being uncertain, those participants were considered to be vaccine
hesitant. Multivariable logistic regression was performed to assess
overall vaccine hesitancy.
The responses to concerns about potential reactions to vaccina-
tion (on a 0–10 scale) were treated as continuous outcome vari-
ables. Relationships between predictor variables and the vaccine
concern variables were investigated using multivariable linear
regression. Adjusted regression coefficients (b) were reported from
these linear regression analyses. b, the estimator of the slope coef-
ficient, represents the average change in an outcome variable for
every unit change in a predictor variable, holding all other vari-
ables constant. Each main source of information about vaccines
was coded as a binary outcome variable and analysed in a separate
multivariable logistic regression model. Predictor variables of vac-
cine decision-making preference were assessed using multinomial
logistic regression. Predictor variables with a p-value < 0.2 in the
univariate analysis were selected for multivariable models along
with other variables of known research importance [31].
All statistical analyses were performed using Stata version 12
(Stata Corp, College Station, TX) [32]. Predictor variables with a
p-value < 0.05 were considered statistically significant in final
regression models.
This study was approved by the Women’s and Children’s Health
Network Human Research Ethics Committee in Adelaide, South
Australia, Australia.
1. To what degree do you believe that vaccines are beneficial?
□ Highly □ Moderately □ Slightly □ Not at all □ Uncertain
2. How important do you think vaccinations are in protecting the whole community against 
diseases?
□ Very important □ Important □ Not sure □ Not important
3. To what degree do you believe that vaccines are risky? 
□ Highly □ Moderately □ Slightly □ Not at all □ Uncertain
4. On a scale of 0-10, where 0 means you are not concerned at all and 10 means you are 
extremely concerned, how concerned are you about the following potential reactions to 
vaccines:
i. Pain at the site where the injection was given: Enter number 0-10 □□
ii. Redness or swelling at site where the injection was given: Enter number 0-10 □□
iii. Fever (temperature >38 degrees) following vaccination: Enter number 0-10 □□
5. What are your main sources of information about vaccination (if relevant, you may choose 
more than one option). Where more than one source is identified, please rank in order of 
usefulness to you (1= most important)?
□ Health professionals □ Family □ Friends/Colleagues  
□ School □ Internet □ TV
□ Newspaper/Magazine □ Others, please indicate: ___________________
6. For vaccines that are recommended as part of the standard vaccination schedule for 
children and adolescents, who should make the decision about vaccination? 
□ Parents □ Adolescents (aged 12-18)
□ Joint decision of parents and adolescents □ Someone else (e.g. GP)
Fig. 1. Survey questions on perception of vaccination.
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In total, 2505 participants completed the online survey between
March and May 2013 including 502 adolescents, 2003 adults with-
out (N = 1003) or with (N = 1000) at least one child aged <18 years
(Table 1). Adult age ranged from 18 to 81 years and adolescents
were aged between 15 and 17 years. Participants were primarilyfrom metropolitan (64.9%) and high socio-economic status
(41.0%) areas with a slight female predominance (51.4%). Adoles-
cents and adults had a similar gender and socio-economic profile,
however more adults were from metropolitan regions (N = 1330,
66.4%) than adolescents (N = 295, 58.8%, p = 0.001). Almost half




Alla (N = 2505) Adolescents (N = 502) Adults (N = 2003) p-Value
N (%) N (%) N (%)
Age (Mean (SD)) 37.6 (16.9) 16.0 (0.8) 43.0 (14.5) <0.001
Gender
Female 1288 (51.4) 256 (51.0) 1032 (51.5) 0.833
Male 1217 (48.6) 246 (49.0) 971 (48.5)
Household size (Mean (SD)) 3.3 (1.4) 4.1 (1.3) 3.1 (1.4) <0.001
1 233 (9.3) 1 (0.2) 232 (11.6) <0.001
2 589 (23.5) 35 (7.0) 554 (27.7)
3 553 (22.1) 133 (26.5) 420 (21.0)
4 687 (27.4) 185 (36.9) 502 (25.1)
5+ 443 (17.7) 148 (29.5) 295 (14.7)
Area of residence
Metropolitan 1625 (64.9) 295 (58.8) 1330 (66.4) 0.001
Rural 879 (35.1) 207 (41.2) 672 (33.6)
Socio-economic status
Low (1st–33rd percentile) 619 (24.9) 119 (23.9) 500 (25.1) 0.842
Medium (34th–66th percentile) 851 (34.2) 172 (34.5) 679 (34.1)
High (67th–100th percentile) 1021 (41.0) 208 (41.7) 813 (40.8)
State
New South Wales 831 (33.2) 162 (32.3) 669 (33.4) 0.970
Victoria 639 (25.5) 131 (26.1) 508 (25.4)
Queensland 483 (19.3) 102 (20.3) 381 (19.0)
Western Australia 248 (9.9) 49 (9.8) 199 (9.9)
South Australia 190 (7.6) 37 (7.4) 153 (7.6)
Tasmania 62 (2.5) 13 (2.6) 49 (2.6)
Australian Capital Territory 39 (1.6) 7 (1.4) 32 (1.6)
Northern Territory 12 (0.5) 1 (0.2) 11 (0.6)
a Area of residence and socio-economic status data were missing for one and 14 participants, respectively.
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Amongst adults, 68.0% (N = 1362) strongly believed that vacci-
nes were beneficial with 22.2% (N = 445) believing they were mod-
erately beneficial, 6.8% (N = 136) believing they were slightly
beneficial and 3.0% (N = 60) disagreeing or uncertain. Compared
with adults, a smaller proportion of adolescents (N = 322, 64.1%)
strongly believed that vaccines were beneficial with 24.7% of ado-
lescents (N = 124) responding ‘‘moderately” beneficial, 6.4%
(N = 32) responding ‘‘slightly” beneficial, and 4.8% (N = 24) dis-
agreeing or uncertain. The majority of females strongly (69.8%,
N = 899) or moderately (21.4%, N = 275) believed in vaccine bene-
fits compared to 64.5% (N = 785) of males believing strongly and
24.2% (N = 294) believing moderately, that vaccines are beneficial.
After adjusting for age category and socio-economic status in the
ordinal logistic analysis, the only factor that was significantly asso-
ciated with perception of vaccine being beneficial was gender
(OR = 0.77, 95%CI: 0.66, 0.91, p = 0.002) with males showing less
confidence in vaccine benefits. Adolescents showed a trend towards
reduced odds of strongly believing that vaccines were beneficial
compared to adults (OR = 0.85, 95%CI: 0.69, 1.04, p = 0.105).3.2. Perception of public health benefit
In total, 1762 participants (70.3%) agreed vaccines were very
important in protecting the whole community against infectious
diseases. Compared to adolescents, a slightly higher percentage
of adults (70.9% (N = 1421) vs 67.9% (N = 341)) strongly supported
the importance of the public benefit from vaccination with a fur-
ther 22.6% (N = 452) (vs 24.1% (N = 121)) indicating ‘‘important”,
6.5% (N = 130) (vs 8.0% (N = 40)) indicating ‘‘not sure”/‘‘not impor-
tant”. Females were more confident of the public health benefit
(73.2%, N = 943) than males (67.3%, N = 819) with 21.0% (N = 271)
vs 24.8% (N = 302) reporting ‘‘important”, and 5.8% (N = 74) vs
7.9% (N = 96) reporting ‘‘not sure”/‘‘not important”.After adjusting for age category, household size, socio-economic
status, and area of residence in the ordinal logistic analysis, the
only predictor variable negatively associated with perception of
community protection was gender with males having less belief
in the public benefits of vaccines (OR = 0.74, 95%CI: 0.63, 0.88,
p = 0.001). There was a trend towards adolescents having reduced
confidence in the public health benefit of vaccines compared to
adults (OR = 0.83, 95%CI: 0.67, 1.03, p = 0.089).
3.3. Perception of vaccines being risky
Only 16.0% (N = 400) of participants completely disagreed that
vaccines were risky. Over half (N = 1467, 58.6%) believed that vac-
cines were slightly risky with one quarter indicating ‘‘moderately
risky” (N = 418, 16.7%), ‘‘highly risky” (N = 111, 4.4%) and ‘‘uncer-
tain” (N = 109, 4.4%). A higher proportion of adolescents (N = 36,
7.2%) were uncertain about vaccine risks versus adults (N = 73,
3.6%). There was no significant difference in risk perception for
any of the predictor variables in the adjusted analysis.
3.4. Predicted vaccine hesitancy
A total of 216 participants (8.62%) demonstrated vaccine hesi-
tancy, as they were not confident of vaccine benefits and/or safety.
After adjusting for age category and other sociodemographic char-
acteristics in a logistic model, adolescents revealed higher odds of
being vaccine hesitant than adults (OR = 1.44, 95%CI: 1.01, 2.04,
p = 0.043). An increased household size was associated with lower
odds of participants being vaccine hesitant (OR = 0.85, 95%CI: 0.76,
0.95, p = 0.003).
3.5. Concerns about potential vaccine side effects
Participants had more concern about systemic adverse effects
such as fever (mean score: 4.4) following injection, than local
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score: 3.3) and injection pain (mean score: 3.2) (ANOVA, p < 0.001).
Results of the multivariable linear regression analyses showed
adolescents had higher concern about pain (b = 1.29, 95%CI: 1.00,
1.58, p < 0.001), redness or swelling (b = 1.05, 95%CI: 0.77, 1.33,
p < 0.001) and fever (b = 0.41, 95%CI: 0.12, 0.71, p = 0.006) following
vaccination thanadults (Table2).Onaverage,maleshad less concern
about vaccine reactions including pain (b = 0.28, 95%CI: 0.51,
0.06, p = 0.012), redness or swelling (b = 0.29, 95%CI: 0.50,
0.08, p = 0.008) and fever (b = 0.38, 95%CI: 0.60, 0.15,
p = 0.001) than females. Participants with high socio-economic sta-
tus expressed less concern about fever (b = 0.32, 95%CI: 0.60,
0.03, p = 0.033) and redness or swelling (b = 0.28, 95%CI: 0.55,
0.00, p = 0.047) than those of low socio-economic status. Partici-
pants with a larger household size tended to have more concern
about fever (b = 0.10, 95%CI: 0.01, 0.18, p = 0.021).3.6. Main source of information about vaccination
For adults, health professionals (78.4%), family members (7.6%)
and the internet (6.2%) were the top three sources of information
about vaccination (Table 3). Adolescents reported health profes-Table 2
Results of multivariable linear regression describing the factors associated with concerns
Score Multiva
Mean (SD) Coefficie
Pain at injection site
Total (N = 2505) 3.23 (2.90) –
Age
Adolescents (N = 502) 4.32 (3.02) 1.29
Adults (N = 2003) 2.96 (2.81) Ref
Gender
Male (N = 1217) 3.09 (2.82) 0.28
Female (N = 1288) 3.37 (2.97) Ref
Household size
– 0.07
Redness or swelling at injection site
Total (N = 2505) 3.27 (2.77) –
Age
Adolescents (N = 502) 4.14 (2.88) 1.05
Adults (N = 2003) 3.05 (2.70) Ref
Gender
Male (N = 1217) 3.12 (2.69) 0.29




Low (N = 619) 3.41 (2.86) Ref
Medium (N = 851) 3.29 (2.78) 0.13
High (N = 1021) 3.15 (2.71) 0.28
Fever
Total (N = 2505) 4.41 (2.90) –
Age
Adolescents (N = 502) 4.80 (2.83) 0.41
Adults (N = 2003) 4.31 (2.91) Ref
Gender
Male (N = 1217) 4.22 (2.88) 0.38




Low (N = 619) 4.54 (2.93) Ref
Medium (N = 851) 4.51 (2.95) 0.03
High (N = 1021) 4.23 (2.86) 0.32sionals (53.6%), family members (30.5%) and schools (10.2%) as
the three most important sources.
Compared to adults, adolescents were less likely to consider
health professionals (OR = 0.32, 95%CI: 0.26, 0.40, p < 0.001) and
the media (OR = 0.57, 95%CI: 0.37, 0.87, p = 0.010) as the most
important sources, and were more likely to seek information from
social networks including family, friends and school (OR = 5.02,
95%CI: 3.97, 6.35, p < 0.001) (Table 4). Unlike females, males
tended to obtain information from social networks (OR = 1.28,
95%CI: 1.03, 1.59, p = 0.028) and were less likely to consider health
professionals as a main source of information (OR = 0.76, 95%CI:
0.63, 0.91, p = 0.003). The media, including internet, newspaper,
magazine or TV, was less likely to be a main source of information
for participants living in rural areas (OR = 0.72, 95%CI: 0.53, 1.00,
p = 0.048) compared to those in metropolitan areas.
3.7. Who should make a decision about vaccination?
The majority of participants agreed that parents should make
vaccination decisions for adolescents (N = 1685, 67.3%), with
22.5% (N = 563) indicating a joint decision between parent and
adolescent was preferable, 2.5% (N = 63) indicating adolescents
should make the decision and 7.7% (N = 194) indicating someoneabout potential reactions to vaccines.
riable linear regression


























Main sources of information about vaccination.
Health professionals Social networks Media and others
Family Friends/Colleagues School Internet TV Newspaper/Magazine Others
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Total (N = 2505) 1839 (73.4) 305 (12.2) 43 (1.7) 91 (3.6) 145 (5.8) 41 (1.6) 13 (0.5) 28 (1.1)
Age
Adolescents (N = 502) 269 (53.6) 153 (30.5) 2 (0.4) 51 (10.2) 20 (4.0) 1 (0.2) 3 (0.6) 3 (0.6)
Adults (N = 2003) 1570 (78.4) 152 (7.6) 41 (2.1) 40 (2.0) 125 (6.2) 40 (2.0) 10 (0.5) 25 (1.3)
Gender
Male (N = 1217) 861 (70.8) 158 (13.0) 26 (2.1) 50 (4.1) 75 (6.2) 24 (2.0) 9 (0.7) 14 (1.2)
Female (N = 1288) 978 (75.9) 147 (11.4) 17 (1.3) 41 (3.2) 70 (5.4) 17 (1.3) 4 (0.3) 14 (1.1)
Socio-economic status
Low (N = 619) 456 (73.7) 76 (12.3) 11 (1.8) 21 (3.4) 34 (5.5) 11 (1.8) 3 (0.5) 7 (1.1)
Medium (N = 851) 620 (72.9) 105 (12.3) 10 (1.2) 27 (3.2) 52 (6.1) 17 (2.0) 9 (1.1) 11 (1.3)
High (N = 1021) 754 (73.9) 122 (12.0) 21 (2.1) 42 (4.1) 59 (5.8) 12 (1.2) 1 (0.1) 10 (1.0)
Area of residence
Rural (N = 879) 658 (74.9) 107 (12.2) 12 (1.4) 33 (3.8) 39 (4.4) 18 (2.1) 3 (0.3) 9 (1.0)
Metropolitan (N = 1625) 1180 (72.6) 198 (12.2) 31 (1.9) 58 (3.6) 106 (6.5) 23 (1.4) 10 (0.6) 19 (1.2)
Note: For each source presented, the number of respondents ranked as the most important (i.e. ranked as the top one) was counted.
Table 4
Results of multivariable logistic regression describing the factors associated with main sources of information about vaccination.




















Adolescents (N = 502) 0.32 0.26, 0.40 <0.001 5.02 3.97, 6.35 <0.001 0.57 0.37, 0.87 0.010
Adults (N = 2003) Ref – – Ref – – Ref – –
Gender
Male (N = 1217) 0.76 0.63, 0.91 0.003 1.28 1.03, 1.59 0.028 1.24 0.95, 1.64 0.119
Female (N = 1288) Ref – – Ref – – Ref – –
Household size
0.99 0.93, 1.06 0.866 1.06 0.98, 1.15 0.133 0.92 0.83, 1.02 0.106
Socio-economic statusa
Low (N = 619) Ref – –
Medium (N = 851) 1.17 0.82, 1.67 0.394
High (N = 1021) 0.79 0.54, 1.16 0.231
Area of residence




a The predictor variables, socio-economic status and area of residence with a p-value > 0.2 in the univariate analysis, were excluded from multivariable logistic regression
models of health professional and social networks.
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adolescents, more than half reported that parents should make
the decision for them (N = 311, 62.0%), with one third preferring
a joint decision with parents (N = 160, 31.9%), 3.8% (N = 19) believ-
ing adolescents should make the decision themselves and 2.4%
(N = 12) reporting someone else. Compared to children, a slightly
higher proportion of adults (N = 1374, 68.6%) believed parents
should make the decision for their children with 20.1% (N = 403)
supporting a joint decision.
In the multinomial logistic model using ‘parents should make
the decision’ as the reference category and adjusting for gender,
household size and socio-economic status, adolescents were more
likely to report that adolescents should make the decision instead
of parents exclusively (RRR = 2.24, 95%CI: 1.25, 4.03, p = 0.007),
and to support a joint decision with parents (RRR = 1.78, 95%CI:
1.41, 2.25, p < 0.001) than adults. Males were more likely to report
that adolescents should make the decision (RRR = 1.73, 95%CI:
1.03, 2.92, p = 0.039), and they had less interest in making a joint
decision between adolescents and parents (RRR = 0.73, 95%CI:
0.60, 0.89, p = 0.002) than females (Table 5).4. Discussion
Immunisation is one of the most successful public interventions
to protect individuals and the community against vaccine-
preventable diseases. As adolescents are an important target group
for immunisation, our study focused on adolescent confidence,
concerns and preference for decision making about vaccination
compared with adults.
The majority of both adolescents and adults were strongly sup-
portive of vaccination and reported that vaccines were highly ben-
eficial. Consistent with our findings, studies conducted in the USA
[5] and European Union (EU) [15] reported the majority of parents
and adolescents were confident of vaccine effectiveness in pre-
venting disease. However, reduced public confidence in vaccina-
tion was observed in more than 10% of participants who doubted
or denied vaccine benefits and their safety. Similar to our findings,
17% of adolescents and 30% of parents in the USA study did not per-
ceive vaccines to be ‘‘very safe” [5]. Even a moderately high per-
centage of parents who strongly supported immunisation also
expressed their concerns over vaccine safety in a large survey in
Table 5
Results of multinomial logistic regression on making a decision about vaccination with ‘parents should make the decision’ as the reference category.
Adolescents should make the decision Joint decision of parents & adolescents Someone else should make the decision
(e.g. GP)
RRR 95% Confidence interval P-Value RRR 95% Confidence interval P-Value RRR 95% Confidence interval p-Value
Age
Adolescents (N = 502) 2.24 1.25, 4.03 0.007 1.78 1.41, 2.25 <0.001 0.37 0.20, 0.67 0.001
Adults (N = 2003) Ref – – Ref – – Ref – –
Gender
Male (N = 1217) 1.73 1.03, 2.92 0.039 0.73 0.60, 0.89 0.002 0.87 0.65, 1.18 0.376
Female (N = 1288) Ref – – Ref – – Ref – –
Household size
0.84 0.69, 1.03 0.092 1.00 0.93, 1.07 0.965 0.79 0.71, 0.89 <0.001
Socio-economic status
Low (N = 619) Ref – – Ref – – Ref – –
Medium (N = 851) 1.13 0.55, 2.33 0.730 1.38 1.07, 1.79 0.014 1.06 0.72, 1.56 0.770
High (N = 1021) 1.51 0.78, 2.92 0.224 1.14 0.88, 1.47 0.312 0.90 0.62, 1.32 0.597
B. Wang et al. / Vaccine 34 (2016) 5595–5603 5601the USA [10]. Lower levels of vaccine confidence could lead to vac-
cine hesitancy [28]. Vaccine hesitant parents might not completely
refuse recommended vaccines, but delay vaccination or reject one
or more specific vaccines for their children [24]. Lack of confidence
may follow adolescents into adulthood, and so could have conse-
quences for parental confidence in vaccine programs in the future.
Adolescents demonstrated lower confidence in vaccine benefits
and/or safety than adults. In the EU study, 41% of adolescents
selected ‘‘not all vaccinations are necessary” as one of the top three
reasons for not being vaccinated [15]. In a study from Belgium, 13%
of adolescents did not consider vaccination as a safe way to pre-
vent disease [16]. Since there is minimal opportunity for adoles-
cents to experience vaccine-preventable diseases due to the
success of vaccination programs, doubts about vaccine necessity
are likely to be relevant to non-compliance with vaccination
schedules.
Our study results also showed gender and household size were
significant factors affecting vaccine confidence. In line with previ-
ous research [21], males demonstrated less confidence in vaccine
benefits but less concern about vaccine side effects. A number of
studies found females were more likely to oppose a specific vac-
cine, for example, influenza vaccines [33–35]. In those studies,
women were expected to have a lower level of influenza vaccine
acceptance due to ‘‘societal inequality effect” [36]. However, gen-
der differences were not observed or not significant in multivari-
able regression analyses in other influenza studies [37]. People
from big families showed more willingness to support vaccination
than those with a small household size. This may be reflection of
higher perceived risks of infections in larger households with more
children. Adolescents from larger families may have more support
in making decisions about vaccination. In contrast, vaccination
coverage studies found the large family size was associated with
reduced vaccination uptake in Kenya, Belgium and Greece
[26,38,39]. However, this is a measure of uptake rather than
intended willingness. The different research questions and study
population may be the reason for disparity in study results.
Adolescents reported a higher concern about local and systemic
vaccine side effects than adults with fever raising the highest con-
cern in our study. The side effects of the vaccine and fear of the
needle were the most frequently reported reasons for not getting
vaccinated in the EU adolescent study [15]. Moreover, other study
results revealed that younger age and female gender were associ-
ated with concerns about needle pain [40,41], which is consistent
with our findings.
Although the majority of adolescents and adults indicated
health professionals and their family were the most important
source of information about new vaccines, not surprisingly adoles-cents sought vaccine information from schools and social networks
more frequently than adults. Similar results were reported in the
EU and Belgium studies [15,16]. Those findings emphasise that
school-based educational programs are imperative and should be
strengthened to provide detailed information of vaccine benefits
and potential risks of contracting and transmitting vaccine pre-
ventable infectious diseases. Previous research also provides evi-
dence that educating students is one of the best practices to
improve coverage rates of school-located influenza vaccination
[42]. Adolescents are frequent users of the internet and therefore
might be expected to seek information from the internet more
often than adults. However, our study showed that adolescents
were less likely than adults to seek information about vaccination
from media sources. A number of qualitative studies have found
that adolescents regard themselves as passive participants in the
vaccine decision making process [43,44]. This finding may indicate
why they might not actively search for information about vaccina-
tion on the internet.
Compared with adults, adolescents were more likely to prefer a
joint decision with parents about vaccinations or to make a deci-
sion on their own. Adolescent’s willingness to be involved in the
decision-making process has been reported in previous studies.
These studies showed more than half of adolescent participants
felt ‘‘somewhat comfortable” or ‘‘comfortable” to make vaccine
decisions for themselves [5], parents stated that adolescents influ-
enced their decisions regarding HPV vaccination [4] and the
majority of adolescent participants wanted to be part of a discus-
sion with parents and health care providers in regards to HPV vac-
cination [6]. The active role that adolescents play in decision
making is important and should not be underestimated, as litera-
ture shows that greater adolescent involvement in decision mak-
ing is likely to lead to higher treatment adherence and
compliance [45–47].
Our study results are subject to some limitations associated
with study design and methodology. Although this is a large
national survey with gender and state stratification, the online sur-
vey necessitated internet access which may imply a higher partic-
ipant socio-economic and educational level, thereby impacting
upon the generalisability of the study results. This is a web-
based survey that ensures anonymity. As such, we could not link
survey data with vaccination records to further investigate the
relationship between attitudes and vaccine acceptance. Although
we aimed to enrol participants independently, we could not verify
their relationship between each participant. Social desirability bias
may also affect our results. However, participants were informed
that data were collected anonymously to minimise socially desir-
able responses.
5602 B. Wang et al. / Vaccine 34 (2016) 5595–5603Our results showed a lack of confidence in vaccine safety and
benefits in a reasonably large proportion of adolescents and adults.
Adolescents did not demonstrate better understanding of vaccine
benefits or safety, showed higher concerns over potential reac-
tions, tended to seek information from their family and school,
and appeared eager to be active participants in the decision-
making process. Adolescents and males might be more likely to
delay or refuse vaccines, which is supported by the fact that rates
of HPV vaccination are lower than infant immunisation programs
(90%) [48] with lower uptake in boys (66%) than girls (77%) [49].
Adding the science of vaccines and immunisation to the school cur-
riculum could be a new approach to improve current vaccination
coverage rates in adolescents and also enhance vaccine confidence
in the next generation of parents. As our study identified vaccine
safety as a concern and potential barrier, engaging adolescents
early in understanding the scientific basis of benefits and risks
associated with immunisation is more likely to improve confidence
in decision making about maternal and infant immunisations in
the future. Tailored school-based educational programs based on
school specific sociodemographic factors should be developed to
provide accurate information on the benefits and risks of vaccina-
tion and alleviate anxiety and concern.
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2.3 VACCINE PREFERENCES 
Adolescent vaccine preferences were evaluated in a national online survey and quantified 
by using a DCE design. The study results were published in “PLOS ONE”. The DCE 
online survey was completed by 800 adolescents. Most adolescents provided valid 
responses with an inconsistency rate of 13.1%. Attributes and levels were selected based 
on a literature review and expert opinions. Expert opinions were solicited from a clinician 
and researchers including three co-authors (HM, GC and BW) to develop attributes and 
attribute levels. The DCE data were analysed using mixed logit regression. Adolescents 
showed strong preferences for vaccination against a life-threatening illness with lower 
price, mild but common side effects, and delivery via a skin patch. Although adolescent 
school-based vaccination programs have been considered as an efficient and effective 
way to provide vaccines to this age group, the survey results showed that GP clinics were 
preferred by adolescents. Understanding drivers for vaccination in this population is key 
to designing effective public health programs. Previous work has only focused on 
particular vaccines rather than the broad approach to adolescent views taken in this study. 
This study has provided valuable insight into adolescent preferences for vaccination. 
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The importance of adolescent engagement in health decisions and public health programs
such as immunisation is becoming increasingly recognised. Understanding adolescent pref-
erences and further identifying barriers and facilitators for immunisation acceptance is criti-
cal to the success of adolescent immunisation programs. This study applied a discrete
choice experiment (DCE) to assess vaccination preferences in adolescents.
Methods
This study was conducted as a cross-sectional, national online survey in Australian adoles-
cents. The DCE survey evaluated adolescent vaccination preferences. Six attributes were
assessed including disease severity, target for protection, price, location of vaccination pro-
vision, potential side effects and vaccine delivery method. A mixed logit model was used to
analyse DCE data.
Results
This survey was conducted between December 2014 and January 2015. Of 800 adoles-
cents aged 15 to 19 years, stronger preferences were observed overall for: vaccination in
the case of a life threatening illness (p<0.001), lower price vaccinations (p<0.001), mild but
common side effects (p = 0.004), delivery via a skin patch (p<0.001) and being administered
by a family practitioner (p<0.001). Participants suggested that they and their families would
be willing to pay AU$394.28 (95%CI: AU$348.40 to AU$446.92) more for a vaccine target-
ing a life threatening illness than a mild-moderate illness, AU$37.94 (95%CI: AU$19.22 to
AU$57.39) more for being vaccinated at a family practitioner clinic than a council immunisa-
tion clinic, AU$23.01 (95%CI: AU$7.12 to AU$39.24) more for common but mild and
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resolving side effects compared to rare but serious side effects, and AU$51.80 (95%CI: AU
$30.42 to AU$73.70) more for delivery via a skin patch than injection.
Conclusions
Consideration of adolescent preferences may result in improved acceptance of, engage-
ment in and uptake of immunisation programs targeted for this age group.
Introduction
Adolescence is a time in life that often features risk taking behaviours, however it also provides
the greatest opportunity for sustained wellbeing into adulthood. Although adolescents are
often treated as younger adults, their views and values are typically overlooked when public
health strategies that affect them are being designed.
One of these strategies is immunisation, with adolescents an increasingly important target
group for immunisation internationally [1]. Routine immunisation of adolescents provides
individual protection and herd protection against vaccine-preventable diseases such as
Human Papillomavirus (HPV) and meningococcal disease, boosts the pre-existing but waning
immunity (e.g. diphtheria/tetanus/pertussis booster vaccination) and delivers catch-up pro-
grams for those who did not receive recommended vaccines during childhood [2]. However,
compared to infant and childhood immunisation, the current adolescent immunisation cover-
age is suboptimal with uptake rates varying between 50% and 80% in high resource countries
(e.g. Australia [3] and the United States [4]). Lack of awareness of vaccination recommenda-
tions, concerns about vaccine side effects, confusion over immunisation schedules and not
actively attending preventive health visits could be barriers to vaccinating adolescents [5, 6].
However, earlier studies in this area have mainly focused on parental or adult preferences for
immunisation or on a specific vaccine, such as for HPV, for adolescents [7–13]. Since there is
an evidence base to indicate that adolescents are willing to be involved and their attitudes can
significantly affect parents’ vaccination decisions [5, 14, 15], adolescent immunisation uptake
could be improved through better understanding adolescent preferences for vaccination.
Understanding their preferences is also important for the development of any vaccination edu-
cation programs. Such programs can overcome vaccine hesitancy or refusal, and can also pro-
vide vaccine providers and health authorities with useful information to inform policy prior to
the introduction of any future targeted adolescent vaccine programs.
Discrete choice experiments (DCEs) are commonly used in health economics to elicit par-
ticipants’ preferences for healthcare programs and policies. The technique uses an attribute
based quantitative survey method and draws on elements of random utility theory, consumer
theory, and experimental design theory. In DCEs, a number of salient attributes are used to
describe characteristics of interventions, and each attribute takes a range of levels. The value
(utility) of each scenario is determined by different levels of attributes. Participants trade off
risks and benefits among alternative scenarios and express their preferences by choosing their
preferred option [16, 17]. Where price is included as an additional attribute, the DCE
approach may also be used to estimate individuals’ willingness to pay (WTP) for healthcare
interventions [16]. Immunisation acceptance by adolescents may be influenced by a number
of factors including severity of illness, side effects, out-of-pocket costs, healthcare facilities
where vaccines are administered, mode of administration, vaccine effectiveness and duration
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of immunity [9, 12]. Adolescents may choose to trade off the potential health benefits against
perceived drawbacks of immunisation in the decision making dynamic.
An adolescent-friendly approach, which includes eliciting adolescent views on public health
programs that we expect them to engage in, is required if we aim to reduce the barriers to tak-
ing part in such programs. Several different methodologies including DCEs have been used
previously to assess adolescent values of health states [18, 19]. However, a limited amount of
research has been conducted to date to assess adolescent preferences and attitudes towards
immunisation program delivery [14, 20–22]. Using an online DCE, this study aimed to investi-




This survey was conducted according to guidelines for the design and conduct of DCE studies
in healthcare [17, 23–25].
For this study, it was important to identify a number of relevant and generic attributes that
enable participants to make a meaningful judgment regarding adolescent preferences for
immunisation. We considered a literature review and expert opinion (interview with a clini-
cian in child and adolescent health and vaccinologist, a health economist/DCE expert, an ethi-
cist and an adolescent health researcher) as the appropriate sources of information. A rapid
systematic review was performed by searching titles and abstracts in the PubMed database for
DCE studies investigating vaccines preferences. Experts were asked to review the list of attri-
butes derived from the literature review, and the following were identified as appropriate to
include in our DCE: disease target [26–29], location of vaccination [9, 13, 30, 31], potential for
side effects [8–10, 13, 30–35], vaccine delivery mechanism [10] and price [9, 10, 13, 30, 31, 35,
36]. Since herd protection is an important factor affecting acceptance of vaccines and out-
comes of cost-effectiveness evaluations [37], “target for protection” was also added to the attri-
bute list based on the expert opinion. The levels of each attribute were selected as to whether
they were plausible and relevant from both the clinical and the policy viewpoint. Based on the
range of private vaccine prices in Australia (approximately AU$ 30–200 per dose) and assump-
tion of at least three doses required, price levels of AU$100 and AU$500 were chosen in addi-
tion to publicly-funded free vaccination. A previous DCE study found the adolescents’
personal financial situation was significantly associated with their vaccination choice rather
than their household financial situation [7]. Considering some adolescents might have already
worked full or part-time, we used the term “cost to self (or family)”. Vaccine efficacy was
selected as an attribute in a number of previous DCE studies [8–10, 13, 26–34], but not
included in our DCE survey as it was not reported as a major contributor to vaccine hesitancy
or refusal [38, 39]. Previous research found participants’ decisions to vaccinate were not sensi-
tive to the probability of disease [35]. Therefore neither disease prevalence nor incidence were
included in order to reduce participants’ cognitive burden.
A D-efficient (Dz-error, i.e. zero priors assumed for all variables) design, for main effects
only, was developed using Ngene 1.1.2 [40], which yielded 36 choice sets that were further
divided into three blocks so as to minimise participants’ cognitive burden. Each participant
was randomly assigned to one of the three blocks. One choice question in each block was
repeated to check for internal consistency. An example of a choice question is shown in
Table 1. Before participants were asked to make a choice between options A or B for each
choice question, a detailed explanation of how to choose between alternatives was presented.
The possible differences in each hypothetical scenario were listed: 1) disease targeted including
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mild-moderate illness (unlikely to be fatal), life threatening illness (could be fatal), sexually
transmitted infection, or chronic illness; 2) target for protection including the individual
(you)–being vaccinated will provide protection against disease affecting adolescents and
young adults, or the individual (you) and others–being vaccinated will protect the individual
(you) and others by reducing spread of disease to others in the community; 3) price including
$0, $100, or $500; 4) setting (location of vaccination) including school/university, GP (i.e. fam-
ily practitioner), or council immunisation clinic; 5) potential for side effects including rare
(1:100,000) but serious (i.e. allergic reaction), or common but mild and resolving (i.e. fever,
local redness or swelling); 6) vaccine delivery mechanism including injection (needle), skin
patch, or oral dose.
The questionnaire included a series of socio-demographic questions and 13 DCE choice
questions. In addition, two questions in relation to attitudes towards risk in general or with
health were measured on an eleven point scale, with zero indicating “not at all prepared to take
risk”, and ten indicating “very much prepared to take risk” [41] to assess risk taking
behaviours.
The draft survey questionnaire was pre-piloted with a convenience sample of three adoles-
cents and only minor changes were made to ensure adolescents could interpret all questions
appropriately. The survey was also pilot tested in 130 participants with approximately 43 par-
ticipants per block to check feasibility and internal consistency. Seventeen participants (13.1%)
failed the internal consistency test. Since the inconsistency rate was comparable to that
reported in previous DCE studies [42, 43], no revisions were made to the DCE survey.
Sample size and study population
Calculation of optimal sample sizes is complex as it depends on the true values of the unknown
parameters estimated in the DCE models [17]. However, as a rule of thumb suggested by
Orme [44], a sample size of 300 would be desirable for a main effects model based on the num-
ber of choice sets, alternatives and analysis cells. We aimed to recruit 20 participants per choice
set resulting in 720 adolescents aged between 15–19 years, which would provide more
Table 1. Example of a DCE question. Please consider that you are making a choice about receiving a vac-
cine/s for yourself. Of the options in the table below (A or B), please select which option you would choose.
Considering the possible scenarios outlined below, which option would you choose?
Features Option A Option B
Disease targeted Chronic illness Mild-moderate illness (unlikely to be
fatal)
Target for protection The individual (you)–being vaccinated
will provide protection against disease
affecting adolescents and young adults
The individual (you) and others–being
vaccinated will protect the individual
(you) and others by reducing spread of
disease to others in the community
Cost to self (or family) $500 $100
Location of
vaccination
General practitioner (GP) School/University
Potential for side
effects
Common but mild and resolving (i.e.
fever, local redness or swelling)




Oral dose Skin patch
Which option would
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statistical power with a sample size larger than in similar adolescent DCE studies described in
the literature to date [7, 8, 32].
Potential participants were identified via Pureprofile (https://www.pureprofile.com/au/), an
online market research company. Pureprofile was contracted to host and distribute the survey
invitation to parents on their database who had children aged between 15–19 years and resided
within Australia. Interested parents were provided with an electronic information sheet
describing the study. Parents were then asked whether they had an adolescent who would be
willing to complete the survey. Subsequent to parent and adolescent dyad consent to partici-
pate in the study, adolescents were then guided through the online survey by screen prompts.
In recognition of the time spent completing the DCE survey, account holders of adolescents
who participated received a small financial reward (AU$3.25).
Statistical analysis
The Socio-Economic Indexes for Areas, Index of Relative Socioeconomic Disadvantage 2011
(SEIFA IRSD) [45] was used to categorise socio-economic status as into tertiles: low (1st–33rd
percentile), medium (34th–66th percentile) and high (67th–100th percentile). SEIFA ranks
residential areas in Australia according to relative socio-economic disadvantage based on
information from the five-yearly Census. Student’s t-tests and χ2 tests were used to compare
means and proportions between two subgroups, respectively. Participants who failed the inter-
nal consistency test were excluded from the analysis and a sensitivity analysis was conducted
by including participants who failed the test.
DCE data were analysed using a mixed-logit model which accounts for preference hetero-
geneity. The price attribute was treated as a continuous variable and dummy-variable coding
was used for all other attributes. The model fit to the utility function was:
Uitj ¼ ðb1þ Z1iÞ life threatening illnessþ ðb2þ Z2iÞ sexually transmitted infection
þðb3þ Z3iÞ chronic illnessþ ðb4þ Z4iÞ protect you＆others
þðb5þ Z5iÞ school=university þ ðb6þ Z6iÞ GPþ ðb7þ Z7iÞ common side effects
þðb8þ Z8iÞ skin patchþ ðb9þ Z9iÞ oral doseþðb10þ Z10iÞ priceþ εitj
Uitj describes the utility of a hypothetical vaccine scenario, i derives from an individual choos-
ing alternative j in choice question t, βi is a vector of coefficients reflecting participants’ prefer-
ence for each attribute level on average, ηi indicates the individual’s specific preference (i.e. a
random effect), and εitj is a random error term describing the unmeasured variation in partici-
pants’ preferences. We assumed coefficients of all attribute levels were independent and ran-
domly distributed with a Normal distribution. A positive (negative) and significant coefficient
indicates a positive (negative) preference for a specific attribute level. The coefficient estimates
(or preference weights) can also be used to compare relative importance between different lev-
els of the same attribute or between levels of completely different attributes [11].
WTP represents a monetary measure of participants’ valuation for a change in the level of




where βcis the price coefficient and βkis the coefficient for attribute k). The pos-
itive and negative results indicate theoretically to what extent the participants and their fami-
lies would be willing to pay/to be compensated for an attribute level. The 95% confidence
intervals were estimated using the Krinsky Robb (parametric bootstrap) method [46]. WTP
estimates do not represent market prices participants and their families wanted to pay for the
various attributes of a hypothetical vaccine. All statistical analyses were performed in Stata ver-
sion 14.1 [47].
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Ethics
This study was approved by the Women’s and Children’s Health Network Human Research
Ethics Committee in Adelaide, Australia. This study has not been registered in a clinical trial
registry because it was not a clinical trial and therefore registration was not required.
Results
A total of 800 adolescents (age range 15–19 years) were enrolled and completed the survey
between December 2014 and January 2015 (S1 Dataset). Females were slightly predominant
(54.9%) in the study population. Of the participants, 90.0% were born in Australia, with
approximately 97.8% non-indigenous (Table 2). Enrolment was initially planned to be strati-
fied by state and gender. Due to difficulties in recruiting adolescent participants in smaller
states or territories such as the Northern Territory (NT) and Australian Capital Territory
(ACT), enrolment did not strictly adhere to the original regional quotas. Except for NT and
ACT, participants were reasonably representative of the adolescent population of each state.
DCE results
Participants who failed the consistency test were excluded from the analysis (N = 105, 13.1%),
generating a useable total sample of 695 adolescents (86.9%) for main DCE analysis. Except for
socio-economic status (SES) and risk taking attitudes, there were no significant differences
between the participants who passed versus those who failed the consistency test. Those who
were excluded were more likely to reside in an area with medium SES (p = 0.008) and exhib-
ited higher general (p = 0.015) and health risk attitudes (p = 0.004).
The vaccination in the case of a life threatening illness (p<0.001) had the highest preference
weight when comparing with a mild-moderate illness (Fig 1 and Table 3). Changing vaccina-
tion targeting from a mild-moderate illness to a life threatening illness could yield 17 times
(2.314 0.135) as much as utility as changing from “rare but serious” to “common but mild
and resolving” side effects. Other stronger preferences were observed for vaccination treating a
chronic illness (p<0.001) and a sexually transmitted infection (p<0.001) with common but
mild and resolving side effects (p = 0.004) and delivery via a skin patch or oral dose (p<0.001)
compared with their reference levels. Despite the success of adolescent school-based vaccina-
tion, participants were more willing to be vaccinated by GPs (p<0.001). Lower price vaccina-
tions were also preferred (p<0.001).
With the exception of one coefficient (for vaccination protecting you and others
(p = 0.274)), the standard deviations (SDs) of other random coefficients were statistically sig-
nificant, which indicated preference heterogeneity was present for those attribute levels.
A sensitivity analysis was performed by including participants who failed the consistency
test and no significant impact was observed. Subgroup analyses were conducted with regard to
SES, risk taking attitudes and participants’ intention to be vaccinated, and the results were
broadly consistent between subgroups.
Willingness to pay
Participants suggested that they and their families would be willing to pay AU$394.28 (95%CI:
AU$348.40 to AU$446.92) more for a vaccine targeting a life threatening illness than a mild-
moderate illness, AU$37.94 (95%CI: AU$19.22 to AU$57.39) more for being vaccinated at a
family practitioner clinic than a council immunisation clinic, AU$23.01 (95%CI: AU$7.12 to
AU$39.24) more for common but mild and resolving side effects than rare but serious side
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effects, and AU$51.80 (95%CI: AU$30.42 to AU$73.70) more for delivery via a skin patch than
injection (Table 4).
Discussion
This DCE has identified preferences of Australian adolescents for immunisations providing
protection against a life threatening illness, causing common but mild and resolving side
effects, being administered by a medical practitioner and delivered via a skin patch at a lower
price. To our knowledge this is the first study to investigate adolescent preferences for immu-
nisation delivery using a DCE design. Because comparable data are lacking, we have reviewed
literature for DCE studies associated with a specific vaccine in both parental and adolescent
populations.
Fatal diseases were the most vital decisive factor in adolescent vaccine acceptance. Another
DCE study reported people valued prevention targeting a serious illness higher than cure [48].
This suggests that vaccines targeted towards a fatal illness could achieve high and sustainable
vaccine coverage, for example, adolescent vaccines for meningococcal disease. Given the
National HPV Vaccination Program started almost ten years ago [49], somewhat surprisingly,
our study participants were not strongly in favour of STI vaccines which may indicate lack of
awareness of HPV being a STI. Parental studies reported similar results that a sexual mode of
transmission had minimal impact on STI vaccine acceptability [27, 28]. Moreover, only 13% of
Table 2. Demographic characteristics of the study population.
All (N = 800) Participants who passed
the consistency test only
(N = 695)




Mean SD Mean SD Mean SD
Age (years) 17.10 1.42 17.11 1.42 17.08 1.39 0.839
Household Size (people) 4.09 1.41 4.05 1.35 4.30 1.77 0.088
Risk attitudes
In general 5.20 2.32 5.12 2.26 5.71 2.64 0.015
For health 4.11 2.61 4.01 2.53 4.79 3.00 0.004
N % N % N %
Gender
Male 361 45.13 317 45.61 44 41.90 0.477
Female 439 54.88 378 54.39 61 58.10
Completed High School 445 55.63 391 56.26 54 51.43 0.353
Born in Australia 720 90.00 629 90.50 91 86.67 0.222
Aboriginal or Torres Strait Islander 17 2.13 16 2.30 1 0.95 0.371
Socio-economic Status
Low (1st–33rd percentile) 203 25.50 183 26.48 20 19.05 0.008
Medium (34th–66th percentile) 252 31.66 205 29.67 47 44.76
High (67th–100th percentile) 341 42.84 303 43.85 38 36.19
State
NSW 257 32.13 224 32.23 33 31.43 0.224
VIC 201 25.13 173 24.89 28 26.67
QLD 166 20.75 149 21.44 17 16.19
SA 70 8.75 55 7.91 15 14.29
WA 79 9.88 68 9.78 11 10.48
TAS 16 2.00 16 2.30 0 0.00
ACT & NT 11 1.38 10 1.44 1 0.95
https://doi.org/10.1371/journal.pone.0181073.t002
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Fig 1. Preference weights for nonmonetary attributes. † Reference (omitted) level for each attribute.
https://doi.org/10.1371/journal.pone.0181073.g001
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adolescent girls were concerned about HPV in an HPV study conducted in the United States
[7]. Perceived transmission risks or severity of STI might be quite low in adolescents, which
resulted in a relatively lower estimated coefficient on STI compared to life threatening and
chronic illnesses. Although previous research indicated participants’ choices to vaccinate were
not sensitive to the probability of disease [35], assumptions made by participants about the
incidence of the disease prevented might influence their preferences. The results of disease
severity may be interpreted with caution, for example, we cannot definitively conclude that
adolescents indicated they and their families would be willing to pay AU$394 more for a vac-
cine against a life-threatening but potentially very rare disease, as compared with a mild-mod-
erate, but common one. Further research may be warranted to tease out the effects of the
disease incidence versus disease severity.
Adolescent immunisation preferences were also influenced by the severity of potential side
effects. Previous research only assessed impact of the frequency of severe reactions [9, 30, 33,
34]. Our study compared preferences between two common occurrences of side effects: rare
Table 3. Mixed logit estimates on vaccination preferences.
Attributes Coefficient SE P value SD SE P value
Disease targeted
Mild-moderate illness a
Life threatening illness 2.314 0.126 <0.001 1.909 0.135 <0.001
Sexually transmitted infection 0.437 0.092 <0.001 1.408 0.101 <0.001
Chronic illness 0.918 0.078 <0.001 0.418 0.178 0.019
Target for protection
Individual a
Individual and others 0.062 0.040 0.126 0.113 0.103 0.274
Location of vaccination
Council immunisation clinic a
School/university 0.172 0.056 0.002 0.267 0.125 0.033
GP 0.223 0.057 <0.001 0.290 0.120 0.016
Potential for side effects
Rare but serious a
Common but mild and resolving 0.135 0.047 0.004 0.558 0.067 <0.001
Vaccine delivery mechanism
Injection a
Skin patch 0.304 0.063 <0.001 0.566 0.091 <0.001
Oral dose 0.283 0.062 <0.001 0.302 0.127 0.018
Price -0.006 <0.001 <0.001 0.006 <0.001 <0.001
Log likelihood -3893.719
Number of participants b 695
Number of observations c 16680
Notes: SE—standard errors. SD—standard deviation. For all random coefficients, normal distribution was used. Price attribute was included as a
continuous variable; all other attributes were dummy coded.
a Reference (omitted) level for each attribute
b A total of 800 adolescents completed the survey. Participants who failed the consistency test (N = 105) were excluded from the main analysis reported in
this table.
c In total, 16680 scenarios (2*12*695) were assessed, with 12 choice sets per participant and each consisting of a choice between two alternative
vaccination programs (A and B).
https://doi.org/10.1371/journal.pone.0181073.t003
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but serious versus common but mild. Compared to the frequency, the severity of side effects
may play a more important role in the decision making process.
Although participants still showed positive preferences for the school or university, GP clin-
ics were their stronger location preference in our study. In Australia, adolescent school-based
vaccination has demonstrated advantages over community or private sectors and achieved a
higher coverage rate [1]. However, a lack of awareness or miscommunication might affect
their preference for school-based vaccination. More chances to communicate with GPs and
understanding benefits and risks of the vaccination might explain why participants preferred
GP clinics in our study. Similar to our finding, a varicella vaccination study reported that the
provision of vaccination at schools did not affect parents’ choices whether or not to immunise
their child [31].
Our study also found that price was an important attribute driving preferences which is in
line with previous research [9, 11, 31, 50, 51]. Recommended but non-publicly funded vaccines
were more likely to be refused by parents due to the price [50]. If a vaccine was not included
on the National Immunisation Program Schedule, vaccine prices would definitely be a finan-
cial barrier to successful implementation of an immunisation program. Although adolescents
usually would not have any income or direct out-of-pocket costs for their medical care, a DCE
study assessing WTP for a meningococcal B vaccine in Australia found a consistent pattern of
results at all attributes and levels between adolescents and adults [12]. That financial barrier
would still affect adolescent actual decision making when it comes to receipt of vaccines.
Table 4. Willingness to pay (AU$) for vaccination (based on mixed logit estimates).
Attributes Willingness to pay (AU$) 95%CI
Disease targeted
Mild-moderate illness a
Life threatening illness 394.28 348.40, 446.92
Sexually transmitted infection 74.43 44.10, 106.37
Chronic illness 156.35 129.76, 185.55
Target for protection
Individual a
Individual and others 10.53 -3.29, 24.52
Location of vaccination
Council immunisation clinic a
School/university 29.33 10.70, 48.54
GP 37.94 19.22, 57.39
Potential for side effects
Rare but serious a
Common but mild and resolving 23.01 7.12, 39.24
Vaccine delivery mechanism
Injection a
Skin patch 51.80 30.42, 73.70
Oral dose 48.25 27.95, 69.82
Number of observations 16680
Notes: Confidence interval (CI) was calculated based on the Krinsky and Robb bootstrap method (with
10,000 replications). Price attribute was included as a continuous variable; all other attributes were dummy
coded.
a Reference (omitted) level for each attribute.
https://doi.org/10.1371/journal.pone.0181073.t004
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The strength of this study is identification of adolescent preferences for immunisation pro-
grams using a DCE survey, which allows us to investigate multiple factors influencing vaccina-
tion decision and trade-off between attribute levels. Based on a large national sample of
adolescents, our study produced meaningful and robust estimates. There were some limita-
tions to our study. Prior qualitative work was not conducted to select attributes and levels. It is
possible that some potentially important attributes were omitted from the design of this study
(e.g. disease incidence). Since preferences were measured to establish which components
define the most preferred vaccine program from an adolescent perspective, an opt-out option
was not provided and participants were forced to choose between two alternatives. Whilst it
may be argued that including an opt-out option might reflect the decisions of participants in
real-life settings, the opt-out option might be selected by participants to avoid making difficult
trade-offs on attribute levels, thereby decreasing the precision of parameter estimates [52].
However, the inclusion of an opt-out option may provide more information about trade-offs
between vaccination and no vaccination. Furthermore the opt-out option would have enabled
the prediction of probabilities of take-up of different vaccine scenarios [17, 31] and might cor-
rect the WTP value for the probability of people opting out [53]. Further research is required
to explore the implications of including an opt-out option in this context. Their identification
and vaccination status cannot be verified, which may affect internal validity of the study. As
our participants were adolescents who might not be financially independent, the WTP values
in our study are a mix of personal values and perception of what their family would sacrifice
and therefore WTP may not be interpreted in the conventional way. Finally, since this is a sur-
vey-research study and only participants with internet access could be enrolled, the sample
may not be entirely representative of the general population of adolescents due to a higher per-
centage of adolescents from areas of high/medium SES with higher educational levels.
Understanding barriers and facilitators to immunisation is an important step to improve
the uptake of adolescent immunisation. Our study showed adolescents’ vaccine decisions were
driven by disease types, healthcare facilities where vaccines were administered, severity of side
effects and vaccine delivery methods. The study results can provide useful information on ado-
lescent views, values and preferences for vaccination to health authorities, vaccine providers,
immunisation educators and healthcare providers. Strategies to increase immunisation uptake
among adolescents may include providing adolescent-tailored education programs, lowering
out-of-pocket costs, and offering vaccinations outside of schools in “complementary” settings
(e.g. GP clinics). This study evaluating adolescent preferences for immunisation may be used
to inform any future health economic studies for individual vaccines before they are publicly
available. For example, the predicted high rates of vaccination against fatal illnesses, may posi-
tively affect outcomes of health economic evaluation. Our study results may also be used to
develop adolescent specific immunisation education programs. When designing an education
program for adolescent immunisation, these factors, particularly the relative severity of the dis-
ease, should be clearly explained to adolescents.
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2.4 SUMMARY 
The online surveys provided satisfactory answers to two research questions. Adolescent 
attitudes about vaccination differed from those of adults. Adolescents demonstrated a 
higher level of vaccine hesitancy with lower confidence and higher concerns about 
vaccination. They preferred vaccines against a life-threatening illness with a low price, 
mild but common side effects, delivery via a skin patch and be administered by a family 
practitioner. IMD is one of life-threatening diseases which is associated with high mortality 
and morbidity rates [18,19]. Since adolescents showed strong preferences for vaccination 
against a life-threatening illness, IMD is chosen to be further investigated as a case study. 
Five serogroups A, B, C, W and Y cause most meningococcal cases in the world. 
Serogroup B is one of the predominant serogroups. There has also been a rapid increase 
in the number of meningococcal serogroup W cases globally [31]. The vaccine for group 
B disease has not been included on the NIP due to failure to meet cost-effectiveness 
criteria in Australia [36]. New MenACWY vaccine programs have been included or are 
being considered to add on national immunisation schedules in a few countries [78]. In 
the next chapter, the burden of IMD and development of meningococcal vaccines have 
been thoroughly evaluated and reviewed. The implication of evaluating the burden of the 
disease and its vaccine development is profound, as this can provide solid evidence to 
inform future cost-effectiveness evaluations, support government funding decisions, and 
improve vaccine acceptance for new meningococcal vaccine programs. 
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CHAPTER 3: A CASE STUDY - INVASIVE MENINGOCOCCAL DISEASE 
(IMD) 
In the previous chapter, vaccine perception and preferences were assessed in 
adolescents. The results showed that adolescents prefer vaccines targeting severe 
diseases with low costs. An example of a severe vaccine preventable disease is IMD. 
The highest peak in incidence of IMD occurs among 0 to 4 year olds, with a second peak 
of IMD during adolescence, attributed partially to the higher pharyngeal carriage rate of 
the bacteria during this stage of life compared to other age groups [18-20].  
 
Taking IMD as an example, the burden of IMD was further investigated. Inclusion of MenB 
vaccines on the publicly funded immunisation schedules has been rejected in several 
countries such as Canada and Spain. If the vaccine is not provided free under the national 
immunisation program, the vaccine price is a financial barrier to achieving a high vaccine 
coverage rate [79]. A better understanding of the burden of IMD may assist in improving 
vaccine acceptance, addressing vaccine hesitancy, and informing future cost-
effectiveness analyses and funding decisions regarding new meningococcal vaccine 
programs.  
 
The chapter aims to answer the third research question and is outlined as follows: 
Sections 3.1.1 - 3.1.3 demonstrate the extent of the clinical and financial burden arising 
from IMD by evaluating the outcomes of IMD. Section 3.1.4 reviews the development of 
meningococcal vaccines.   
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3.1 LITERATURE REVIEW (incl. a systematic review and meta-analysis) 
IMD is one of the most common causes of death from infectious diseases in childhood in 
developed countries [80]. IMD is caused by the bacterium N. meningitidis. N. meningitidis 
strains are traditionally classified into serogroups based on serological typing [81]. There 
are 13 known serogroups (A, B, C, D, E, H, I, K, L, W, X, Y and Z) causing IMD. These 
serogroups are distinguished by differences in surface polysaccharides of the outer 
membrane capsule. Globally, serogroups A, B, C, W and Y are the most common causes 
of the disease [82,83]. Four major serogroups (B, C, W and Y) cause most IMD cases in 
Australia [84]. The Meningococci can be further differentiated by differences in their outer 
membrane proteins and are referred to as serotypes, serosubtypes and immunotypes. 
Due to insufficient discrimination and limitations associated with serological typing 
methods [85], molecular typing (e.g. multilocus enzyme electrophoresis (MLEE), 
multilocus sequence typing (MLST), etc.) has been developed and used to characterise 
meningococcal strains [23] and complement serological classification. MLST has become 
a preferred method to classify meningococcal strains into different sequence types (STs) 
[86]. Meningococci with clonal complexes such as ST-5, ST-11, ST-32 or ST-41/44 show 
an increased tendency to cause invasive infections or disease outbreaks [23,81,87].  
 
Approximately 150 - 300 cases of IMD are notified each year in Australia, with the highest 
notification rates occurring in Northern Territory followed by Tasmania, South Australia, 
Western Australia, Victoria, Queensland and New South Wales in 2017 [88]. MenB 
disease predominated nationally before 2015 [89]. MenW became the dominant 
serogroup in 2016 and 2017 due to a rise in incidence of MenW disease [84,88,90]. 
However, MenB is still the predominant serogroup in South Australia [35] and nationally 
in the first two quarters of 2018 [89]. 
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Whilst IMD in Australia affects all age groups, the surveillance data show a bimodal age 
distribution with the highest rate in the 0 to 4 year age group and a second peak in the 15 
to 25 year age group [88]. The age specific annual average hospitalisation rate 
(19.7/100,000) and death rate (0.85/100,000) were highest in infants aged less than one 
year [91].  
 
Limited research has been conducted to evaluate the clinical and financial burden of the 
disease, especially in Australia [92-97]. IMD has been a notifiable disease since 1991. 
Surveillance of this disease within Australia is carried out by the National Notifiable 
Disease Surveillance System (NNDSS) with additional laboratory surveillance completed 
by the National Neisseria Network (NNN). However, The NNDSS and NNN concentrate 
on meningococcal strain characterisation and only collect basic demographic details such 
as age. More detailed clinical information and outcomes are not captured sufficiently to 
estimate the burden of IMD.  
 
To answer the third research question an extensive systematic review was conducted to 
evaluate the clinical and financial burden of the disease using electronic databases: 
PubMed, Embase, and the Cochrane Library. The following keywords were used to 
develop search strategies: meningococcal, meningococcal meningitis, meningococcal 
septicaemia, Neisseria meningitidis AND burden, costs, cost analysis, fees, hospital 
charges, economic model, economics, expenditure, utilisation, case fatality, 
complications, sequelae, morbidity, mortality, death rates, incidence, survival analysis, 
health status. The final search terms included combinations of Medical Subject Headings 
(MeSH)/Emtree and text words contained in the title and abstract (See Appendix: IMD 
systematic review protocol). Meta-analyses were performed to estimate CFRs by age and 
serogroup, and the results are included in Section 3.1.1. The most common sequelae 
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identified in the systematic review are summarised in Section 3.1.2. The systematic 
review results regarding financial costs associated with IMD are presented in Section 
3.1.3.  
 
To further understand available vaccine programs against the disease, a literature review 
was performed. The literature review pertinent to vaccine development and vaccine 
strategies is presented in Section 3.1.4.  
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3.1.1 MORTALITY CAUSED BY MENINGOCOCCAL DISEASE 
Despite timely access to healthcare services, IMD can still cause severe outcomes such 
as death. After systematically reviewing the literature, all published evidence pertinent to 
IMD associated mortality was quantitatively synthesised. The effects of age and 
serogroup on CFRs were further explored by using appropriate statistical methods. A 
manuscript titled “Case fatality rates of invasive meningococcal disease by serogroup and 
age: A systematic review and meta-analysis” has been prepared and submitted to the 
journal “Vaccine” for publication (accepted). 
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Invasive meningococcal disease (IMD) is uncommon but still causes considerable public 
health burden due to its high mortality and morbidity. This review aims to quantitatively 
synthesise all published evidence pertinent to mortality caused by IMD and assess the 
effect of age and serogroup on case fatality rates (CFRs). 
 
METHODS 
The PubMed and Embase databases, and the Cochrane Library were searched. Articles 
reporting national CFRs and published in English between January 2000 and May 2018 
were eligible. The studies reporting mortality resulting from a specific symptom of IMD 
(e.g. meningococcal meningitis) were excluded. Mixed-effects logistic regression with a 
restricted cubic spline was used to analyse CFRs as a function of age. Random-effects 
meta-analyses were performed to estimate an overall CFR and CFRs by serogroup. 
 
RESULTS 
Among 48 eligible studies reporting national CFRs, 40 studies were included in meta-
analyses representing 163,758 IMD patients. CFRs ranged from 4.1% to 20.0% with the 
pooled overall CFR of 8.3% (95% confidence interval (CI): 7.5%-9.1%). Serogroup B was 
associated with a lower pooled CFR (6.9% (95%CI: 6.0%-7.8%)) than other serogroups 
(W: 12.8% (95%CI: 10.7%-15.0%); C: 12.0% (95%CI: 10.5%-13.5%); Y: 10.8% (95%CI: 
8.2%-13.4%)). The meta-analysis was not performed for serogroup A (MenA) cases due 
to a small number of MenA patients who were enrolled in eligible studies. For laboratory 
confirmed IMD cases, the predicted CFR was 9.0% in infants, gradually decreased to 7.0% 
in 7-year olds, subsequently increased to 15.0% in young adults aged 28 years, stabilised 
between 15-20% in mid-aged adults and reached a high in elderly people. 




Our findings can provide useful information for better understanding the mortality risks, 
and quantifying the burden associated with IMD mortality. 
 
KEYWORDS 
meningococcal; systematic review; case fatality rates; age; serogroup  
 
ABBREVIATIONS 
AIC Akaike's information criterion 
CFR Case fatality rate 
CI Confidence interval 
ICD International Classification of Diseases 
IMD Invasive meningococcal disease 
MenA Meningococcal serogroup A disease 
MenB Meningococcal serogroup B disease 
MenC Meningococcal serogroup C disease 
MenW Meningococcal serogroup W disease 
MenY Meningococcal serogroup Y disease 
MRR Mortality rate ratio 
OR Odd ratio 




• Our review quantitatively estimated the risk of death following IMD. 
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• Our meta-analyses confirmed and quantified the effect of serogroup and age on 
CFRs. 
• Adolescents and young adults had the higher risk of mortality than infants.  
• Serogroup W disease resulted in a high CFR.  
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INTRODUCTION  
Neisseria meningitidis is estimated to be carried by around 10% of a healthy population 
and can result in invasive meningococcal disease (IMD), a life-threatening infection [1]. 
Vaccines have been developed to protect against serogroups A, B, C, W and Y, which 
are the most common serogroups causing IMD. The meningococcal serogroup C vaccine 
has been included on the national immunisation schedule for decades in many developed 
countries. New surface protein-based meningococcal serogroup B (MenB) vaccines have 
been recently developed and licensed in most developed countries. Quadrivalent 
(serogroups A, C, W, Y) conjugate vaccines have been included on the publicly funded 
immunisation schedule or are being considered for public funding in some countries. The 
evaluation of the cost-effectiveness of a vaccination program is one of the key inputs into 
the decision-making process. The cost-effectiveness of these preventive strategies 
depends on a number of factors including disease incidence, mortality, costs associated 
with the management of the disease and its sequelae, serogroup distribution, herd 
immunity, vaccine efficacy, and immunity duration. The case fatality rate (CFR) is not only 
an important parameter in cost-effectiveness evaluation, but also a key component in 
epidemiological studies and an essential measure of the burden of IMD. The mortality 
associated with IMD has been well documented in disease surveillance reports especially 
in developed countries [2-6], and frequently discussed in review articles [7-11]. Key 
factors such as age and serogroup have been reported as important factors influencing 
IMD outcomes [2,7,9]. However, the CFR has not been quantified and key factors such 
as age and serogroup in estimating CFRs have yet to be explored in a meta-analysis. In 
this paper, we conducted a systematic review and meta-analysis to identify published 
contemporary evidence worldwide, to estimate the CFR, and to investigate the impact of 
age and serogroup on CFRs.   
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METHODS 
Search strategy and selection criteria 
A search of the literature was conducted using electronic databases: PubMed, Embase, 
and the Cochrane Library. Primary search strategies identified articles that reported the 
clinical and financial burden of IMD using the following keywords: meningococcal, 
meningococcal meningitis, meningococcal septicaemia, Neisseria meningitidis AND 
burden, costs, cost analysis, fees, hospital charges, economic model, economics, 
expenditure, utilisation, case fatality, complications, sequelae, morbidity, mortality, death 
rates, incidence, survival analysis, health status. The final search terms included 
combinations of Medical Subject Headings (MeSH)/Emtree and text words contained in 
the title and abstract (Supplementary Table 1). Only studies pertaining to CFRs are 
presented here (Figure 1). The systematic review regarding the financial burden 
associated with IMD was published elsewhere [12]. Grey literature available online was 
searched for relevant abstracts and/or posters from the following organisations: 
Meningitis Research Foundation, Infectious Diseases Society of America, International 
Pathogenic Neisseria Conference, European Society for Paediatric Infectious Diseases, 
International Congress on Infectious Diseases, World Society for Pediatric Infectious 
Diseases, and Australian Society for Infectious Diseases. Emails were sent to the first 
authors for additional information as required. Reference lists of relevant review articles 
[7,9,11] were searched for additional citations of interest. The search was conducted by 
one reviewer (BW) on 3 August 2016 and updated on 3 May 2018.  
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Figure 1: The Preferred Reporting Items for Systematic Reviews and Meta-analyses 
(PRISMA) flow diagram for article inclusion and exclusion 
 
* The full systematic review aimed to estimate clinical and financial burden of IMD. Only studies 

































Records identified through 
database searching (n=2548) 
Duplicates removed (n=178) 
Records excluded by title/abstract 
(n=2043) 
Full-text articles assessed for eligibility 
(n=344) Full-text articles excluded, with 
reasons (n=209): 
• NOT national CFR (n=80) 
• CFR reported only for IMD 
patients with specific syndromes 
(n=27) 
• No outcome of interest (n=69) 
• Results not presented for IMD 
patients specifically (n=14) 
• Full text not available (n=12) 
• Commentary (n=1) 
• Duplicates (n=5) 
• Review (n=1) 
Additional records identified through 
other sources and search updates (n=17) 
Studies reporting CFR included in quantitative synthesis (meta-analysis) (n=40) 
• Overall CFR (n=29) 
• CFR by serogroup (n=21) 
• CFR by age group (n=27) 
 
Studies included in systematic review 
(n=135*) 
Studies pertaining to CFR presented here 
(n=48) 
Records screened (n=2387) 
Studies excluded from quantitative 
synthesis (meta-analysis) because 
more comprehensive results reported 
in other articles using the same 
population (n=8) 
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The article selection process occurred in two phases: 1) title and abstract screen: titles 
and abstracts of articles identified from the electronic databases and from Internet 
searches were reviewed; 2) full text review: the full text of articles selected at the title and 
abstract screen were obtained and reviewed for eligibility. The screening process was 
completed according to a predefined protocol. 
 
Studies were eligible if national IMD CFRs were reported through primary data collection. 
Studies only reporting mortality resulting from a specific symptom of IMD (e.g. 
meningococcal meningitis) were excluded. Comments, letters, editorials, case reports, 
and reviews were excluded. Following the first publicly funded meningococcal C (MenC) 
vaccine program in the UK in 2000, several countries have added MenC vaccine onto 
their national immunisation programs. Since the epidemiology of IMD might be affected 
by the large scale implementation of MenC vaccine programs, the search was restricted 
to articles published from 1 January 2000 to 3 May 2018.Studies reported in languages 
other than English were excluded. Several national population or surveillance-based 
studies replicated data by containing patient populations which were completely included 
in other studies; in these instances, the publication with more comprehensive information 
presented was selected in meta-analyses to avoid double counting of evidence. 
 
Reporting and performing this review was guided by the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) 2009 statement [13] and meta-
analysis of observational studies in epidemiology guidelines [14]. All analyses were 
performed using Stata 14.2. This systematic review was registered with PROSPERO 
(CRD42016043213). 
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Data extraction and analysis 
Data were independently extracted by two reviewers (BW and RS). The following 
characteristics of each study were collected: type of study including study design, setting 
and study period, study population (sample size, mean or median age at illness, 
serogroup, case definition, etc.), country, follow-up duration, outcomes (sequelae, CFR 
and costs relevant to IMD), and funding.  
 
The Joanna Briggs Institute Critical Appraisal Tools were used to assess studies reporting 
the clinical burden of IMD including case-control, case series, cohort, quasi-experimental 
(non-randomised experimental studies), and randomised controlled studies [15]. Two 
independent reviewers (BW and RS) assessed the quality of studies, and any divergence 
between them was resolved through discussion. When disagreement was not resolved, 
senior researchers (HM and LG) were consulted. Through quality assessment, we found 
demographics and follow-up period of the study patients were not reported in a large 
number of studies. However, most studies reported national surveillance results and 
surveillance networks might receive limited demographic and follow-up information.  
 
Meta-analyses were performed for overall CFR and CFRs by serogroup. Heterogeneity 
was assessed statistically using the I2 statistic. Because substantial variability 
(heterogeneity) was expected across studies, a DerSimonian-Laird random-effects model 
was used [16]. 
 
Since we expected the relationship between CFRs and age to be non-linear, multilevel 
mixed-effects logistic regression (QR decomposition) with a restricted cubic spline was 
used to model CFRs as a function of age. As patient individual level data were not 
available, aggregate data for each age group in a study were used. The outcome measure 
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was the number of deaths observed in the study population recorded in binomial form, 
with denominator the number of IMD cases in the study population. We estimated the 
mean age for each age group using midpoint age of an age band if the true mean age 
was not presented. The model also included covariates: case definition, enrolment period, 
study and country. Different case definitions were used in various population studies and 
national surveillance networks, and therefore studies were classified into two groups: 
definite laboratory confirmed cases of IMD and notified cases of IMD. The notified cases 
of IMD included a combination of laboratory confirmed, probable and clinically diagnosed 
IMD. Studies were assigned to a decade in which most of study patients were enrolled if 
the study spanned more than one decade. For open-ended older age bands, an upper 
age limit of 99 years was chosen to calculate a midpoint of this age group, as the highest 
age limit of 99 years was used in the included study [17]. Studies were excluded from the 
regression analysis if the study population was only divided into two groups, adults and 
children, without specific age ranges.  
 
The model was adjusted by case definition and enrolment period as fixed effects, with 
study nested within country as nested random effects. Fixed effects were used for those 
variables based on the assumption of a constant effect across all studies. The enrolment 
period (decade of study) was removed from the final regression model due to a lack of 
statistical significance. The variables selected for random effects were assumed to have 
random intercepts normally distributed with common variance and population mean. The 
model allows for multi-levels of nested clusters of random effects, on the assumption that 
observations within the same cluster are correlated. This model structure was decided a 
priori based on previous research [1,18] and the assumption that CFR by age has the 
same shaped curvilinear relationship across countries but estimates in a specific country 
might be higher or lower than the mean value. The adequacy of models containing a 
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restricted cubic spline with different numbers and locations of knots were assessed using 
Akaike's information criterion (AIC). The restricted cubic spline with five knots placed at 
the ages of 0.5, 7, 17, 42 and 82 years based on Harrell's recommended percentiles [19] 
was chosen because of the lowest AIC. 
 
In sensitivity analyses, studies in French South Pacific Islands (New Caledonia) [20], 
Israel [21] and Kuwait [22] were excluded. Studies in European countries, Australia, the 
US and Canada were retained because these latter countries have comparable national 
surveillance systems. Saudi Arabia [23] was also excluded in the sensitivity analyses 
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RESULTS 
Forty-eight studies met inclusion criteria and reported national CFRs in 34 countries 
(Table 1). Seven studies [24-30] were not included in meta-analyses due to data 
overlapping with other published reports that were included in the meta-analyses. IMD 
cases in these seven studies were completely included in other studies. Another study 
was excluded from meta-analysis because all-cause mortality rates within the first year 
of diagnosis of IMD were reported [31]. One article was available as a conference abstract 
and additional information was provided by the first author [32]. In total, 11807 deaths 
were observed in 163758 IMD patients. Although the review was limited to articles 
published after 2000, the observation time reported in studies spanned the period from 
1974 to 2017 with most data reported from developed countries (e.g. the EU, the US, 
Canada, and Australia). Around half of studies (n=19, 47.5%) enrolled laboratory 
confirmed IMD patients only. Among 40 studies [2,4-6,17,20-23,32-62] included in the 
meta-analyses, 29 studies [4-6,17,20-23,32,34,35,38,42,43,45,46,48,49,51-58,60-62] 
were used to estimate the overall CFR with 21 studies [4-
6,17,20,23,32,33,39,44,46,48,49,52-56,58,61,62] used to derive pooled estimates of 
CFRs by serogroup, and 28 studies [2,4,17,20,21,23,33,35-37,39-43,47,48,50-55,58-62] 
used to examine the age effect on CFR. 
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Table 1: Characteristic of eligible studies identified through systematic review 




Study setting Case definition Serogroup 
Age 
group 
Sample size Case fatality rate 
1.  
Archer et al 
(2017) [33]  
Australia 1999-2015 
National surveillance 
based on notification 
and laboratory data 
Laboratory 
confirmed cases 
B & C All 4774 (B&C) 
By age and serogroup: <5 years: B: 5%, C: 5%; 5-9 
years: B: 2%, C: 8%; 10-14 years: B: 1%, C: 2%; 15-
24 years: B: 2%, C: 6%; 25+ years: B: 6%, C: 12%; 
all ages: B: 4%, C: 8% 
2.  
Baker et al 





based on notification 




All All 3547  Overall: 4.5%; laboratory confirmed cases: 4.9% 
3.  
Ben-Shimol 
et al (2013) 
[21] 
Israel 1989-2010 









Overall: 9.9%; by age: <1 year: 9.2%, 1–4 years: 




al (2004) [35] 
Australia 2001-2002 
National surveillance 
based on notification 







All All 1355 
88 deaths in 1355 cases; by age: 0-4 years: 26/393, 
5-14 years: 8/213, 15-24 years: 21/391, 25-59 years: 
24/286, 60+ years: 9/72 
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Study setting Case definition Serogroup 
Age 
group 
Sample size Case fatality rate 
5.  
Brotherton et 
al (2007) [36] 
Australia 2003-2005 
National surveillance 
based on notification 








69 deaths in 1355 cases in 2003-2005; 46 deaths in 
955 cases in 2003-2004 (using IMD notification 
numbers reported from national notifiable diseases 
surveillance system): 0-4 years: 12/292, 5-14 years: 
1/116, 15-24 years: 12/273, 25-59 years: 10/199, 60+ 
years: 11/74 
6.  




based on notification 








32 deaths in 700 cases in 2005-2006 (using IMD 
notification numbers reported from national notifiable 
diseases surveillance system): 0-4 years: 15/242, 5-
14 years: 2/84, 15-24 years: 3/177, 25-59 years: 
7/153, 60+ years: 5/44; 21 deaths in 622 cases in 
2006-2007 
7.  
Cizman et al 
(2001) [38] 
Slovenia 1993-1999 
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Study setting Case definition Serogroup 
Age 
group 
Sample size Case fatality rate 
8.  



















Overall: 10%; by age: <1 year: 45/482, 1-3 years: 
15/397, 4-11 years: 12/272, 12-17 years: 33/315, 18-
20 years: 7/90, 21-60 years: 40/274, 61+ years: 
18/59; by serogroup: A: 0/1, B: 62/1010, C: 94/616, 
Y: 0/8, W: 2/31, ungrouped: 10/202 
9.  








2005 - 2011 
National surveillance 
based on notification 












Overall: 7.8%; by age: <1 year: 2/4, 1-4 years: 2/12, 
5-9 years: 0/10, 10-14 years: 0/11, 15-19 years: 0/10, 
20-24 years: 0/9, 25-34 years: 0/1, 35-44 years: 1/2; 
45-54 years: 0/1, 55-64 years: 0/3, 65-74 years: 0/2, 
75+ years: 0/1; by serogroup: B: 3/29 
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Study setting Case definition Serogroup 
Age 
group 
Sample size Case fatality rate 
10.  








based on notification 














CFRs in estimated laboratory confirmed cases by 
age: <1 year: 5.3%, 1-4 years: 7.3%, 5-9 years: 4.7%, 
10-14 years: 7.9%, 15-19 years: 13.9%, 20-24 years: 
12.9%, 25-29 years: 14.6%, 30-34 years: 13.3%, 35-
39 years: 17.9%, 40+ years: 18.3% 
11.  
de Greeff et 











All All 752 Overall: 6.7%; by serogroup: B: 6.3%, C: 5.2% 
12.  




based on notification 




All All 1015 
Overall: 48/1015; by age: <1 year: 10/163, 1-4 years: 
5/184, 5-14 years: 1/118, 15-24 years: 9/266, 25-49 
years 10/154, 50-64 years: 5/77, 65+ years: 8/53  
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Study setting Case definition Serogroup 
Age 
group 
Sample size Case fatality rate 
13.  









All All 4619 
30-day CFR: 4.5%; overall CFR (after 30 days): 
4.7%; by age: <1 year: 3.3%, 1-4 years: 3.0%, 5-14 
years: 2.2%, 15-24 years: 5.4%, 25-44 years: 3.7%, 
45-64 years: 4.7%, 65+ years: 18.0%; by serogroup: 
B: 4.2%, C: 3.4%, W: 9.5%, Y: 9.9%, other: 0.7% 
14.  
Gil-Prieto et 
al (2011) [42] 
Spain 1997-2008 
National surveillance 










All All 11611 
Overall: 7.3%; by age: <1 year: 5.2%, <2 years: 
5.1%, 0-4 years: 5.0%, 5-9 years: 3.6%, 10-14 years: 
4.6%, 15-19 years: 8.7%, 20-24 years: 9.5%, 25-29 
years: 10.2%, 30-49 years: 9.8%, 50-54 years: 
12.6%, 55-59 years: 12.4%, 60-64 years: 15.1%, 65-
69 years: 15.2%, 70-74 years: 14.7%, 75-79 years: 
20.2%, 80-84 years: 29.5%, 85+ years: 37.7%  
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Study setting Case definition Serogroup 
Age 
group 
Sample size Case fatality rate 
15.  
Goldacre et 











on ICD codes 
All All 19113 
30-day CFR: 4.9%; by age: <1 year: 3.0%, 1-4 years: 
2.9%, 5-9 years: 1.6%, 10-14 years: 3.8%, 15-19 
years: 5%, 20-24 years: 4.1%, 25-29 years: 5.5%, 
30-34 years: 7.2%, 35-39 years: 8.7%, 40-44 years: 
8.0%, 45-49 years: 9.5%, 50-54 yeas: 7.5%, 55-59 
years: 14.3%, 60-64 years: 12.9%, 65-69 years: 








based on notification 
and laboratory data 
Laboratory 
confirmed cases 
All All 362 




et al (2011) 
[45] 
Iceland 1975-2004 Population based study 
Laboratory 
confirmed cases 
All All 541 30-day CFR: 7.9% 
18.  












All All 21712 
Overall: 6.7%; by serogroup: B: 5.1%, C: 11.6%, 
others: 5.0% 
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Study setting Case definition Serogroup 
Age 
group 
Sample size Case fatality rate 
19.  
Hanquet et 
al (2014) [47] 
Belgium 2004-2010 
National surveillance 





All All 933 
Overall: 7.0%; by serogroup: B: 5.4%, C: 15.6%; by 
age: <1 year: 6.7%, 1‐4 years: 4.9%, 5‐9 years: 3.2%, 
10‐19 years: 4.2%, 20‐64 years: 10.3%, 65+ years: 
16.3% 
20.  




based on notification 






All All 5924 
31-day CFR: 7.6%; by age: <1 year: 5.9%, 1–4 years: 
7.5%, 5–9 years: 3.5%, 10–19 years: 5.6%, 20–49 
years: 9.4%, 50+ years: 17.9%; by serogroup: A: 
3.9%, B: 7.9%, C: 9.1%, W: 10.3%, other known: 
17.0% 
21.  







All All 293 13.5% 
22.  







based on notification 
and laboratory data 
Laboratory 
confirmed cases 
W All 79 11% 
23.  






based on notification 
and laboratory data 
Laboratory 
confirmed cases 
B, W All 
215 (B); 138 
(W) 
W: 12%, B: 4% 
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Study setting Case definition Serogroup 
Age 
group 
Sample size Case fatality rate 
24.  








based on notification 
and laboratory data 
Laboratory 
confirmed cases 
All All 5471 
Overall: 5.3%; by serogroup: B: 5.2%, C: 9.9%, Y: 
9.2%, W: 5.5% 
25.  







based on notification 
and laboratory data 
Laboratory 
confirmed cases 
Y All 143 
19% for all MenY cases in 2009; 13% for 114 
genotypically characterized isolates in 2007-2009 
26.  








based on notification 
and laboratory data 
Laboratory 
confirmed cases 
W All 270 
Number of death: 30/270; by age: <5 years: 2/65; 5-
19 years: 5/43, 20-44 years: 5/35, 45-64 years: 4/49, 
65+ years: 14/78 
27.  




based on notification 




All All 7924 
Overall: 14.9%; by age: <1 year: 8.6%, 1 year: 5.9%, 
2-4 years: 11.8%, 5-10 years: 10.5%, 11-15 years: 
11.5%, 16-20 years: 14.3%, 21-25 years: 16.7%, 26-
44 years: 16.8%, 45-64 years: 16.9%, 65-84 years: 
17.4%, 85+ years: 28.0%; by serogroup: B: 11.5%, 
C: 20.2%, W: 20.9%, Y: 13.7% 
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Study setting Case definition Serogroup 
Age 
group 
Sample size Case fatality rate 
28.  




based on notification 





3720 (all IMD); 
159 (W) 
Overall: 4.7%; by serogroup: B: 4.2%, C: 9.1%, W: 
10.7%, Y: 4.1% 
29.  
McDonald et 





based on notification 
and laboratory data 
Laboratory 
confirmed cases 
B All 1028 B: 5.7%  
30.  
McIntyre et 
al (2002) [51] 
Australia 1998-2000 
National surveillance 
based on notification 










103 deaths in 1655 cases (1998-2000) (using IMD 
notification numbers reported from national notifiable 
diseases surveillance system in 1998): 0-4 years: 
33/588, 5-14 years: 8/208, 15-24 years: 25/492, 25-
59 years: 28/289, 60+ years: 9/78 
31.  










All All 1103 
Overall: 18.0%; by age: <1 year: 6.8%, 1-4 years: 
9.4%, 5-14 years: 9.3%, 15-45 years: 19.4%, 46+ 
years: 32.6%; by serogroup: A: 21.8%, B: 21.2%, C: 
20%, W: 19.7%, Y: 33.3% 
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Study setting Case definition Serogroup 
Age 
group 
Sample size Case fatality rate 
32.  










on ICD codes 
All All 9479 
Overall: 6.5%; by age: 0-4 years: 4.7%, 5-9 years: 
3.4%, 10-14 years: 3.8%, 15-19 years: 7.9%, 20-24 
years: 8.7%, 25-29 years: 11.8%, 30+ years: 12.2% 
33.  










All All 233 
Overall: 12%; by age: < 1 year: 7 %, 1-9 years: 6 %, 
10-19 years: 13 %, 20-44 years: 13 %, 45+ years: 
23 %; by serogroup: B: 13/87, C: 5/18 
34.  
Parent du 










All All 5894 
Overall: 10.4%, by age: <1 year: 9.9%, 1-4 years: 
8.9%, 5-14 years: 5.9%, 15-24 years: 10.3%, 25-59 
years: 9.3%, 60+ years: 20.0%; by serogroup: B: 
8.8%, C: 13.2%, W: 11.9%, Y: 15.5% 
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Study setting Case definition Serogroup 
Age 
group 
Sample size Case fatality rate 
35.  








based on notification 
and laboratory data 
Laboratory 
confirmed cases 
All All 3411 
28-day CFR: 6.9%; by age: <1 year: 4.0%, 1-4 years: 
4.8%, 5-14 years: 4.8%, 15-24 years: 6.2%, 25-44 
years: 7.8%, 45-64 years: 6.3%, 65-74 years: 12.7%, 
75-84 years: 17.0%, 85+ years: 31.9%; by 
serogroup: B: 5.4%, C: 10.1%, W: 11.9%, Y: 12.1% 
36.  
Perrocheau 













Overall: 14.0%; by age: < 2 years: 15.3%, 2-14 years: 
11.2%, 15-24 years: 9.6%, 25-99 years: 21.1%; by 
serogroup: B: 11.3%, C: 17.9%, W: 20.0% 
37.  








All All 60 20.0%  
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Study setting Case definition Serogroup 
Age 
group 
Sample size Case fatality rate 
38.  










on ICD codes 
All All 5356 
All-cause mortality: within the first year of diagnosis 
of IMD: 8.3%; during the observation period: 6.4%: 
overall mortality rate ratio (MRR): 1.27 (95%CI: 1.12-
1.45), adjusted MRR: 1.21 (95%CI: 1.06-1.37), 
adjusted MRR for death due to nervous, digestive 
and genitourinary system diseases, respectively: 
3.15 (95%CI: 1.59-6.23), 1.99 (95%CI: 1.16-3.43), 
6.26 (95%CI: 1.58-24.81) 
39.  











All All 626 
Overall: 9.1%; by age: <1 year: 6.8%, 1-4 years: 
15.1%, 5-9 years: 2.8%, 10-19 years: 4.0%, 20-29 
years: 11.9%, 30+ years: 12.2%; by serogroup: B: 
8.3%, C: 8.5%, other or unknown: 10.8% 
40.  
Sadarangani 







All All 868 
Overall: 8.4%; by serogroup: A: 50.0%, B: 6.1%, C: 
12.8%, W: 8.7%, Y: 9.5% 
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Study setting Case definition Serogroup 
Age 
group 
Sample size Case fatality rate 
41.  
Schrauder et 
al (2007) [57] 
Germany 2003 
National surveillance 
based on notification 































based on notification 




All All 12074 
Overall: 5.8%; laboratory confirmed cases: 8.2%; 
probable cases: 2.5%; laboratory confirmed CFR by 
age: <1 year: 6.1%, 1-4 years: 4.3%, 5-14 years: 
4.8%, 15-17 years: 7.6%, 18+ years: 15.3%; by 
serogroup: B: 5.8%, C: 13.8%, W: 15.0% 
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Study setting Case definition Serogroup 
Age 
group 
Sample size Case fatality rate 
43.  
Skoczynska 




based on notification 






During the period 2010-2011, overall: 10.0%; by age: 
0-5 years: 10.3%, 5-9 years: 12.5%, 10-14 years: 
5.6%, 15-19 years: 3.7%, 20-24 years: 15.4%, 25-44 
years: 7.9%, 45-64 years: 2.9%, 65+ years: 46.2%; 
by serogroup: B: 10.3%, C: 8.8% 
44.  




based on notification 






All All 439  
Overall: 8.9%; by serogroup: B: 5.4%, C: 12.4%, Y: 
14.3%, others: 4.8%, clinical cases: 9.2%; number of 
death by age group for the year 1997 and 1998, 
respectively: <1 year: 1/47, 0/21; 1-4 years: 4/43, 
0/39; 5-14 years: 1/39, 1/20; 15-19 years: 6/39, 1/24; 
20-64 years: 9/73, 9/54; 65+ years: 6/24, 1/14 
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Study setting Case definition Serogroup 
Age 
group 
Sample size Case fatality rate 
45.  




based on notification 







805 (214 in 
1999, 241 in 
2000, 350 in 
2001) 
Overall: 10.7%, 8.7%, and 9.4% in 1999, 2000, and 
2001 respectively; in 1999 by age: <1 year: 2.6%, 1-
4 years: 8.30%, 5-9 years: 15.4%, 10-14 years: 
20.0%, 15-19 years: 6.5%, 20-24 years: 12.5%, 25-
64 years: 15.4%, 65+ years: 18.7%; in 2000 by age: 
<1 year: 10.5%; 1-4 years: 4.0%; 5-9 years: 11.8%; 
10-14 years: 10.0%; 15-19 years: 6.0%; 20-24 years: 
3.8%; 25-64 years: 12.3%, 65+ years: 11.1%; in 2001 
by age: <1 year: 10.0%, 1-4 years: 9.1%, 5-9 years: 
9.1%, 10-14 years: 6.2%, 15-19 years: 2.6%, 20-24 
years: 6.5 %, 25-64 years: 15.2%, 65+ years: 15.2% 
46.  
Steindl et al 
(2011) [30]  
Austria 2010 
National surveillance 
based on notification 
and laboratory data 
laboratory 
confirmed cases 
All All 80 12.5% 
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Study setting Case definition Serogroup 
Age 
group 
Sample size Case fatality rate 
47.  











All All 939 
30-day CFRs: 8%; by age: 0-6 months: 2%, 6-24 
months: 7%, 2-4 years: 5%, 5-9 years: 4%, 10-19 
years: 4%, 20-64 years: 8%, 65+ years: 39%; by 
serogroup: B: 8%, C: 9%, W: 13%, Y: 13% 
48.  
Whittaker et 
al (2017) [6] 
EU 2004-2014 
National surveillance 




All All 41206 
Overall: 8.6%; by serogroup: B: 7.4%, C: 14.3%, W: 
10.3%; Y: 10.2% 
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The overall CFR was estimated to be 8.3% and the included studies were very 
heterogeneous (I2=96.3% (95% confidence interval (CI): 95.7%-96.8%)) (Supplementary 
Figure 1). Among 21 studies, 19 [4,6,17,20,23,32,33,44,46,48,49,52-56,58,61,62] 
reported CFRs in MenB cases (n= 67324) (Figure 2A); 17 [4,6,17,20,23,33,44,46,48,52-
56,58,61,62] reported CFRs in MenC cases (n=18954) (Figure 2B); 13 [4-
6,17,23,39,48,49,53,54,56,58,62] reported CFRs in serogroup W (MenW) cases (n= 
3017) (Figure 2C); 10 [4-6,23,39,53,54,56,61,62] studies reported CFRs in serogroup Y 
(MenY) cases (n= 3356) (Figure 2D). The pooled estimate of MenB CFR was lower than 
serogroups W, C and Y. Heterogeneity reduced when meta-analyses were stratified by 
serogroup, especially in MenW and MenY cases. The number of serogroup A (MenA) 
cases was low in the identified studies. Only two of six studies enrolled more than ten 
MenA cases with CFRs ranging from 3.9% [48] to 21.8% [23]. Therefore, meta-analysis 
was not performed for MenA disease. 
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CFRs by age group were reported in 28 studies, including 83649 IMD cases. Among 
those cases, 22308 were definite laboratory confirmed cases with 61341 were defined as 
notified IMD cases (a combination of laboratory confirmed, probable and/or clinically 
diagnosed cases). Besides the variables created for the spline function of age, the type 
of case definition was significantly associated with CFR, after adjusting the nested 
random-effects of country and study (likelihood ratio test P<0.0001). At a given age, the 
chance of death for patients with laboratory confirmed IMD was double in comparison 
with those notified IMD cases (Table 2). The estimated variance in CFRs was higher for 
between studies than between countries. For laboratory confirmed cases, the predicted 
CFRs were highest in Saudi Arabia and lowest in Australia.  
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Table 2: Fixed and random effect estimates from the main analysis 
Fixed effect parameter estimates: 
 Estimates 95%CI (p value) 
Notified IMD cases (a 
combination of laboratory 
confirmed, probable or 
clinically diagnosed 
cases) 
OR: 1  
Laboratory confirmed IMD 
cases 
OR: 1.906 1.491-2.434 (p<0.0001) 
Random effect parameter estimates 
Country Variance: 0.080 0.020-0.331 
Study Variance: 0.127 0.057-0.284 
 
Predicted CFRs by age were non-linear (Figure 3). Predicted CFRs for laboratory 
confirmed cases decreased from 9.0% in infants to 7.0% in 7-year olds, stayed stable in 
children aged 7-10 years, gradually increased to 10.4% in adolescents aged 16 years, 
reached a peak of 15.0% in young adults aged 28 years, remained steady in adults aged 
between 28 and 45 years, rose rapidly in older adulthood, and reached 32.8% in 80-year 
olds (Supplementary Table 2). 
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Figure 3: Estimates of CFR by age  
3A 
 
—— Fitted values for laboratory confirmed IMD cases 95%CI █ 
─  ─ Fitted values for notified IMD cases  
3B 
 
○ Observed CFRs  —— Fitted values  95%CI █ 
The size of circles is proportional to the number of cases included in each study, with the 
larger circles indicating a larger sample size.  
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In the sensitivity analysis of studies reporting CFRs by age in the EU, the US, Canada 
and Australia only (n=25), laboratory confirmation of case was still a significant factor 
affecting CFRs (odd ratio (OR): 1.92; 95%CI: 1.48-2.49; p<0.0001). However, the 
predicted CFRs tended to be slightly lower in general compared with the main analysis, 
increasing to 10.1% in 16-year olds, remaining stable through young adulthood, and 
increasing to 32.2% in elderly patients aged 80 years. Similar to the main analysis, 
variation in CFRs was still lower between countries (0.092; 95%CI: 0.019-0.445) than 
between studies (0.137; 95%CI: 0.058-0.322).  
 
After removing studies in New Caledonia, Israel, Kuwait and Saudi Arabia, the pooled 
estimates of overall, MenB and MenY CFRs were slightly lower: 7.8% (95%CI: 7.0%-
8.6%; I2=96.3% (95%CI: 95.6%-96.8%)), 6.8% (95%CI: 5.9%-7.6%; I2=92.7% (95%CI: 
90.3%-94.3%)), 10.6% (95%CI: 8.1%-13.2%; I2=69.8% (95%CI: 19.2%-83.7%)), 
respectively. The pooled estimate of the MenW CFR dropped from 12.8% to 11.3% 
(95%CI: 10.1%-12.5%; I2=0.0% (95%CI: 0.0%-49.8%)). The pooled estimate of MenC 
CFR stabilised at 12.0% (95%CI: 10.4%-13.5%; I2=85.7% (95%CI: 77.8%-89.8%)). 
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DISCUSSION 
This is the first meta-analysis to estimate the CFR and to quantitatively examine the effect 
of age and serogroup on CFRs. 
 
The meta-analysis showed the greatest CFRs in MenW and MenC cases, which 
highlighted the significant impact of the recent increase in incidence of MenW disease in 
many countries. After removing fatality data reported in the Saudi Arabia, the pooled 
MenW CFR decreased and became lower than MenC in the sensitivity analysis. The 
reduction in the pooled estimate may reflect very high fatality associated with the MenW 
outbreak during Hajj in Saudi Arabia [63]. As we expected, a high level of heterogeneity 
was found in the synthesis of overall CFR. After analyses stratifying by serogroup, 
heterogeneity reduced especially in cases due to serogroup W and Y disease. This 
finding is reassuring as we expected serogroup was an important factor in predicting 
CFRs. However, heterogeneity was still high in MenB related cases. In our review, almost 
70% of IMD cases were caused by MenB disease with diverse age groups and study 
design reflecting the epidemiology of MenB disease. Especially for endemic MenB 
disease, organisms causing the infection are genetically diverse, which may explain the 
heterogeneity in CFRs [64]. Previous research has demonstrated that certain 
serotypes/serosubtypes and clonal complexes were associated with a higher CFR [65-
68]. For example, MenC disease of the phenotype 2a:P1.2,5 was associated with an 
increased risk of mortality [48]. MenW disease has traditionally been caused by strains of 
the ST-22 clonal complex which is usually associated with fatal disease outcomes in the 
elderly population. However, the recent rise in cases of MenW disease, which is caused 
by strains of the ST-11 clonal complex in many countries, can also be fatal in children 
and young adults [50]. 
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Although the disease incidence peaks in infants and IMD remains a leading infectious 
cause of death in early childhood in developed countries [69], our regression model 
indicated that CFRs were lower in infants compared to adolescents and young adults. In 
addition to the highest carriage rate estimated in young adults aged 19 years [1], our 
finding of an increased CFR in young adults would help researchers and policy makers 
to further understand the potential impact of vaccination strategies. CFR doubled with 
age from 15% in young adults to 30% in those aged around 75 years. Reasons for the 
significant variation in CFR by age are not fully understood [9]. Higher prevalence of 
serogroup W and Y disease was observed in older people especially with underlying 
medical conditions [5,27,50,70,71]. The highest mortality rate may be explained by 
predominant serogroups and frailty. The highest CFR in elderly patients may also be 
associated with delay in appropriate treatment, because the symptoms may be more 
difficult to recognise in frail older patients coupled with a relatively lower prevalence of 
IMD in this age group. Moreover, factors related to host may explain different CFRs. For 
example, previous research reported genetic factors were clearly associated with 
mortality and severe outcomes of meningococcal disease [72-73]. 
 
Our regression model showed an increased variance between studies compared with 
between countries. After removing data collected in Israel, New Caledonia and Saudi 
Arabia in sensitivity analysis, the results still revealed the same trend. Although we did 
not limit our search to Western countries, most included studies were conducted in 
developed countries. The low variance between countries might be due to similar 
healthcare setting and comparable epidemiological transition across developed countries. 
Case definitions used by different studies varied substantially. For example, some studies 
[2,42] enrolled patients based on ICD codes at hospital discharge without laboratory 
confirmation; some studies used national surveillance or notification data. Even for 
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surveillance data, a number of studies [23,44,55] restricted IMD notification to laboratory 
confirmed cases, but several studies had included probable or clinically diagnosed cases 
[34-37,60,61]. Furthermore, laboratory confirmed cases were defined inconsistently in 
different studies [8]. Although our regression model was adjusted by case definition and 
we only categorised case definitions into two groups, variation between studies may still 
result from inconsistent case definitions used in different studies. Our regression model 
could not be adjusted by serogroup due to very limited serogroup data for each age group. 
Although we only included papers published after 2000, the enrolment period still 
spanned from 1974 to 2015 for included studies. The decade of study was not statistically 
significant in our initial regression model, which may support previous research [48,74] 
and confirm CFR has not significantly decreased despite improvements in diagnostic 
techniques, clinical management and healthcare access. This is likely to be due to the 
pathophysiology of the disease process with an overwhelming effect of the cytokine storm 
limiting effectiveness of current treatment strategies. 
 
We aimed to estimate CFR with minimum bias by searching publications and grey 
literature, contacting authors for additional information, and not restricting our search to 
developed countries. However, national surveillance networks are well established in 
developed countries, but very little data were identified from developing countries in Asia 
and South America. Countries with high endemic rates of IMD in Africa often reported 
mortality data associated with meningococcal meningitis only. Those studies were not 
included in this review as per the inclusion and exclusion criteria. The CFRs may be 
generally underestimated, as timely, reliable, and affordable health services may not be 
available in some countries especially in remote areas, which could substantially increase 
mortality from IMD [9]. Also, sudden deaths caused by IMD without hospitalisation were 
not considered in most studies. As notification or hospital discharge data were usually 
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used to identify IMD cases, those studies only included IMD patients who were admitted 
to hospital. Goldacre et al. found 616 deaths with meningococcal disease as a cause on 
the death registration record but those deaths did not have a corresponding hospital 
admission in a UK study [43]. During the same study period, 940 deaths occurred within 
30 days after hospital admissions. The true mortality rate of IMD might be much higher 
than we estimated. A large proportion of CFR data were collected in young children aged 
less than 5 years. The concentration of data on this age group is likely to be due to the 
incidence peaking in young children. Only articles published in English were included 
which may result in publication bias. Historically N. meningitidis serogroup A has been 
the cause of the epidemics in the meningitis belt of sub-Saharan Africa. Since eligible 
studies in our review were conducted in non-African countries, the number of studies 
reporting MenA cases was small and most studies only enrolled one or two patients. 
Therefore, the meta-analysis was not performed for serogroup A related disease. 
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CONCLUSIONS 
Despite those limitations and differences between countries, our review explored factors 
influencing CFR and emphasised the importance of age and serogroup as key factors 
determining CFRs by using different meta-analytic techniques. Our meta-analyses can 
provide clear, informative and contemporary results, advance our understanding of the 
disease burden and epidemiology of IMD, and assist in evaluating the potential benefits 
of new meningococcal vaccine programs.  
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Supplementary Table 2: Estimates of CFR by age for laboratory confirmed IMD cases 
only 
Age Predicted CFR (%) 95%CI (%) 
1 9.0 6.8-11.3 
2 8.5 6.4-10.6 
3 8.0 6.0-10.1 
4 7.7 5.7-9.6 
5 7.3 5.5-9.2 
6 7.1 5.3-9.0 
7 7.0 5.2-8.9 
8 7.1 5.2-8.9 
9 7.2 5.3-9.1 
10 7.4 5.5-9.4 
11 7.8 5.8-9.7 
12 8.2 6.1-10.2 
13 8.6 6.5-10.8 
14 9.2 6.9-11.5 
15 9.8 7.4-12.2 
16 10.4 7.8-12.9 
17 11.0 8.3-13.6 
18 11.5 8.7-14.3 
19 12.1 9.2-15.0 
20 12.6 9.6-15.6 
21 13.0 9.9-16.1 
22 13.4 10.2-16.6 
23 13.8 10.5-17.1 
24 14.1 10.8-17.5 
25 14.4 11.0-17.8 
26 14.7 11.2-18.1 
27 14.9 11.4-18.4 
28 15.0 11.5-18.6 
29 15.2 11.7-18.7 
30 15.3 11.7-18.8 
31 15.4 11.8-18.9 
32 15.4 11.9-19.0 
33 15.5 11.9-19.1 
34 15.5 11.9-19.1 
35 15.5 11.9-19.1 
36 15.5 12.0-19.1 
37 15.5 12.0-19.1 
38 15.5 12.0-19.1 
39 15.6 12.0-19.1 
40 15.6 12.0-19.2 
41 15.6 12.0-19.2 
42 15.7 12.0-19.3 
43 15.7 12.1-19.3 
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44 15.8 12.2-19.5 
45 15.9 12.3-19.6 
46 16.1 12.4-19.8 
47 16.2 12.5-19.9 
48 16.4 12.6-20.2 
49 16.6 12.8-20.4 
50 16.8 13.0-20.6 
51 17.0 13.2-20.9 
52 17.3 13.4-21.2 
53 17.6 13.6-21.5 
54 17.9 13.8-21.9 
55 18.2 14.1-22.3 
56 18.5 14.4-22.7 
57 18.9 14.7-23.1 
58 19.3 15.0-23.5 
59 19.7 15.3-24.0 
60 20.1 15.7-24.5 
61 20.5 16.1-25.0 
62 21.0 16.5-25.5 
63 21.5 16.9-26.1 
64 22.0 17.3-26.6 
65 22.5 17.8-27.2 
66 23.1 18.2-27.9 
67 23.6 18.7-28.5 
68 24.2 19.2-29.2 
69 24.8 19.8-29.9 
70 25.5 20.3-30.6 
71 26.1 20.9-31.3 
72 26.8 21.5-32.1 
73 27.5 22.1-32.9 
74 28.2 22.7-33.7 
75 28.9 23.3-34.5 
76 29.6 24.0-35.3 
77 30.4 24.6-36.2 
78 31.2 25.3-37.1 
79 32.0 26.0-37.9 
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Supplementary Figure 1: Forest plot for the overall CFR 
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3.1.2 SEQUELAE ASSOCIATED WITH MENINGOCOCCAL DISEASE 
The burden of IMD was systematically reviewed (See Appendix: IMD systematic review 
protocol) including mortality and sequelae. In the previous section, the mortality due to 
IMD was reviewed and quantitatively synthesised. Published evidence of sequelae 
associated with IMD was systematically reviewed and presented in this section. With 
earlier diagnosis and prompt treatment, outcomes for most IMD patients are good. 
However, IMD can cause permanent and devastating disabilities. Viner et al found 9% of 
children infected with MenB had potentially lifelong deficits such as severe cognitive 
disabilities, seizures, hearing loss, motor impairment, visual loss, or major communication 
disability [98]. Symptoms of fatigue and headache may persist for months after acute 
illness [96]. Up to 58% of adolescents had minor and major sequelae following the 
disease [22].  
 
Most commonly reported sequelae are arthritis, chronic migraine, neurocognitive 
sequelae, hearing loss, seizures/epilepsy, speech and communication problems, and 
amputation. As the definition of sequelae, serogroups of the disease, follow-up period, 
study population and study design varied significantly across studies, published evidence 
of sequelae/complications associated with IMD were not quantitatively synthesised. 
Furthermore, the quality of healthcare services in different countries may impact the 
outcomes of the disease. Results derived from studies with small sample sizes often 
produce wide variance [99]. Therefore, only studies conducted in developed countries 
with large sample sizes are discussed here. 
 
Neurocognitive sequelae 
Hearing loss, vision impairments, seizures 
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Those sequelae were often reported separately in the literature. Hearing loss, 
impairments or deficits were observed in 1.9% [100] - 12.9% [101] of IMD patients. IMD 
patients were interviewed 1 - 3 years post infection in a UK study. There were 65 out of 
504 (12.9%) patients stating they had sustained hearing loss [101]. By searching ICD 
codes relevant to hearing loss, a Danish study found 44 of 2286 (1.9%) IMD patients 
experienced hearing loss [100]. In a case-control study (MOSAIC), pure tone audiometric 
tests were performed for children infected with MenB disease and controls [98]. It was 
found that 15/232 cases (6.5%) and 4/318 controls (1.3%) had hearing loss ≥20 db. 
Blindness or visual impairments were reported in 0.3% [102] - 8.7% [101] of IMD patients. 
The MOSAIC study identified 1/239 (0.4%) had registered blindness with no blindness in 
controls [98]. Darton et al reported that the percentage of self-reported vision impairment 
was 44/506 (8.7%) [101]. The rates of self-perceived hearing/vision impairments are 
much higher than the rates of impairments documented in medical records or detected in 
the studies.  
 
It was estimated that 0.6% [103] - 13.9% [104] of IMD patients had seizures/epilepsy. In 
a retrospective study conducted in Iceland, epilepsy was less common (3/541; 0.6%) than 
either hearing loss (14/541; 2.6%) or renal failure (15/541; 2.8%) [103]. However, two US 
studies that employed searches of ICD codes reported epilepsy/seizure was one of the 
most common complications associated with IMD, with seizures (11.7% [105] - 13.9% 
[104]) and epilepsy (5.8% [104] - 7.0% [105]) affecting notable proportions of patients.   
 
Other neurocognitive impairments 
Depending on definitions of neurocognitive sequelae, sample sizes, study population and 
study design, the rates of other neurocognitive impairments varied between 1.7% [106] 
and 10.9% [107], including brain injuries [102,106], motor deficits/motor disabilities 
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[12,22,102,107], impaired muscle functions [108], brain nerve damage [108], paresthesia 
[108], developmental delay [109], etc. Chronic migraine (0.6% [103] - 4.6% [97]) was also 
reported in two studies through medical note review [96,103].  
 
Musculoskeletal sequelae 
Amputation following septicaemia was observed in 1 - 3% of IMD patients. The severity 
of amputation ranged from digit amputation to multiple limb amputation. The rate of 
multiple limb amputation was less frequent (0.5% [102] - 0.8% [110]). Limb 
deficiency/deformities were often reported in children with meningococcal septicaemia or 
septic shock [12,111-113]. Lower limb-length discrepancy occurred in 7 of 120 (6%) 
children with meningococcal septic shock [112]. It was also reported that 16 of 122 
children (13.1%) with meningococcal septicaemia experienced physeal growth arrests 
[113]. Almost ten percent of IMD patients experienced arthritis. Although all patients 
recovered, some of them required long-term steroid treatment [114]. 
 
Dermatological sequelae 
Skin scars with or without graft resulting from skin necrosis were commonly reported in 
the literature. Depending on the method of identification (through medical note review or 
ICD code search) and definition of skin scarring (with or without grafting), the sequelae 
rate of skin scarring ranged from 0.9% [108] - 18.0% [102].  
 
Renal sequelae 
Bettinger et al found that children (3.6%) were significantly less likely to experience renal 
dysfunction compared with adults (33%), which may explain a lower proportion of renal 
impairment observed in paediatric patients [96,109]. The frequency of renal sequelae 
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including renal dysfunction, acute renal failure, chronic renal failure and renal 
insufficiency have been reported from 0.4% [115] to 8.7% [104]. 
 
Psychological sequelae 
In a qualitative study, one patient recalled that when he was sent to the intensive care 
unit, all of his father’s hair went grey overnight because of the sudden stress of his child 
having a life-threatening infection [116]. However, limited research has been conducted 
to assess the psychological impact of IMD in patients [98,106,117-119] and their families 
[120]. In the Netherlands, Vermunt et al assessed psychological and behavioural 
problems in paediatric patients with septic shock [117-119]. Their study results indicated 
the younger the child at the time of the disease, the more problems were reported by their 
patients after four years following the infection [118]. Scars were a significant predictor of 
unfavourable outcomes on social acceptance or close friendship [119]. Anxiety disorders 
(e.g. generalised anxiety disorder, social phobia, separation anxiety disorder), post-
traumatic stress disorder, behavioural and emotional disorders (oppositional defiant 
disorder, conduct disorder) and attention deficit hyperactivity disorder (ADHD) have been 
reported in those studies. ADHD was also reported to be potentially associated with 
bacterial meningitis [121]. Fellick et al reported three cases (2.6%) and one control were 
formally diagnosed with ADHD by using Connor’s Rating Scales–Revised assessment 
tool [106]. Viner et al identified ADHD at 50% probability or more in 17 cases (11.4%) and 
4 controls by using a development and wellbeing assessment tool [98]. A diagnosis of 
ADHD can be controversial and cannot be made with a single tool or test. In the research 
setting, the percentage of real ADHD cases may be subject to uncertainties in the 
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Devastating long-term disabilities can result from IMD. However, this systematic review 
found most patients were followed up less than five years in the included studies. 
Psychological problems caused by the acute infection and long-term disabilities may be 
under-recognised in patients and their family members. Diversity in sample size, study 
population, follow-up period, data collection methods, and definition of sequelae may be 
partly responsible for the significant heterogeneity in study results. For example, the rate 
of patient-perceived hearing loss is much higher than the rate of hearing loss confirmed 
by audiology tests during the study. Only a very limited number of studies prospectively 
followed patients and performed hearing, psychological, or neurocognitive tests. The 
MOSAIC study provided informative estimates of the range of disabilities experienced by 
children who had MenB. Since the incidence of MenW disease has continuously 
increased, the serogroup-specific study results may not be representative of 
contemporary patterns. It was reported that patients with MenB disease had less severe 
outcomes than those with MenC disease [102,103]. Data on MenB disease burden may 
underestimate disability outcomes caused by IMD in general or compared to other 
serogroups.  
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3.1.3 COSTS OF MENINGOCOCCAL DISEASE 
IMD is associated with an increased risk of disabilities in young children and adolescents. 
A systematic review was performed to estimate the burden of IMD including the costs and 
resource use associated with IMD. Results in regard to IMD costs and resource use 
published in the journal “PharmacoEconomics”, are presented in Section 3.1.3.2. 
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Abstract
Background Invasive meningococcal disease remains a
public health concern because of its rapid onset and sig-
nificant risk of death and long-term disability. New
meningococcal serogroup B and combination serogroup
ACWY vaccines are being considered for publicly funded
immunization programs in many countries. Contemporary
costing data associated with invasive meningococcal dis-
ease are required to inform cost-effectiveness analyses.
Objective The objective of this study was to estimate costs
and resource utilization associated with acute infection and
the long-term care of invasive meningococcal disease.
Data Sources and Methods PubMed, EMBASE, The
Cochrane Library, health economic databases, and elec-
tronically available conference abstracts were searched.
Studies reporting any costs associated with acute infection
and long-term sequelae of invasive meningococcal disease
in English were included. All costs were converted into
purchasing power parity-adjusted estimates [international
dollars (I$)] using the Campbell and Cochrane Economics
Methods Group and the Evidence for Policy and Practice
Information and Coordinating Centre cost converter.
Results Fourteen studies met our eligibility criteria and
were included. The mean costs of acute admission ranged
from I$1629 to I$50,796, with an incremental cost of
I$16,378. The mean length of hospital stay was reported to
be 6–18 days in multiple studies. The average costs
reported for readmissions ranged from I$7905 to I$15,908.
Key variables such as the presence of sequelae were
associated with higher hospitalization costs and longer
inpatient stay. No studies estimated direct non-healthcare
costs and productivity loss. Ten studies reported only
unadjusted mean values without using appropriate statisti-
cal methods for adjustment.
Conclusions Invasive meningococcal disease can result in
substantial costs to healthcare systems. However, costing
data on long-term follow-up and indirect costs used to
populate health economic models are lacking.
Electronic supplementary material The online version of this
article (https://doi.org/10.1007/s40273-018-0679-5) contains supple-
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Key Points for Decision Makers
Invasive meningococcal disease (IMD) is a public
health concern worldwide. Assumption and expert
opinions have been commonly used in health
economic evaluations to estimate unit costs
associated with acute admission and long-term care
of IMD.
We systematically reviewed and synthesized
published evidence of costs and resource utilization
relevant to acute infection and long-term sequelae of
IMD. The average healthcare costs of acute infection
ranged from I$1629 in Colombia to I$50,796 in USA
with an incremental cost of I$16,378.
The public health burden of the disease is substantial
with significant increases in healthcare costs and
resource use for meningococcal patients with
sequelae.
1 Introduction
Although the incidence of invasive meningococcal disease
(IMD) is relatively low in high-income countries, the dis-
ease still causes public health concern and anxiety because
of its rapid onset, an increased risk of mortality in ado-
lescents, and high rates of severe sequelae in children
[1–4]. Results from retrospective and prospective studies
show almost 40% of children had sequelae following IMD
infection [2, 5]. Major disabling deficits including ampu-
tation, deafness, epilepsy, and learning difficulties were
identified in around 10% of pediatric survivors [2]. Among
13 known serogroups, serogroups A, B, C, W, and Y are
responsible for most cases of IMD with serogroup X
mainly causing disease in Africa [6]. Vaccines against
serogroup B disease (MenB), which causes around 40–85%
of cases in Australia [7, 8], 64% of cases in Europe [9], and
almost 50% in USA [10], have recently been developed.
However, the MenB vaccination is publicly funded in a
limited number of countries. The recommendation of
funding the MenB vaccine under the National Immunisa-
tion Program Schedule in Australia has been rejected three
times by the Pharmaceutical Benefits Advisory Committee,
mainly owing to uncertainty around evidence on the
effectiveness of the vaccine and potential for herd immu-
nity response [11–13]. Although initially rejected in the
UK [14], the Joint Committee on Vaccination and Immu-
nisation (JCVI) finally recommended inclusion of the
MenB vaccine into the UK immunization schedule at a
‘cost-effective’ price, which was significantly lower than
the list price for the MenB vaccine [15]. Changes such as
adding litigation costs to the final analysis supported the
cost effectiveness of a MenB vaccination program in
infants. The JCVI also noted that a similar model with key
differences in a number of important parameters including
healthcare resources could reach different conclusions on
cost effectiveness when comparing an independent study
with another unpublished cost-effectiveness study [14].
Because direct and indirect costs associated with acute
treatment and long-term care in patients with IMD are
important inputs into cost-effectiveness models, detailed
costing data are required to inform cost-effectiveness
analyses. The paucity of costing data and its potential
impact on cost-effectiveness analyses have been acknowl-
edged in recent economic evaluations of the MenB vaccine
[16, 17].
By assessing the direct and indirect costs of a particular
condition, the results of cost-of-illness (COI) studies can be
used to inform public funding decisions such as estimating
the magnitude of costs that can potentially be saved by
preventative programs (e.g., MenB vaccination). Cost-of-
illness studies have also been frequently cited to attract
public attention to specific health problems by describing
their impact on healthcare resources and productivity loss
[18].
To our knowledge, no systematic reviews have been
performed to estimate the financial impact associated with
acute treatment and long-term follow up of IMD. Anony-
chuk et al. systematically reviewed the costs related to
containment strategies for IMD outbreaks and concluded
that the outbreaks result in substantial disruption and costs
to society [19]. In a review article, Martinón-Torres
delineated the extensive clinical and economic burden of
IMD including the overlooked family burden, legal costs,
and adaptive measures required for IMD survivors with
disabilities [20]. However, this narrative review was based
mainly on the author’s experience and knowledge, without
a description of the literature searching methodology. This
review article also used several costing studies related to
all-cause bacterial meningitis including pneumococcal and
other causes of meningitis to outline the financial burden of
IMD.
The aim of the present study is to provide a systematic
review of the global evidence on direct or indirect costs of
IMD published since 2000. In addition, we compared
methodologies used in each study and summarized the key
factors affecting healthcare costs.
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2 Methods
2.1 Literature Search
A search of the literature was conducted using the elec-
tronic databases: PubMed, EMBASE, The Cochrane
Database of Systematic Reviews, The Cochrane Central
Register of Controlled Trials, and the Database of
Abstracts of Reviews of Effectiveness. The search terms
included combinations of Medical Subject Headings/
Emtree and text words contained in the title and abstract.
Details on search strategies are presented in Table 1 of the
Electronic Supplementary Material (ESM). Only studies
reporting costing results are included in this review
(Fig. 1). Health economic databases were also searched,
including the Health Economic Evaluation Database, Cost-
effectiveness Analysis Registry, Health Technology
Assessment Database, and the Paediatric Economic Data-
base Evaluation. Gray literature available online was
Fig. 1 Preferred reporting
items for systematic reviews
and meta-analyses flow diagram
for article inclusion and
exclusion. IMD invasive
meningococcal disease
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searched for relevant abstracts and/or posters from the
following organizations: Meningitis Research Foundation,
Infectious Diseases Society of America, International
Pathogenic Neisseria Conference, European Society for
Paediatric Infectious Diseases, International Congress on
Infectious Diseases, World Society for Pediatric Infectious
Diseases, and the Australian Society for Infectious Dis-
eases. If conference abstracts were eligible at the title and
abstract screen, the first authors were contacted by e-mail
and detailed study information was sought. The reference
lists of eligible articles and other relevant review articles
[19, 20] were searched for additional studies. The search
was conducted by one reviewer (BW) from August 2016 to
September 2017.
2.2 Inclusion and Exclusion Criteria
The article selection process occurred in two phases: (1)
citation screen: titles and abstracts of articles identified
from the electronic databases and from Internet searches
were reviewed; and (2) full-text screen: the full text of
articles selected at the citation screen were obtained and
reviewed for eligibility. One reviewer (BW) completed the
screening process according to a predefined protocol.
Studies were eligible if direct and/or indirect costs
associated with acute infection and long-term complica-
tions/sequelae of IMD were reported through primary data
collection. We excluded studies only recruiting patients
with IMD as part of a larger population but not presenting
outcomes for the IMD group separately. Comments, letters,
editorials, case reports (fewer than ten patients with IMD),
and reviews were excluded. Because the first national
meningococcal vaccination (meningococcal C vaccines)
program was implemented in the UK in 1999, we expected
the vaccination could make significant changes to the
epidemiology of IMD. Therefore, the search was restricted
to studies published after January 2000. Studies reported in
languages other than English were excluded.
Reporting and performing this review was guided by the
Preferred Reporting Items for Systematic Reviews and
Meta-analyses 2009 statement [21]. The inclusion and
exclusion processes were documented.
2.3 Data Extraction and Quality Assessment
Data were independently extracted by two reviewers (BW
and RS) using predefined data fields. Data extracted were:
direct and indirect costs, and healthcare resource utilization
[e.g., length of hospital stay (LOS), frequency of outpatient
services and readmissions], study design, funding, study
location, study population (e.g., sample size, serogroup,
and age at illness), perspective, data sources, cost items,
model type, time horizon, discount rates, cost adjustment
approaches, sensitivity analysis, statistical methods, and
limitations considered by authors.
As there are no consensus agreement or validated
guidelines explicitly designed to perform critical appraisal
for the COI studies, the quality of included studies was
assessed using a checklist (Table 2 of the ESM), which was
developed on the basis of the Drummond 10-point
Checklist [22], the International Society For Pharma-
coeconomics and Outcomes Research checklist for retro-
spective database studies [23], and criteria used in previous
COI systematic reviews [24–28]. Two independent
reviewers (BW and RS) assessed the quality of the studies
and any divergences between reviewers were resolved by
discussion.
No studies fulfilled all criteria, as most studies were only
conducted from the healthcare system or third-party payer
perspective without covering all relevant perspectives, used
national hospital discharge or insurance claim databases
with no description of data reliability and validity, or
reported mean values with no adjustment for confounding
variables.
2.4 Data Synthesis
To compare costing data across heterogeneous studies, all
cost estimates were converted into international dollars
using purchasing power parity according to the recom-
mended guideline [22] and similar studies in the literature
[29–31]. Henceforth, all cost estimates are presented with
the sign of I$. The purchasing power parity-adjusted esti-
mates were calculated using the Campbell and Cochrane
Economics Methods Group and the Evidence for Policy
and Practice Information and Coordinating Centre cost
converter [32]. Because the Campbell and Cochrane Eco-
nomics Methods Group and the Evidence for Policy and
Practice Information and Coordinating Centre cost con-
verter requires cost estimates reported in the original
study’s local currency for inflation adjustment, the cost
estimates were converted back into the local currency for
studies not reporting their results in the study country’s
local currency but in US$. If the exchange rate was not
presented in the article, the average exchange rate (ac-
cording to OANDA historical exchange rates [33]) for the
reported year was used. If the price year was not specified
in the publication, the last year of the study period was
utilized. All costs were adjusted to the year 2014, as that
was the last price year reported in the included studies.
A meta-analysis was performed using the metaan ado
package [34] in STATA 14.2 (StataCorp LLC., College
Station, TX, USA) [35]. Owing to marked variation in data
sources, age group, follow-up period, cost items, statistical
methods, and confounder adjustment across studies, a
significantly high level of heterogeneity (I2 = 96.61%,
B. Wang et al.
s2 = 4.6 9 108) was found in the pooled estimate of
unadjusted acute admission costs. Owing to the consider-
able heterogeneity demonstrated in the meta-analysis, only
descriptive results are presented here.
3 Results
3.1 Overview of Studies
The search strategy identified 2370 studies that met the
inclusion criteria (Fig. 1). After title and abstract screening,
full manuscripts of 326 articles were reviewed so as to
exclude additional articles. Among 115 articles retained to
assess the clinical and financial burden of IMD, 14 articles
reported costing results (Table 1). The majority of the
studies were conducted in high-income countries, including
six studies in USA, two in Spain, one in Belgium, one in
Italy, and another study in Australia. Three studies reported
costs associated with IMD outbreaks in the UK, Colombia,
and Brazil.
3.2 Methodological Heterogeneity
Although all studies were conducted from the perspective
of the healthcare system or third-party payers with a bot-
tom-up approach, the range of cost items included in each
study varied considerably (Table 2). Except for three out-
break studies, all other studies used retrospective insurance
claim or hospital discharge databases. Five studies did not
provide detailed cost breakdowns with three of them
reporting costs based on Diagnosis Related Group codes
[36, 38, 41, 45, 48]. Five studies provided a breakdown of
healthcare costs by age groups. The main cost item
reported was inpatient costs. Some studies also included
other cost components such as emergency department,
hospital outpatient services, physician office visits, nursing
home services and rehabilitation facilities, pharmacy
claims, and associated costs. Cost adjustment was not
documented in three studies [36, 41, 45]. One study com-
pared costing data and resource utilization between cases
and controls [38]. Four studies reported healthcare costs
relevant to medical follow-up after hospital discharge
[39, 40, 43, 49]. The follow-up period varied between 0
and 3659 days. Serogroup information was only available
for six studies.
Only four studies used statistical models to adjust cost
and resource utilization data [38, 39, 43, 49]. Among those,
a generalized linear model was commonly used for costing
data adjustment, with three studies fitting a generalized
linear model with a log link function and a gamma distri-
bution. Resource utilization was analyzed using negative
binomial regression, Cox proportional hazard, or Poisson
regression models. Two studies chose the same set of
confounding variables [39, 43]. There is considerable
variability in selecting confounding variables between the
aforementioned two studies and other studies. Both unad-
justed and adjusted analyses were presented in three studies
[39, 43, 49]. Except for patients without sequelae in two
US studies, all adjusted costs were reported to be lower
than unadjusted costs. For those performing only unad-
justed analyses, four of them presented mean and/or
median values with no variability measures (e.g., range,
interquartile range, 95% confidence interval or standard
deviation) [40, 41, 45, 46].
3.3 Direct Medical Cost Estimates and Healthcare
Resource Utilization
The unadjusted acute admission costs per patient ranged
from I$1629 in Colombia [47] to I$50,796 in USA [39]
(Tables 3, 4). The unadjusted mean cost of follow-up care
during 1-year post-admission was reported as I$23,565 in
USA including readmission costs and other healthcare
expenses [40]. The unadjusted total healthcare cost for
initial admission, readmissions, and other healthcare ser-
vices was around I$60,000 on average in USA during
1-year post-admission [39, 40, 43]. Readmissions resulted
in I$15,908 in USA [40] and I$7905 in Australia [49] in
unadjusted analyses with varied follow-up periods. The
adjusted mean costs associated with acute admission were
reported in four studies ranging from I$8571 in Australia
[49] to I$23,792 in USA [38]. The adjusted mean cost
relevant to IMD readmissions was estimated to be I$935 in
Australian pediatric patients with sequelae [49]. Both
unadjusted and adjusted healthcare costs including inpa-
tient costs almost doubled in patients with sequelae com-
pared with patients without sequelae [38, 43, 49]. The
incremental cost and LOS of acute admission (I$16,378,
4.3 days) could only be inferred from a case-control study
[38].
Of the 14 included studies, ten reported an estimated
hospital resource use. The mean LOS during acute
admission was reported from 8 to 18 days in unadjusted
analyses with around 1 week in adjusted analyses.
Approximately 40% of patients with IMD had sequelae
after discharging from hospital. Those patients were 1.5–3
times more likely to stay in hospital longer and visit out-
patient clinics during the acute admission and/or in the year
following admission [39, 43, 49].
The total cost associated with an outbreak was reported
as I$55,778 in Brazil and I$7873 in Colombia [37]
(Table 4). As MenB vaccines were not available for the
outbreak in Colombia, the cost of managing the outbreak
was lower in Colombia than the one in Brazil. It was
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reported in the UK study that the incremental cost of
managing a second case of IMD was I$7815 [44].
3.4 Direct Non-medical Costs and Indirect Costs
We have not found any studies reporting direct non-med-
ical costs and indirect costs relevant to IMD. We excluded
studies that estimated productivity loss based on assump-
tion or expert opinions without any primary data collection.
3.5 Factors Impacting Healthcare Costs
Studies in USA and Australia suggested sequelae/compli-
cations, serogroup B infection, male sex, and previous
medical history were significantly associated with higher
healthcare costs and resource use compared with their
counterparts [5, 38, 39, 43]. Infants aged less than 1 year
had the highest healthcare costs and LOS in pediatric
patients and young patients aged \ 21 years [38, 49].
However, unadjusted mean costs or LOS reported in other
studies did not show a similar trend. In contrast, adoles-
cents or adults were reported as having higher costs and
longer LOS than other age groups [41, 42, 45, 46, 48].
4 Discussion
This systematic review included 14 studies that reported
costs associated with acute infection and/or long-term care
of patients with IMD, and descriptively described and
compared study results and methodologies. To our
knowledge, this is the first study to systematically review
and investigate the financial impact of IMD.
The results show a considerable impact of IMD on
healthcare resources, which reflects severe outcomes
associated with the disease requiring resource-intensive
treatments. The costs of acute treatment and readmissions
were the most important components of total healthcare
costs. The national costs per year were estimated to be
around €5 million in Spain [41, 45] and US$50 million in
USA [40, 46]. Although total costs of controlling IMD
outbreaks are not significant in Brazil and Colombia, the
management of outbreaks cost 2.7 times more than the
annual gross domestic product per capita in Brazil
including vaccination costs and 9.5% of Colombia’s annual
gross domestic product per capita without using any vac-
cination [37].
The financial impact of long-term sequelae on the
healthcare system has not been well investigated. The
included studies consistently reported that the presence of
sequelae is an important predictor of high healthcare costs
and resource use. Clinical data show that around 10% of
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amputation, skin scarring, or neurological disabilities
[1, 2, 5]. However, most patients were only followed up
until discharge, and costs for other healthcare services such
as rehabilitation associated with long-term care were not
included. Studies in USA followed patients up to
12 months post-discharge [39, 43] and one study in Aus-
tralia assessed readmission costs in one tertiary pediatric
hospital [49]. Including costs relevant to care and clinical
management of long-term sequelae may lead to substan-
tially higher cost estimates. A few case studies show that
the discounted lifetime cost associated with severe long-
term sequelae could be more than €1 million. However,
those severe IMD cases were developed on the basis of
expert opinions and interviews with patients and their
families [50–52]. Future studies are warranted to investi-
gate the longer term financial burden imposed on the
healthcare system, patients, their families, and society as
well as the negative effect on economically meaningful
health outcomes (e.g., quality of life) [53, 54]. The cost and
quality of life are key inputs into health economic evalu-
ation, and therefore reliable data on the costs of long-term
care would be valuable in reducing parameter uncertainty.
Undertaking studies to follow patients with IMD over a
long period of time (e.g., lifetime) could be time and
resource consuming. It might be problematic to link dif-
ferent administrative, costing, and clinical databases, as
researchers would need to follow ethics, privacy, and legal
guidelines and fulfill local and national requirements.
Because the incidence rate of IMD peaks in infants [55],
those infant survivors with neurological sequelae and
motor deficits would need multiple hospital readmissions,
special education, and long-term carers. The time frame of
follow-up is a critical point to consider. For example, fol-
lowing adult patients until their conditions stabilize may
only take 2 years. It may take at least 3–5 years to confirm
diagnoses of permanent neurological and psychological
sequelae in infant survivors. Given the previous literature
indicating that around 20–40% of IMD survivors had
multiple sequelae following IMD [1, 56], determining the
long-term effect of each single sequela separately could be
very difficult. The cost associated with individual sequela
has been used to develop decision analytical models to
assess the cost effectiveness of meningococcal vaccines.
Those parameters were determined mainly on the basis of
data collected for similar medical conditions, assumptions,
or expert opinions [42, 48, 57, 58].
The impact of the disease on individuals and the com-
munity has been widely discussed and considered sub-
stantial [19, 20], but we have not found any studies
reporting data associated with direct non-healthcare costs
and indirect costs. The financial burden of the disease
estimated in our review was relatively conservative, as
third-party payers were the only perspective taken by the
included studies. The measurement of reduced employ-
ment, absenteeism, presenteeism, and productivity loss
associated with informal carers is controversial [59]. In a
small number of cost-effectiveness studies taking the
societal perspective, the productivity costs were based on
assumptions or average national employment data
[57, 58, 60].
Our review found that around one third of included
studies reported costing results by serogroup
[37, 42, 44, 47, 49]. One study compared serogroup B with
non-B and reported serogroup B disease was likely to result
in the highest costs to the healthcare system in pediatric
patients [49]. Clinical literature indicated serogroup C
disease was associated with high rates of morbidity and
mortality [1, 61]. The serogroup may be an important
Table 4 Summary of included studies reporting healthcare costs and resource utilization during outbreaks




Personnel, office supplies, gasoline consumption,
chemoprophylaxis, and vaccines
Colombia: total cost of investigation and outbreak
management: I$1239 (I$207 per notified case); total
cost of disease surveillance: I$6634
Brazil: total cost of investigation and outbreak
management: I$46,728 (I$15,576 per notified case),




Time and cost attributed to staffing, microbiology,
pharmacy, and media liaison
Total cost of managing an outbreak (two cases): I$8286,





Direct treatment costs and costs associated with
outbreak control including personnel costs, measured
in time and estimated as a fraction of the salary of
each. An outbreak care team consisted of two
pediatricians, two nurses, an epidemiologist, and two
public health experts.
Mean cost of hospital care per patient: I$1629 (median:
I$1332); total cost of the disease response phase:
I$1216; total cost of disease surveillance: I$6511
No
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factor in predicting the disease severity and hence health-
care expenditures. Cost-of-illness analyses should reflect
the epidemiology of the disease and variations in serogroup
distribution in relation to time period and geographical
region. Serogroup comparison may be necessary to con-
sider in COI analyses to support cost-effectiveness evalu-
ations assessing vaccines against certain serogroups.
Because of the limited number of COI studies examining
the effect of serogroups on healthcare costs, some cost-
effectiveness studies used the average acute admission cost
for all IMD cases derived from International Classification
of Diseases codes [48, 62]. Several studies estimated the
average acute hospitalization cost based on Diagnosis
Related Group costs associated with meningococcal diag-
nosis [57, 58].
Although the new MenB vaccines are protein based, the
preliminary results obtained from studies evaluating the
impact of meningococcal vaccines on disease carriage
prevalence show that MenB vaccines could potentially
offer a certain level of protection against non-B serogroup
disease [63]. All MenB vaccines are licensed to provide
protection against serogroup B disease only. Serogroup-
specific COI analyses may still be warranted to provide
useful information on disease burden for cost-effectiveness
evaluations. Pentavalent vaccines that protect against five
serogroups (A, B, C, W, and Y) causing the majority of
IMD are currently in phase III clinical trials. It may be less
important to compare and evaluate healthcare resource use
by serogroup in a decade.
Invasive meningococcal disease has become uncommon
especially in industrialized countries, which may be owing
to vaccine pressure, a reduction in smoking, or natural
fluctuations of disease incidence [55]. However, outbreaks
of IMD continue to occur in schools and universities
[64, 65]. Surveillance networks have closely monitored
capsule switching and capsule replacement after imple-
menting meningococcal vaccination programs. The impact
of the new protein-based MenB vaccines on clearing car-
riage and interrupting transmission in adolescents remains
unclear. It is too early to envisage eradication of the
meningococcus bacteria at the current stage, when most
developing countries have not implemented meningococcal
vaccine programs because of the high costs of vaccines
[66]. Although inclusion of the MenB vaccine on the
government-funded National Immunisation Program was
rejected by the Pharmaceutical Benefits Advisory Com-
mittee in Australia, the Australian Technical Advisory
Group on Immunisation provided clinical advice to the
Pharmaceutical Benefits Advisory Committee and recom-
mended routine MenB vaccination of infants, young chil-
dren, and adolescents owing to their higher risk of MenB
infection [11, 67]. The COI analyses would still be required
to inform a cost-effectiveness review of a new submission
or resubmission to national decision-making bodies for
publicly funding new meningococcal vaccines. However,
we acknowledge that the evaluation of the true costs of
IMD may be more challenging in the future because of a
reduced number of patients infected with IMD.
The incremental cost-effectiveness ratios derived from
the estimate of costs and quality-adjusted life-years are one
of the key inputs to inform public funding decisions in
countries such as the UK and Australia. An evaluation of
IMD vaccines by national funding bodies in Australia and
the UK found that the results of economic evaluations of
meningococcal prevention strategies were, among others,
highly sensitive to herd immunity and vaccine effective-
ness [12, 15]. After considering new evidence in 2014, the
JCVI recommended the MenB vaccine for inclusion on the
UK national immunization program with a reduced dose
schedule at a very low price of £7 per dose based on the
revised analysis [16]. Including litigation costs associated
with the disease, updating cost data relevant to long-term
care, and using a quality-of-life adjustment factor affected
the outcome of a cost-effectiveness analysis in the UK [15].
With very limited COI analyses conducted for this severe
but uncommon disease, there may be a risk of underesti-
mating the true disease burden. The results of model-based
evaluations are subject to a significant level of parameter
uncertainty as emphasized by the Global Meningococcal
Initiative [68]. Because of considerable uncertainty around
the duration of protection against IMD and potential for
reduction in the carriage in adolescents, the JCVI rejected
the inclusion of the routine MenB vaccine schedule in
adolescents. If the true value of COI is ultimately shown to
be high enough, for example, considering all important
direct and societal costs, it may be argued that this could
potentially offset the significance of indirect protective
effects/herd immunity that play an important role in
determining the cost effectiveness of new meningococcal
vaccine programs.
Therefore, comprehensive COI analyses could provide
important inputs into economic evaluations of meningo-
coccal vaccines to better inform public funding decisions.
It is worth noting that individuals, charity organizations,
and clinicians strongly criticized the JCVI’s initial rejec-
tion and called for re-evaluation of the vaccine program.
Subsequently, the JCVI reviewed and revised the analysis
that included more favorable assumptions, optimized
parameters, and additional costs associated with the dis-
ease, thereby amending its interim position [69]. Economic
evidence is only one of several inputs into decision mak-
ing. Guidelines developed by decision-making bodies in
countries such as Australia and Canada recommend con-
sidering less-readily quantifiable factors for health tech-
nology funding decisions [70, 71]. In Australia, for
example, national funding bodies consider factors such as
B. Wang et al.
severity and rapid onset of the condition under study, the
age at which a person with the condition might die, and
rarity of the condition. Such societal values are all relevant
to IMD and hence should be considered in evaluating IMD-
related vaccines. However, as reported by Drew et al., there
is a lack of transparency and consistency in defining and
integrating these values into decision making [72].
The quality and methodologies varied significantly
between studies. Although we converted costs from origi-
nal studies to international dollars, extremely high hetero-
geneity including differences in the treated population,
study design, cost items, or data analysis hinders direct
comparison between studies, which may also explain the
conflicting results of inpatient costs and healthcare
resource use in infants. The included studies used insurance
claims, hospital charges, or payments to estimate costs that
may not represent the same ‘market value’ between studies.
Only four out of 14 studies reported adjusted mean values
using a regression model to adjust for confounding factors
including sociodemographic characteristics, disease out-
comes, comorbidities, and/or medical history. Differences
between unadjusted and adjusted mean values were
apparent within the same study, reflecting the importance
of consideration of potential confounders in any analyses.
It is of concern that overlooking the nature of highly
skewed costing data and not using any appropriate statis-
tical models to deal with skewness and adjusting for
potential confounders could lead to biased results
[18, 26, 73]. Among those studies presenting only unad-
justed results, four studies reported average costs and/or
LOS without any variability measures. Incremental costs
are commonly recommended for health economic analyses
and have been frequently reported in the COI studies of
other diseases [26, 28, 74]. The incremental costs were
only reported in one included study through a comparison
of patients with IMD with matched controls.
We understand various methodologies are used to gen-
erate estimates in the COI studies to serve different pur-
poses [75]. However, this variation in study conduct may
also reflect a lack of guidelines to standardize COI study
designs and methodologies [76]. A review of COI studies
highlighted the need for standardized methods of cost
calculation, mathematical modeling, choice of cost com-
ponents, disease classification, and selection of study per-
spective [77]. The findings of COI studies are often used to
support funding decisions and attract public attention.
Developing and implementing best-practice recommenda-
tions will improve the comparability and generalizability of
the costing studies.
As some studies enrolled patients with meningitis
caused by a range of bacteria, including Haemophilus
influenzae type B, Neisseria meningitides, and Strepto-
coccus pneumoniae, we were unable to separate the costs
for patients with meningococcal meningitis from those
with other bacterial meningitis. We excluded studies
describing the financial burden of meningitis during epi-
demics of serogroup A meningococcal disease in the
meningitis belt of sub-Saharan Africa because those studies
did not report costs associated with meningococcal
meningitis specifically. Because the authors’ first language
is English and not all languages were included, there may
be important studies not included in this review, resulting
in regional or English-language bias.
5 Conclusions
Despite the variability in estimates of medical costs and
hospital resource use, all included studies concluded IMD
resulted in substantial costs to healthcare systems or third-
party payers. The public concerns and fears caused by IMD
have been frequently reported. However, few have imple-
mented appropriate research methods, for example, using
micro-costing methodology and collecting primary data
prospectively from the societal perspective [22], to inves-
tigate the true costs of the disease. This systematic review
provides important information for the selection of an
appropriate unit cost for future cost-effectiveness studies,
identifying the financial burden of the disease in prioritiz-
ing healthcare policies, and estimating potential cost sav-
ings accrued from the introduction of new vaccines, and
also reinforces the need to standardize methodology and
improve the quality of the COI studies.
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3.1.4 MENINGOCOCCAL VACCINES 
IMD vaccines are available to protect against five major serogroups: A, B, C, W, Y. In this 
section, the disease burden, vaccine development, and vaccination strategies were 
reviewed and discussed in the published journal article entitled “Control of invasive 
meningococcal disease: Is it achievable?”.   
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AB S T R AC T
Neisseria meningitidis still leads to deaths and severe disability in children, adolescents and adults. Six different
capsular groups of N. meningitidis cause invasive meningococcal disease in the form of meningitis and septicaemia in
humans. Although conjugate meningococcal vaccines have been developed to provide protection against four of the
capsular groups causing most diseases in humans, vaccines against capsular group B, which causes 85% of cases in
Australia and the United Kingdom, have only recently been developed. A capsular group B meningococcal vaccine –
4CMenB (Bexsero) – has recently been licensed in the European Union, Canada and Australia. In Australia, a
submission for inclusion of 4CMenB in the funded national immunization programme has recently been rejected. The
vaccine will now be introduced into the national immunization programme in the United Kingdom following
negotiation of a cost-effective price. With the current low incidence of invasive meningococcal disease in many
regions, cost-effectiveness of a new capsular group B meningococcal vaccine is borderline in both the United
Kingdom and Australia. Cost-effectiveness of an infant programme is determined largely by the direct protection of
those vaccinated and is driven by the higher rate of disease in this age group. However, for an adolescent programme
to be cost-effective, it must provide both long-term protection against both disease and carriage. The potential of
vaccination to reduce the rate of severe invasive disease is a real possibility. A dual approach using both an infant and
adolescent immunization programme to provide direct protection to those age groups at highest risk of meningo-
coccal disease and to optimize the potential herd immunity effects is likely to be themost effectivemeans of reducing
invasive meningococcal disease. This commentary aims to describe the known disease burden and consequences of
meningococcal disease, and the development and potential effectiveness of new capsular group B meningococcal
vaccines.
Key words: carriage, herd immunity, immunization policy, invasive meningococcal disease, meningococcal B
vaccines
Int J Evid Based Healthc 2015; 13:000–000.
INTRODUCTION
A lthough uncommon, invasive meningococcal dis-ease (IMD) causes death in young healthy children
and adolescents in up to 10% of cases.1–3 Debilitating
consequences frequently follow resolution of the
infection, with 21–57% of cases developing long-term
complications, including amputation, cerebral infarction
and severe skin scarring.4–7 The WHO estimates that
there were approximately 171 000 deaths in 2000 caused
by IMD.8 A high proportion of these deaths occur in
developing countries such as Africa, where traditionally
the sub-Saharan ‘meningitis belt’ has been associated
with high mortality rates from IMD caused by seasonal
outbreaks due to capsular group A.
The highest incidence of IMD occurs in children below
5 years of age (particularly those under 12 months of
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age), with a second peak in adolescents and young
adults 15–24 years of age.9–12 The average annual
incidence of IMD in Australia is 1 : 100 000,13 and in
the United Kingdom, it is 2 : 100 000,14 and is higher in
young infants (1.1–8.4 : 100 000 age-specific rate).12 The
meningococcus is carried in the nasopharynx, and IMD
results following invasion of the blood or meninges by a
hypervirulent strain. Adolescents have the highest
prevalence of naso-pharyngeal carriage of both benign
and hypervirulent meningococcal subtypes.15
IMD causes high anxiety in both the medical com-
munity and the general public due to its rapid onset, with
the potential for a fatal outcome within 24 h of onset of
infection, in previously healthy children and adolescents.
Despite advances in early diagnosis and treatment with
antibiotics, children remain vulnerable to IMD due to the
relative immaturity of their immune system.16
This commentary aims to present the best available
evidence for use of meningococcal vaccines in the con-
trol of IMD in children, adolescents and adults. Our
literature review was confined to publications most
relevant to the evaluation of IMD immunization pro-
gammes in relation to disease burden and epidemiology,
meningococcal vaccine safety and efficacy, and potential
programme barriers and facilitators. We identified
relevant articles with searches of PubMed and Embase,
and references from identified papers on these topics.
Only papers published in English were included.
EPIDEMIOLOGY
There are 13 known capsular groups of Neisseria men-
ingitidis identified by their different capsular polysac-
charide structure; however, almost all invasive diseases
are caused by six meningococcal capsular groups (A, B, C,
W, Y and X).17,18 There is a seasonal variation in disease
incidence, with most cases in temperate climates occur-
ring in winter and early spring, whereas those in sub-
Saharan Africa occur during the dry season.8,19 Viral
infections, in particular, influenza, have been shown to
predispose to secondary infection with meningococci.20
Prior to the Second World War, capsular group A
meningococcal disease (MenA) was a common cause
of meningococcal infection in the United Kingdom and
caused a high proportion of disease in the Australian
Indigenous population in the early 1970s, but is now
rarely found in either country.21–23 The reason for this
decline is unknown, but it remains the most common
capsular group worldwide due to the high incidence of
group A disease in sub-Saharan Africa, though this is
falling rapidly as a result of a targeted vaccine pro-
gramme.24 Capsular group Y is more common in some
settings and causes 30% of cases in the USA.10 Group Y is
more often associated with disease in the elderly,25
particularly in adolescents. This increase has been seen
globally, including a slight increase in Australia and the
United Kingdom in 2011–2012.19,26 Capsular group W is
a more common cause of IMD in Asia and Africa than in
the United Kingdom and Australia, and an increasing
cause of IMD in Latin America. However, recent surveil-
lance in the United Kingdom has identified an increase in
group W disease in all age groups in England and Wales,
which does not appear to be related to travel or an
association with pilgrimage to Hajj (historically associ-
ated with increase in cases). Capsular group X is rare and
tends to cause sporadic outbreaks, the majority of which
occur in Africa.27
Prior to the implementation of the national capsular
group C meningococcal (MenC) immunization pro-
gramme in the United Kingdom (November 1999) and
in Australia (January 2003), one-third of the cases in both
the countries were due to MenC. A large decline in the
group C disease occurred following MenC vaccine intro-
duction in both countries; however, there has been no
impact on disease caused by other capsular groups
including capsular group B disease.
Capsular group B disease is endemic in high and
middle-income countries, including North America,
Australia, South America and the European Union
(EU). In Australia, 85% of the cases of IMD are now
due to group B – a significant change in the serogroup
epidemiology – with 65% of the cases occurring in
children and adolescents.12,19 In England and Wales,
764 cases were notified in 2011–2012, with themajority
due to group B.26 In the USA, around 30% of the cases
were due to group B, and in the EU, 70% of the
cases were due to group B since the introduction of
MenC vaccines.9,28
THE BURDEN OF INVASIVE
MENINGOCOCCAL DISEASE: OUTCOMES
AND CONSEQUENCES
The true global burden of disease is unknown due to
varying quality of surveillance systems in different
regions of the world, leading to under-reporting in many
countries. A study conducted in the United Kingdom
prior to the introduction of a MenC vaccine, identified
that 57% of the 58 cases had major physical sequelae,
with greater cognitive deficits associated with younger
age at diagnosis.4 The study also found that medical
follow-up was poor with only 53 of the 101 (52%) cases
reporting any follow-up after IMD, with significant unrec-
ognized and untreated morbidity. Another recent UK
study –meningococcal outcome study in adolescents
and children (MOSAIC) – using a case-control approach,
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identified major sequelae in 36% of meningococcal
survivors with a lower quality of life, greater risk of
depression and poor mental health function in child
and adolescent survivors of IMD compared with age
and sex-matched controls.29 Although this study pro-
vided a detailed assessment of the outcomes of IMD in
the United Kingdom in children and adolescents, the
burden of disease is likely to be different in different
countries where different meningococcal genotypes cir-
culate, and in the United Kingdom during different
periods. In comparison, a Canadian study of IMD cases
found 21% of survivors developed major sequelae.30 The
outcomes and impact from IMD in Australian children are
poorly documented.19,31–34
In a recent audit of 10 years of IMD cases in children in
South Australia, 37.6% (41/109) developed sequelae
including limb amputation, hearing loss, skin scarring
and chronic headaches and lethargy.7 A long-term fol-
low-up of survivors who had experienced bacterial men-
ingitis in childhood was reported in the year 2000.31 The
study prospectively followed a cohort of 166 children
admitted to the Royal Children’s Hospital, Melbourne,
between the ages of 3 months and 14 years between
1983 and 1986. This case-control study indicated 8.5% of
bacterial meningitis survivors had major neurological,
auditory or intellectual impairment. A further 18% of
survivors had an attributable risk of minor impairment.
A retrospective 5-year case-review study of IMD cases in
Western Australia between 1990 and 1995 found a mor-
bidity rate of 8.6%, with sequelae including hearing loss,
limb amputation and skin scarring, and a case fatality rate
of 8.6%.34 As it is difficult to predict which children are at
risk of IMD, apart from those with immunodeficiency
conditions, studies have attempted to predict children
that develop severe disease or sequelae.7,35 In the recent
review examining outcomes of IMD in South Australian
children, those admitted with a diagnosis of meningitis
and septicaemia compared to meningitis or septicaemia
alone were more likely to develop sequelae [odds ratio
(OR) 7.8, P¼ 0.002; OR 15.5, P< 0.001, respectively), with
high fever on presentation to hospital a predictor of
development of sequelae (OR 4.5, P¼ 0.012).7 This study
also highlighted the controversial finding that antibiotics
given early prior to hospital admission may be associated
with a more severe outcome, although children who
receive antibiotics are likely to have more severe disease
on presentation and be more easily diagnosed as a
possible IMD case. A systematic review delineated the
contradictory results from studies of the effects of early
antibiotic treatment, suggesting confounding factors and
the proportions of cases receiving antibiotics could
explain the heterogeneity in results between studies.36
In addition to the devastating direct consequences of
the disease, affected children and their families may also
be compromised by the neuropsychological con-
sequences of this infection, including depression, post-
traumatic stress disorder, reduced educational attainment




Pure polysaccharide meningococcal vaccines against dis-
ease caused by capsular groups A, C, W and Ywere initially
developed and derived from capsular polysaccharides of
the bacteria. The capsular polysaccharide is a virulence
factor for the bacteria and helps prevent immune-medi-
ated bacterial killing. These vaccines are relatively ineffec-
tive in young children below 2 years of age, because they
are unresponsive to these T-cell-independent antigens.38
The effectiveness of these vaccines is therefore limited as
the burden of disease is concentrated in the age group
amongst whom these vaccines are least effective.39 In
addition, these vaccines have mostly shown no effect on
nasopharyngeal carriage and therefore do not contribute
to herd immunity – an important community benefit of
childhood immunization programmes.40
Conjugate meningococcal vaccines to provide
broad protection (MenC, MenA, MenACWY
vaccines)
Conjugate polysaccharide vaccines have been devel-
oped in which the polysaccharide capsules are conju-
gated to a carrier protein to induce a T-cell-dependent
response, making these vaccines immunogenic from
early infancy. In the United States, a quadrivalent con-
jugate vaccine is recommended routinely for adoles-
cents from 11 years of age in a two-dose schedule.41
In Australia, the United Kingdom and other EU countries,
monovalent MenC vaccines have been introduced in
response to the large proportion of cases due to capsular
group C in the past few decades. These MenC vaccines
have been associated with a decrease in group C disease
in other, unvaccinated, age groups providing evidence of
the effect of conjugate vaccines on carriage and the
additional benefits to the community of herd immunity.
In Australia, the MenC vaccine is given as a single dose at
12 months of age, and at the time of introduction in
2003, a catch-up programme to 20 years of age was
implemented. In the past few years, group C disease has
rarely been reported in those aged below 20 years in
Australia, and there have been only a handful of cases in
older adults. In the United Kingdom, where the MenC
vaccine was initially provided as a three-dose than a two-
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dose infant schedule, again accompanied by a catch-up
campaign incorporating adolescents and young adults,
the incidence of MenC disease has decreased by 94% in
immunized populations and 67% in non-immunized
populations.24,42,43 Concerns about waning of MenC
antibodies in populations immunized in early childhood
resulted in a booster dose being added to the infant
schedule in the United Kingdom, which now consists of
one dose at 3 months, a second dose at 12 months and a
further dose in adolescence at 13–15 years of age.44
A conjugate group A vaccine was recently developed
in response to the enormous disease burden from cap-
sular group A disease in the sub-Saharan meningitis belt.
A large reduction in group A disease has been observed
in sub-Saharan countries that have already implemented
the programme.45,46
Capsular group B meningococcal vaccines
Difficulties developing a group B meningococcal
vaccine to provide protection against endemic
strains
The development of an effective and safe capsular group B
meningococcal (MenB) vaccine has been a priority in
combating meningococcal disease, since this capsular
group is now the predominant cause of infection in the
United Kingdom, Australia and other countries. MenB
vaccine development has been impeded because the
groupBcapsular polysaccharide – ahomopolymerof alpha
(2–8)-linked polysialic acid – is identical to sugars decorat-
ing human foetal neural cell adhesionmolecule, and there-
fore a human self-antigen. A capsular polysaccharide
vaccine is unsuitable for vaccine development due to lack
of immunogenicity (presumably as a result of tolerance to a
self-antigen) and the theoretical risk of autoimmunity.
When purified capsular group B polysaccharide was used
to vaccinate adult volunteers, no measurable increase in
anti-capsular antibody was demonstrated.47 The use of
capsulargroupBpolysaccharidenon-covalently complexed
to outermembrane proteins as a human vaccine generates
only short-lived IgM responses.48 Evenwhen conjugated to
a carrier protein, it was noted to have poor immunogenic-
ity.49,50 Therefore, development of a conjugate MenB
vaccine was not possible, and other ways to developMenB
vaccines were considered.
Development of group B meningococcal
vaccines against specific group B meningococcal
serosubtypes causing epidemics (e.g. MeNZB
vaccine; outer membrane vesicle-based
serotype-specific vaccines)
In response to themeningococcal epidemics in countries
such as New Zealand and Cuba, serosubtype-specific or
‘tailor-made’ MenB outer membrane vesicle (OMV)
vaccines were developed. The meningococcus continu-
ously releases ‘blebs’ or outer membrane vesicles during
development containing hundreds of different antigens.51
These outer membrane blebs contain lipopolysaccharide
(LPS) and outer membrane proteins (OMPs). In these
OMVs, the OMP Porin A (PorA) is an immunodominant
protein which has been shown to be immunogenic and
has over 600 different variants.52 These variants induce
limited cross-protection in young children, and in this age
group, any vaccine developed from OMVs tends to pro-
vide protection limited to the specific serosubtype causing
the epidemic. Such vaccines were developed and imple-
mented during long epidemics in New Zealand (MeNZB),
Norway (MenBVac) and Cuba (VA-MENGOCOC-BC), caused
by specific serosubtypes, but could not protect against
endemic group B disease. The MeNZB vaccine, which was
based on a typical isolate from the outbreak, was used in
New Zealand with success,53 but this does not provide
sufficient coverage of other circulating subtypes in Aus-
tralia and globally.54 It was established early in clinical trials
that immunogenicity waned and that a booster dose was
important in maintaining protective antibody levels. Post-
licensure surveillance of 200000 children who received
MeNZB vaccine found no increase in serious adverse event
rates of pre-selected conditions (e.g. acute flaccid paraly-
sis, encephalopathy, seizures), in excess of the background
rates to be expected in the general population for these
conditions.55 Injection site reactions (redness and/or swel-
ling) occurred more frequently in infants than in control
vaccines (MenC vaccine), but were of short duration, and
short-term fevers were common but comparable to those
receiving the control vaccine and did not require medical
intervention.53 With more than 3 million doses of MeNZB
administered to individuals under 20 years of age, no new
or unexpected safety concerns were identified. More
specifically, systemic events including fever were not
associated with any increased risk of febrile convulsion
in young children following vaccination.56 Although the
MeNZB vaccine was considered protective only against
the epidemic MenB strain, there was some evidence of
protection (vaccine effectiveness¼ 54%) against non-epi-
demic MenB strains.57 The effectiveness of the New Zea-
land immunization programme was estimated to be 80%
for children below 5 years of age58 and 77% overall.57
New capsular group B meningococcal vaccines
with the potential for protection against
endemic disease (outer membrane vesicle and
outer membrane protein-derived vaccines)
In view of the difficulties with polysaccharide vaccines
against capsular group B meningococcal disease,
researchers have focused on non-capsular targets in
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search of candidate vaccine antigens. This, however, has
been problematic due to the high level of antigenic
diversity of the meningococcus.59
Two newly developed vaccines designed to protect
against capsular group B disease (although lacking the
capsular polysaccharide that defines this group) have
been developed with the potential to offer protection
against endemic and epidemic disease; one licensed in
several countries including Australia, Canada and the EU
– 4CMenB (Bexsero; Novartis Vaccines and Diagnostics,
Siena, Italy) and one recently licensed in the United
States – rLP2086 (Trumenba; Pfizer Vaccines, Philadel-
phia, Pennsylvania, USA)60 The rLP2086 vaccine received
the US Food and Drug Administration’s (FDA’s) Break-
through Therapy designation (to expedite the develop-
ment and review of potential new medicines for serious
and life-threatening diseases),61 which includes more
intensive US FDA guidance on an efficient drug develop-
ment programme.62
The 4CMenB vaccine
A new approach to vaccine development known as
‘reverse vaccinology’ identified new OMPs as potential
vaccine candidates. In contrast to the traditional
approaches that have been used to develop vaccines,
reverse vaccinology uses the genome sequence of the
bacteria to identify likely surface-exposed candidate
antigens and then, after expression of the protein and
preclinical immunization experiments, selects those
proteins that meet set criteria as potential vaccine can-
didates. In the case of 4CMenB, these antigens include
factor H-binding protein (fHbp), neisserial adhesion A
(NadA) and neisserial heparin-binding antigen (NHBA),
which were formulated with the New Zealand outbreak
vaccine to produce 4CMenB. In December 2010, a file on
4CMenB was submitted to the European Medicines
Agency for a marketing authorization and was assigned
the trade name Bexsero.63
Safety and predicted effectiveness of 4CMenB: The
safety and reactogenicity profile of 4CMenB was eval-
uated in early-phase studies, the majority of which were
conducted in the United Kingdom, with a large phase 3
trial conducted in five European countries.64,65 Studies
involving over 8000 participants have shown that
4CMenB has an acceptable safety profile. Overall, reac-
togenicity rates amongst participants receiving 4CMenB
with routine vaccines were increased compared with the
rates amongst those receiving routine vaccines only or
those receiving MenC and routine vaccines. Use of para-
cetamol to reduce the proportion and level of fever in
infants and children below 2 years of age at the time of
vaccination has been studied and shown to be effective,
and was therefore recommended in Australia, the United
Kingdom and Quebec, Canada. In contrast to a previous
study that showed a reduction in immunogenicity when
concomitant paracetamol was received with routine
infant immunizations,66 a phase II study of children
receiving 4CMenB and routine vaccines with or without
prophylactic paracetamol showed no important effect
on immune response to the concomitant vaccine anti-
gens.67,68
Safety data from the first population implementation
of 4CMenB, in Quebec, has shown an acceptable safety
profile ‘in the field’. Of the 12 332 completed telephone
surveys of a total of 43 740 persons aged 2 months–
20 years receiving their first dose of 4CMenB, 14–15% of
children below 2 years were reported as having a fever,
with one febrile convulsion reported in a 1-year-old
child.69 Predicting efficacy of MenB vaccines is compli-
cated, not only due to the low incidence of disease but
also due to the number of vaccine antigens and the
number of naturally occurring protein variants. When
clinical efficacy trials are not feasible, appropriate surro-
gate markers of protection that allow interpretation of
immunogenicity are therefore essential. Use of the
serum bactericidal antibody (SBA) assay as a correlate
of protection has been used in the case of 4CMenB, and
is the licensure criterion for the vaccine. The SBA
measures functional activity of antibody through comp-
lement-mediated lysis of the bacteria. This is the
accepted correlate because complement-mediated bac-
terial killing by bactericidal antibodies is believed to be
the primary mechanism of protection against meningo-
coccal disease. The role of antibodies in natural immun-
ity to meningococcal disease was established by
Goldschneider et al.70 in which case an inverse corre-
lation between the incidence of disease and the preva-
lence of SBA against MenA, MenB and MenC was
reported. The presence of anti-meningococcal anti-
bodies, measured by bactericidal activity (hSBA titre
1 : 4) using an intrinsic human complement source in
the assay, was indicative of protection against systemic
meningococcal infection. Thus, an hSBA titre of at least 4
was used as the established end-point measurement for
MenB vaccine efficacy. This approach was affirmed in
2005 at a WHO-sponsored meningococcal serology
standardization workshop,71 and from several efficacy
studies of OMV vaccines.72,73 However, an hSBA value of
at least 1 : 5 was used in a number of phase 2 and 3
studies of 4CMenB, to be conservative and due to
regulatory requirement.74 Despite variation of assays
between laboratories, the proportion of participants with
a four-fold rise in antibodies remained relatively con-
stant.75 Data on SBA activity of pooled serum obtained at
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approximately 13 months of age from infants immu-
nized with three-dose priming and one-dose booster
course of 4CMenB indicated 88% of a panel of 40
invasive strains in England and Wales were susceptible
to killing by post-immunization sera.76 Nevertheless,
whether titres of anti-group B meningococcal bacteri-
cidal antibody correlate with true protection from
meningococcal disease is unknown without a longi-
tudinal vaccine efficacy trial. Indeed, some studies have
suggested that protection against group B infection
may also be due to opsonic antibodies and to innate
immune responses, which are not demonstrated in
the SBA.77–80
The 4CMenB vaccine is immunogenic against a set of
four reference strains by testing hSBA responses to
vaccine antigens NadA, fHbp, NHBA and NZ PorA P1.4
in infants (from 2 months of age), toddlers, adolescents
and adults up to 50 years of age.64,65,81–85 A booster dose
at 1 year of age is licensed in the approved vaccination
schedule for infants in Australia86 and any child immu-
nized under 2 years of age in the EU to support waning
immunity.74,87
Although immunogenicity studies have demon-
strated a robust immune response to 4CMenB, efficacy
or effectiveness has not yet been proven as efficacy
studies are unachievable due to the large number of
participants required to show an effect (reduction in
meningococcal disease) in view of the rarity of the
disease. Strain coverage as determined by Meningo-
coccal Antigen Testing (MATS) suggests that this
vaccine could protect against 76% of circulating gen-
otypes causing invasive meningococcal disease in
Australia and 73% in England and Wales.88,89 Predicted
coveragewas shown to vary between states in Australia,
with coverage potentially as high as 90% in South
Australia, 71% in New South Wales and 84% in Queens-
land, and other state coverage estimates less likely to be
accurate due to the small number of samples analysed
(Tasmania 45%).90 The true effectiveness will not be
known until the vaccine is used at a population level;
however, the PorA component in 4CMenB is common to
the MeNZB vaccine, which showed 73% effectiveness
when implemented in a national immunization pro-
gramme in New Zealand. In addition, the potential
effect of MenB vaccines on carriage of the meningo-
coccus in the nasopharynx is limited.1,67,91,92 Very little is
known about the effects of a MenB vaccine on carriage,
but there is the potential that introduction of newMenB
vaccines may disrupt the usual carriage ecosystem with
non-vaccine-type replacement genotypes. Provisional
results from a phase III study show 4CMenB had a
modest impact on N. meningitidis carriage with a
decrease of 16.5% in existing carriage.93 Therefore,
monitoring of clinical severity of disease and sequelae
and causative genotypes will be essential prior to,
during and after vaccine introduction.19
The rLP2086 MenB vaccine
The new MenB vaccine developed by Pfizer includes a
MenB outer membrane protein, designated as LP2086,
which has been shown to be a bacterial virulence factor
and a target for functional bactericidal antibodies.
LP2086 was subsequently determined to be fHbp which
the bacterium uses to evade complement-mediated
bacteriolysis and which is also contained in 4CMenB.
The LP2086 amino acid sequences from MenB isolates
can be divided into two sub-families – A and B – and one
member from each family has been included in this
vaccine to provide broad coverage against all MenB
isolates. Although 4CMenB also contains this important
OMP, it only contains fHbp from one sub-family, and not
from both.
Clinical trials have been conducted in adolescents,
children and toddlers using an initial formulation of
the rLP2086 vaccine, which then underwent optimiz-
ation to improve the stability of the vaccine and
increase the immunogenicity.94 The initial formulation
showed robust immune responses against strains
matched to the vaccine antigens, but reduced immu-
nogenicity against divergent strains. Overall, the
vaccine has been well-tolerated in clinical trials in
adults, adolescents, children and toddlers.95–97 An
improved formulation of the rLP2086 has been pro-
duced and tested in adults and adolescents, with
robust immune responses elicited against divergent
strains.98 Results of a small pilot study of the safety and
immunogenicity of rLP2086 in 46 infants showed high
fever rates, with 64 and 90% of infants developing
fever after receiving one 20 or 60-mg rLP2086 dose,
respectively. Only two infants in the 20-mg group and
one infant in the 60-mg group experienced fevers
above 39.08C. Due to these high fever rates, the study
was terminated early with the potential use of this
vaccine for infants still undetermined.99 The majority
of clinical trials of the Pfizer candidate rLP2086 MenB
vaccine have been conducted in Australia through a
network of vaccine trials units – the National Vaccine
Research Network.94–98
This vaccine has been developed primarily to provide
protection for adolescents. Several recent MenB out-
breaks in universities in the USA have confirmed the
importance of having available MenB vaccines to control
disease transmitted by hyper-virulent strains where
young people live in close proximity.100
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Potential additional benefits of group B
meningococcal vaccines
One potential advantage of these OMP-containing MenB
vaccines is the possibility that they may provide cross-
protection against diseases caused by other capsular
groups. As all capsular groups contain OMPs such as
fHpb, an incidental benefit may be even broader pro-
tection than intended. In-vitro studies support this
potential benefit.101,102
As suggested above, the impact of the MenB vaccine
on carriage remains uncertain, but even a modest
reduction in colonization rates, or colonization density,
could potentially contribute to reduction in disease in
unvaccinated populations.93,103
DISCUSSION
Vaccines are now available for the first time with the
potential to provide protection against a high proportion
of strains causing endemic and epidemic IMD in humans.
Until recently, vaccines to provide protection against the
MenA, C, W and Y have been available and funded in
many countries. A vaccine to provide protection against
the commonest strain (MenB) in high-income countries
is now licensed and available, but not yet implemented
in a national immunization programme. Although group
B disease accounts for 85% of IMD cases in Australia, the
Pharmaceutical Benefits Advisory Committee (PBAC),
Australia, has rejected the inclusion of 4CMenB in the
National Immunization Programme Schedule for the
prevention of MenB disease in infants and adolescents
due to unsatisfactory cost-effective estimates.104 The
PBAC concluded the rarity of the disease does not justify
the cost of a mass vaccination programme, with uncer-
tainties around effectiveness and duration of immunity
contributing to this decision. However, medical pro-
fessionals and meningococcal research organizations
in Australia and the United Kingdom have argued that
the burden of the disease and long-term impact is not
fully understood, with effectiveness unlikely to be estab-
lished until the vaccine is introduced into a national
programme.105,106
In the United Kingdom, the vaccine has borderline
cost-effectiveness, with an initial analysis finding the
vaccine to be just cost-effective at a very modest
price,107 a further analysis [published in an interim Joint
Committee on Vaccination and Immunisation (JCVI)
statement] finding it unlikely to be cost-effective,67
and a final analysis, conducted using updated data,
concluding that the vaccine could be cost-effective at
a low vaccine price.103 The UK process uses published
guidance to determine cost-effectiveness and included a
period of stakeholder consultation to ensure the best
evidence was used to inform the cost-effectiveness
model.108
The final position statement from the JVCI, included a
recommendation to the UK Departments of Health that
the MenB vaccine should be included in the funded
national immunization programme, if a cost-effective
price could be negotiated.103 Acknowledged uncertain-
ties about herd immunity, strain coverage, projected
disease rates, duration of protection, costs to the health
service and efficacy of 4CMenB have resulted in difficulty
in evaluating the cost-effectiveness of the vaccine,
essential to any funding decision.107 Paradoxically, many
of these data will only be available through use of the
vaccine in large populations.72 The success of a mass
immunization campaign against group C disease in the
United Kingdom has demonstrated strong evidence of
high vaccine efficacy and herd immunity, with a 80%
reduction in serogroup C disease within 18 months of
programme implementation.109
Cost-effectiveness considerations of funding a
group B meningococcal vaccine
Despite the difficulties with cost-effectiveness estimates,
it is expected that a programme will be implemented in
the United Kingdom in 2015. The final position state-
ment from JCVI acknowledged the importance of con-
tributions frommeningitis charities and commented that
‘the rapid and severe nature of IMD, the burden of
disease in infants and young children and the value
society places on preventing diseases in its youngest
members were considered throughout the committee’s
deliberations’.103 Reducing the number of vaccinations
for MenB immunization, as decided by the JCVI (two
primaryþ one booster compared to the three primaryþ
one booster dose recommended by the manufacturer),
will contribute to a more cost-effective national pro-
gramme; however, there are limited data on the immu-
nogenicity of this reduced regime. A phase 2 study
comparing four doses to a single dose of 4CMenB
vaccine, reported good immunogenicity after two doses
at 2 and 4 months of age.64 Reduced dose schedules
have been introduced with other vaccine programmes
(three doses rather than the recommended four doses of
Prevenar 7/13 in the UK and Australian immunization
programmes).
The availability of two licensed MenB vaccines in
Australia is a much closer reality, with the second MenB
vaccine being licensed in the USA very recently for use in
adolescents and young adults 10–25 years of age.
There are other likely societal benefits from introduc-
tion of MenB vaccines including reduction in public
anxiety and fear about IMD.
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Education of parents and immunization providers
about the use of MenB vaccines is important prior to
introduction of a funded programme. The increased
incidence of fever seen with 4CMenB could result in
increased medical attention or lead to lower uptake of
subsequent vaccinations, and therefore, parental and
healthcare professional education about the potential
reactogenicity of 4CMenB when administered with other
concomitant immunizations will be important, in
addition to the use of paracetamol/acetominophen. A
recent study identified that despite the potential for
4CMenB to cause fever in infants, parents and the
community as a whole considered the benefits of this
vaccine outweighed the risks.110 Only 10.8% [95% con-
fidence interval (CI) 8.5–13.2] of parents reported they
would be less likely to have their child immunized with a
MenB vaccine due to potentially associated mild-to-
moderate fever. A further study has indicated that family
physicians regard the MenB vaccine for children the
highest priority for a funded programme compared to
currently unfunded but recommended pertussis, influ-
enza and human papillomavirus vaccine programmes.111
CONCLUSION
Although eradication of the meningococcus bacteria is
not achievable through vaccination and not necessarily
desirable, the potential to reduce severe invasive menin-
gococcal disease is a real possibility. There is a strong
theoretical basis and early emerging evidence to suggest
that these OMP-based vaccines such as the new MenB
vaccines may provide not only protection against group
B strains but potentially could provide cross-protection
against other capsular groups. However, significant
reduction in meningococcal disease is likely to require
the dual approach of both an infant and adolescent
immunization programme to provide protection to age
groups in which the highest rates of IMD occur, and to
optimize the potential herd immunity effects which have
been so important in the success of conjugate menin-
gococcal vaccines. Such an impact depends critically on
the extent and duration of protection against carriage
(and therefore herd immunity), which remains an
unknown parameter. Furthermore, while an infant or
adolescent programme could be cost-effective depend-
ing on the different modelling scenarios applied, for an
adolescent programme, this would be dependent on the
vaccine providing long-term protection against both
disease and carriage.112
Surveillance of IMD following introduction of a MenB
vaccine in the United Kingdom, Australia and other
countries will be essential to determine how effective
the vaccine is, and identify problems with increased
reactogenicity, including additional healthcare utiliz-
ation, any herd immune effects and any replacement
disease with new virulent or non-virulent meningococcal
strains emerging.
The opportunity to reduce rates of meningococcal
disease is within reach and is an important consideration
when prioritizing vaccines for national immunization
programmes.
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3.2 LIFETIME COSTS: A MARKOV MODEL 
Based on a review of the literature, it was found that no studies estimated direct non-
healthcare costs representing the cost to patients and the government (e.g. transportation, 
special education), productivity loss representing the cost to society (e.g. reduced 
employment fraction) and long-term healthcare costs associated with IMD. The cost of 
illness (COI) studies can help policy makers and researchers to understand the financial 
impact of IMD on the patients, their families, the healthcare system and society. The COI 
study can provide estimates of the potential cost savings that might result from 
preventative programs (e.g. meningococcal vaccination) to inform cost-effectiveness 
analyses. 
A cohort-based state-transition (Markov) model was developed to predict the average 
lifetime cost of IMD. The best available published evidence was used to populate the 
model. A manuscript titled “Lifetime costs of invasive meningococcal disease: A Markov 
model approach” has been prepared for publication and will be submitted to the journal 
“Vaccine”. 
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manuscript entitled: Lifetime costs of invasive meningococcal disease: A Markov 
model approach. 
 
Understanding the financial costs of invasive meningococcal disease (IMD) is an 
important step in developing health economic models for preventative health programs 
such as immunisation. To our knowledge, no cost of illness studies have estimated costs 
associated with IMD by using health economic modelling techniques to provide 
information for healthcare resource prioritising.  
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Abstract  
Background. Invasive meningococcal disease (IMD) is an uncommon but life-
threatening infectious disease associated with high sequelae rates in young children and 
an increased risk of mortality in adolescents and young adults. Funding decisions to reject 
inclusion of new meningococcal serogroup B vaccines on national immunisation 
schedules have been criticised by IMD patients, their families, paediatricians and charity 
organisations. We aim to estimate the lifetime costs of IMD with the best available 
evidence to inform cost-effectiveness analyses. 
 
Methods. A Markov model was developed taking healthcare system and societal 
perspectives. A range of data including age-specific mortality rates, and probabilities of 
IMD-related sequelae were derived from a systematic review and meta-analysis. All 
currencies were inflated to year 2017 prices by using consumer price indexes in local 
countries and converted to US dollars by applying purchasing power parities conversion 
rates. 
 
Results. The estimated lifetime societal cost is US$319,896.74 per IMD case including 
the direct healthcare cost of US$65,035.49. Using a discount rate of 5%, the costs are 
US$54,278.51 and US$13,968.40 respectively. Chronic renal failure and limb amputation 
result in the highest direct healthcare costs per patient. Patients aged <5 years incur the 
higher healthcare expenditure compared with other age groups. The costing results are 
sensitive to the discount rate, disease incidence, acute admission costs, and sequelae 
rates and costs of brain injuries and epilepsy. 
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Conclusions. IMD can result in substantial costs to the healthcare system and society. 
Understanding the costs of care can assist decision-making bodies in evaluating cost-
effectiveness of new vaccine programs. 
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Introduction  
Although invasive meningococcal disease (IMD) is uncommon, the disease causes major 
public health and societal concerns due to its rapid onset and potentially severe or life-
threatening outcomes. Despite advanced clinical management, the disease is still 
associated with a high disability rate in young children and an increased mortality risk in 
adolescents and young adults. Up to 58% of adolescents develop sequelae [1] and 9% 
of young patients have major disabling deficits after the disease [2]. Case fatality rates 
(CFRs) vary between 5 and 20% [3].  
 
Vaccines are available to protect against five major serogroups: A, B, C, W and Y. New 
meningococcal serogroup B (MenB) vaccine programs are publicly funded in a limited 
number of countries or states (e.g. UK, Ireland, Italy and South Australia). Meningococcal 
serogroup ACWY vaccines have been added to national immunisation schedules or are 
being considered by national funding bodies in several countries due to the continuing 
rapid rise in serogroup W disease. Although guidelines developed by funding bodies (e.g. 
Australia and UK) consider factors such as disease severity and rarity, economic 
evaluation is one of the key inputs that inform decisions on whether to publicly fund new 
meningococcal vaccine strategies.  
 
Cost of illness (COI) studies can provide important baseline information for future cost-
effectiveness analyses [4]. COI results help policy-makers understand the financial 
impact of IMD on the healthcare system and the potential lifetime cost savings that might 
arise from new meningococcal vaccine programs [5,6]. Previous costing studies 
estimating IMD direct healthcare costs were conducted in the US and Australia, but the 
financial impact of long-term care associated with IMD disabilities were not investigated 
[7-10]. Although lifetime costs were estimated in a COI study [11] and several case 
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studies by using two hypothetical cases of severe meningococcal meningitis and 
septicaemia [12-14], decision analytic models (e.g. Markov models) are required to 
capture all important healthcare and societal costs over a lifetime. Such models predict 
the experience of health states that are likely to be experienced by the patient, often over 
the lifetime of a study population. Costs are then applied to the time spent in different 
health states to estimate lifetime costs.  
 
Decision analytic models have been used to assess cost-effectiveness of meningococcal 
vaccines [15-26]. However, few studies fully justified the choice of model structure 
(representing health states included in the model) and approaches to systematically 
identify the best available evidence to populate the model. It is well noted that the choice 
of inappropriate model structure, even if we use the true value of inputs, can lead to 
biased model predictions and, hence, poorly informed policy decisions [27]. Some model-
based studies of IMD vaccines excluded important health states such as renal failure or 
speech/communication problems [15-17,20]. Recent guidelines for good modelling 
practice highlight the need for the development of a conceptual model (reflecting the 
current clinical understanding of the condition under study) as a basis for defining the 
structure of cost-effectiveness models [28]. In terms of populating processes, it was found 
that wide-ranging parameter values (e.g. sequelae rates varied from 13% [17] to 77% 
[22]) were extracted from the published literature and used in these models. Modelling 
results are sensitive to the choice of model inputs and structure. Two prior modelling 
studies estimated the rate of cognitive problems as 23-25% [18,22] based on a follow-up 
study in Iceland. However, the rate of cognitive dysfunction was reported as 1.5% in the 
original retrospective study [29]. Furthermore, societal costs associated with long-term 
disabilities and premature death have been considered substantial [30], but some 
evaluations focused solely on direct healthcare costs [20,22,24,26].  
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Our study therefore aims to address these issues to further improve the estimation of the 
lifetime cost associated with IMD from healthcare system and societal perspectives. 
Following recent guidelines for good modelling practice [28,31,32], we report on the use 
of a conceptual framework of the progression of IMD to guide the development of a 
Markov model to predict IMD costs to a maximum age of 100 years.    
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Methods 
A Markov model with yearly cycles was built using TreeAge Pro (version 2018 R2.0). In 
the base case, future costs were discounted to their present value at 5% annually and 
the healthcare system perspective was employed as recommended by Australian 
guidelines [33].  
 
The healthcare system perspective captures direct medical costs associated with IMD 
and public health management. The analysis was also performed from the societal 
perspective, including direct healthcare costs, direct non-healthcare costs (e.g. home 
modification and special education) and indirect costs associated with productivity loss.  
 
Based on the number of births registered in Australia in 2016, a hypothetical birth cohort 
of 311,104 newborns was followed over a 100-year time horizon. All costs were inflated 
to price year 2017 based on the Consumer Price Indexes in local countries and 
converted to US dollars using Purchasing Power Parities [34]. 
 
Model structure 
To inform model structure, we systematically reviewed clinical and health economics 
literature published after 2000, documenting disease progression and important health 
states associated with IMD. Based on clinical and health economic literature review, we 
drafted a conceptual framework (Supplementary Figure 1).  
 
To further guide the development of model structure, four clinical consultants in 
immunisation, paediatrics, infectious diseases, and paediatric rehabilitation, two experts 
in public health, two senior researchers working in the field of IMD, and a health 
economist were invited to be part of an advisory meeting, in which a focus group 
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discussion was conducted to obtain expert opinions on likelihood and importance of 
sequelae. Experts were also asked to complete a questionnaire following the discussion 
(Supplementary Table 1).  
 
The main structure of the draft conceptual model was agreed by the expert panel. Based 
on the discussion, hearing impairments, amputation and renal failure were further 
disaggregated. The rating results were used to assist in excluding health states. We 
further excluded hepatic dysfunction from the model due to low probability and impact 
scores derived from the questionnaires (a mean likelihood score ≤3 and all mean impact 
scores ≤3).  
 
Owing to a low probability and limited data availability, two health states, bone and joint 
diseases and vasculitis, were removed from the final conceptual framework 
(Supplementary Figure 2) to develop the final costing model (Figure 1). Based on data 
availability, motor deficits, cognitive impairments and other neurological impairments 
were aggregated into one health state, brain injuries. Social functioning problems were 
specified as severe speech and communication problems. Psychological problems were 
separated into two health states: depression and generalised anxiety disorder.   
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Model inputs and assumptions 
We assumed all IMD cases would be hospitalised. As IMD was associated with an 
increased risk of death due to nervous system diseases (mortality rate ratio (MRR): 3.15) 
and genitourinary diseases (MRR: 6.26) [34], IMD patients with brain injuries and chronic 
renal failure were assumed to have a higher probability of death. As recurrent IMD is rare 
[36], each survivor would not have recurrent IMD. Ages of onset of generalised anxiety 
disorder and depression are 6 and 13 years, respectively [37].  
 
Epidemiological/clinical inputs 
A systematic review was performed to identify probabilities of health states. 
Sequelae/complications reported in the literature were highly heterogeneous, as study 
populations, sequelae definitions, study design and follow-up periods varied significantly 
between studies. Therefore, we did not synthesise clinical evidence. Clinical data 
reported in studies with small sample sizes (n<100) were excluded from data identification, 
as studies with small sample sizes might produce low quality results with wide variance 
[38]. We only included studies conducted in developed countries (e.g. UK, US, Australia, 
etc.) due to applicability issues. Twenty-two studies were used to select clinical 
parameters (Supplementary Table 2). If more than one study reported a specific sequela 
rate, the value of the sequelae rate was determined based on the quality of studies (study 
limitations and imprecision) as suggested by GRADE criteria [39] (Supplementary Table 
3).  
 
The disease incidence was determined using Australian notification data in 2017. The 
national life table in the 2014-2016 period was used to predict non-meningococcal 
mortality after removing premature deaths caused by IMD. The CFRs presented in 
national surveillance reports in Australia used two different datasets. Those datasets 
 
~ 183 ~ 
 
were not linked. The CFRs were relatively lower than other developed countries. 
Therefore, we used age-specific CFRs derived from a systematic review and meta-
analysis (manuscript in preparation). 
 
Cost inputs 
Direct healthcare costs associated with admissions, rehabilitation, outpatient visits and 
prostheses were included (Supplementary Table 4). The costs associated with acute 
admissions were derived from the National Hospital Cost Data Collection reports between 
2013 and 2016. Direct healthcare costs relevant to amputations, stump revisions and skin 
scars were estimated by using cost weights for Australian Refined Diagnosis Related 
Groups (AR-DRGs). Due to a lack of costing data pertaining to long-term disabilities, 
costs associated with sequelae were derived from COI studies describing the cost burden 
on similar medical conditions. A targeted literature search was performed to identify cost 
parameters. It was assumed that 15% of primary amputations performed before 12 years 
of age would have two stump revisions at a three year interval [40-43].  
 
Direct non-healthcare costs associated with long-term care, informal carers, early 
intervention/special education, home/vehicle modification, and/or personal out-of-pocket 
costs were included (Supplementary Table 4).  
 
To estimate indirect costs, two approaches were used: human capital (HC) and friction 
cost (FC) methods [44]. The HC method estimates the reduction in gross earnings due to 
morbidity and/or premature mortality. The FC method only considers the time span 
employers need to restore the initial production level [45].  
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A friction period of 3 months was used for premature death caused by IMD [46,47]. We 
also considered a friction period of 1.5 months for patients with blindness, brain injuries, 
multiple limb amputation and renal failure [19].  
 
By using the HC method, the productivity loss associated with acute admissions for 
patients without sequelae was estimated by multiplying national average weekly income 
and an average length of stay in hospital [15]. For patients with sequelae, three additional 
days plus an average length of hospital stay were considered due to the severity of the 
disease. The value of lifetime income foregone due to premature death was calculated 
on an annual basis from the age of death to the retirement age using age-specific wage 
weighted by age-specific employment rate.  
 
Model validation 
Three clinical consultants in infectious diseases or paediatrics (not involved in the model 
development process) were invited to investigate the model’s face validity regarding the 
model structure, model inputs, assumptions and results. A focus group discussion was 
conducted. They concluded the lifetime costs generated from our model were highly likely 
to be underestimated. To address this concern, we further investigated onset ages of 
depression/generalised anxiety disorder and economic parameter values relevant to 
amputation and severe speech problems. The onset ages of depression/generalised 
anxiety disorder were revised based on a large survey study in the US [37]. The costs 
associated with amputation and severe speech problems were revised after interviewing 
a paediatric rehabilitation consultant, senior speech pathologist and senior 
prosthetist/orthotist. The costs associated with prostheses, surgical revisions and 
rehabilitation services were considered for patients with amputation.  
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Verification was performed by BW and HHAA independently to examine and confirm 
whether all equations and parameters populated the model correctly. External validity 
was checked through comparison of population figures predicted in the model against the 
Australian population in 2016. Cross validation of our final model was assessed by 
comparing costing results with previous modelling studies.  
 
Sensitivity analyses 
One-way sensitivity analyses were conducted to test the sensitivity of the base case 
model predictions to model inputs. Australian historically low and high incidence rates in 
2013 and 2002 respectively, and 95% confidence intervals of CFRs were used. Due to 
lack of estimates of precision (e.g. confidence intervals), all other model inputs were 
varied between 75% and 125% of their point estimates. Discount rates of 0%, and 5% 
were also considered in the analyses. 
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Results 
The model predicted 419 IMD cases with a total direct healthcare cost of 
US$5,860,991.21 (discounted at 5%) or US$27,288,190.17 (no discounting) after 
following a birth cohort of 311,104 newborns over the model’s 100-year horizon (Table 
1). The expected direct healthcare cost per IMD case is US$13,968.40 (discounted at 5%) 
or US$65,035.49 (no discounting) over a lifetime. The societal cost estimate using HC 
method is much higher than the estimate using FC methods. 
 
Table 1 lifetime costs per IMD case (US$) estimated from the healthcare system and 
societal perspectives and discounted at 5, 3.5 and 0% 
Discount 
rate 




5% $13,968.40 (base case) $54,278.51 $24,109.56 
3.5% $19,072.94 $84,189.32 $32,066.91 
0% $65,035.49 $319,896.74 $96,809.26 
 
With a discount rate of 5%, the first-year healthcare cost is US$19,236.91 in patients 
aged one and decrease gradually by age (Figure 2). For patients with disabilities requiring 
long term care, the average clinical follow-up cost is estimated to be US$11,225.79 for 
children aged two and has shown a steady decline by age.  
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Figure 2 Direct healthcare cost per IMD case by age group 
 
 
Without discounting, the first-year healthcare cost is around US$20,000 on average 
(Figure 2). The average long-term healthcare cost is expected to be US$11,787.08 for 
two-year old children and remains stable for adult patients aged >25 years.  
 
Patients with chronic renal failure, limb amputation, epilepsy and brain injuries are 
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Figure 3 Direct healthcare cost per IMD case by sequelae type (discounted at 5%) 
 
 
The discount rate and disease incidence are key drivers of uncertainty in the one-way 
sensitivity analyses. A tornado diagram presents model inputs with at least 5% impact on 
the base case result, including the discount rate, disease incidence, acute admission cost, 
sequelae rate and annual healthcare cost of brain injuries, and sequelae rate and annual 
healthcare cost of epilepsy (Figure 4). Those parameters modified the cost results by 
more than 5% and generated the wider uncertainty. The cost result was most strongly 
affected by discount rates, which produced the largest cost difference of US$51,067.09. 
The variation in incidence rates also greatly impacted the cost result with a cost difference 
of US$32,701.70. Other parameters modified the cost result by less than 5% 
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The single birth cohort population shows a steady decline in the model after the cohort 
reached the age of 50 (Supplementary Figure 3) and presents a similar trend to the 
Australian population in 2016. Variation in cost results was observed when comparing our 
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Discussion 
Different from previous modelling studies, quantitative and qualitative research methods 
were used in our study to develop model structure, potentially improving the accuracy of 
our model predictions.   
 
In a Canadian cost-effectiveness study, the cumulative direct medical cost would average 
at C$7,055-8,001 per case discounted at 5% (2014 Canadian dollar) [16]. After adjusting 
inflation and converting to US dollars, the direct cost per case was only half of our 
estimates. However, in another Canadian study, the average treatment cost of MenB 
cases could be around C$27,410 with a discount rate of 5% (2012 Canadian dollar) [26]. 
In a cost-effectiveness study conducted in the Netherlands, the direct cost per case could 
be approximately €16,667 (2009 euro) discounted at 4% with a total cost of €0.65 million 
for 39 cases [21]. A French cost-effectiveness study reported that the cumulative direct 
healthcare cost could be €600 million (2010 euro) for 52,800 cases which would equal 
€11,036 per case (discounted at 4% within the first 30 years and 2% thereafter) [20]. 
Variations in perspectives, model structures, input values and methods may be reasons 
for differences in costs. 
 
The costs are sensitive to changes in the discount rate. This factor was reported to be 
most influential parameters in other cost-effectiveness analyses [16,17,20]. The more 
time that has elapsed between birth and predicted events, the higher the reduction in the 
current value of costs. How and whether to use discounting is controversial when 
evaluating vaccine programs with potentially long time lags between the time of 
vaccination and time of its prevention effects [48,49].  
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Our study showed the disease incidence is another key driver of differences in costs. The 
disease incidence is highest in infants, which may partially explain why the infant 
vaccination was more cost-effective than other strategies without considering carriage 
reductions and indirect protection [15]. In our study, the highest direct healthcare cost 
was predicted to be incurred in infants, consistent with the highest disease incidence 
occurring in this age group. Despite widespread vaccination providing protection against 
serogroup C disease, there are unpredictable natural fluctuations in the incidence of other 
serogroup diseases over time. In Australia, the number of IMD notifications declined to 
147 in 2013 and rose to 381 in 2017. Although the number of IMD cases might be low 
over a short period of time, the disease burden should not be underestimated in the long 
term.  
 
Our model was developed based on a thorough review of clinical and modelling literature 
and expert engagement. Unlike previous health economic analyses, surgical revision 
costs were included in our model. Multiple surgical reinterventions after initial amputation 
are often required to treat bony outgrowth, growth arrest, and skin contracture in young 
children [50].  
 
Model inputs were collected from the published literature, which may not represent the 
current treatment guidelines and costs associated with IMD. Limited epidemiological and 
costing studies exist especially in paediatric population to inform clinical and economic 
parameters. Several parameter estimates were derived from the adult population which 
may underestimate the higher disease burden in children. Moreover, in large 
observational studies, most patients with disabilities were followed for less than five years. 
Psychological and social behaviour problems associated with the disease and permanent 
disabilities (e.g. scaring and amputation) could not be fully investigated. The additional 
 
~ 192 ~ 
 
costs resulting from long-term disabilities are highly likely to be underestimated. Owing to 
difficulties in estimating frequency and combinations of sequelae, we assumed each 
patient would have one sequela, consistent with other modelling studies. In reality, among 
patients with sequelae, around one third had multiple sequelae [51]. To minimise this bias, 
we attempted to include all important sequelae identified in the literature and suggested 
by experts. However, the costing impact of multiple sequelae might be enormous, which 
could not be investigated in sensitivity analyses. Overall, the cost results in our study are 
conservative.  
 
IMD can result in substantial costs to the healthcare system and society especially in 
young children. The introduction of new meningococcal vaccine programs deserves 
substantial consideration because of a significant reduction in disease burden in infancy. 
Further COI and epidemiological studies on long-term disabilities associated with IMD are 
warranted to improve model accuracy and reduce parameter uncertainty.  
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Supplementary Figure 3 Comparison of population figures predicted in the Markov 
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Supplementary Table 1 
IMD Panel Meeting Survey Name: __________________ 
 
Do you think invasive meningococcal disease (IMD) 






1 very rare 





5 very common 

















5 very strong 
Impact on 
quality of life 
Enter number 1-
5:  









Yes  If yes, please rate the likelihood and impact. 
    




Yes  If yes, please rate the likelihood and impact. 
    
Visual impairments No  
Yes  If yes, please rate the likelihood and impact. 
    
Seizures No  
Yes  If yes, please rate the likelihood and impact. 
    
Motor deficits No  
Yes  If yes, please rate the likelihood and impact. 
    
Cognitive impairments No  
Yes  If yes, please rate the likelihood and impact. 
    
Chronic headache No  
Yes  If yes, please rate the likelihood and impact. 




Yes  If yes, please rate the likelihood and impact. 
    
Social functioning No  
Yes  If yes, please rate the likelihood and impact. 
    
Psychological problems No  
Yes  If yes, please rate the likelihood and impact. 
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Do you think invasive meningococcal disease (IMD) 






1 very rare 





5 very common 

















5 very strong 
Impact on 
quality of life 
Enter number 1-
5:  




5 very strong 
Amputation No  
Yes  If yes, please rate the likelihood and impact. 
    
Arthritis No  
Yes  If yes, please rate the likelihood and impact. 
    
Other bone/joint diseases No  
Yes  If yes, please rate the likelihood and impact. 
    
Vasculitis No  
Yes  If yes, please rate the likelihood and impact. 
    
Hepatic dysfunction No  
Yes  If yes, please rate the likelihood and impact. 
    
Renal dysfunction No  
Yes  If yes, please rate the likelihood and impact. 
    
Skin necrosis/grating No  
Yes  If yes, please rate the likelihood and impact. 
    
Skin scarring No  
Yes  If yes, please rate the likelihood and impact. 
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Do you think invasive meningococcal disease (IMD) 






1 very rare 





5 very common 

















5 very strong 
Impact on 
quality of life 
Enter number 1-
5:  




5 very strong 
Others:  
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Supplementary Table 2 Sequelae rates reported in the literature 
Paper















Mean/median age at onset
Control
n N % n N % n N % n N % n N % n N % %* n N % n N % n N % n N % n N % n N % n N % n N % n N % n N % n N % n N % n N % n N % %* n N % n N % Min Max
Any seuelae 74 391 18.93% 58.0% 148 504 29.4% 173 41.00% 44 407 10.81% 343 34.10% 32 340 9.41% 59 458 12.88% 157 868 18.09% 763 29.00% 18 150 12.00% 31 251 12.35% 87 245 35.51% 20.57% 41 109 37.61% 9.41% 58.00%
Multiple complications 17 391 4.35% 58 868 6.68% 4.35% 6.68%
Hearing 
problems/impairment 12.0% 4 109 3.67% 3.67% 12.00%
Perceptive hearing loss 44 2286 1.92% 1.92% 1.92%
Sensorineural hearing loss 13 109 11.93% 10.11% 13 407 3.19% 3 340 0.88% 9 150 6.00% 0.88% 10.11%
Hearing loss/deficit 65 504 12.90% 173 9.30% 19 109 17.43% 11.98% 14 541 2.59% 13 295 4.41% 343 10.50% 46 868 5.30% 43 763 5.64% 3 251 1.20% 1.20% 12.90%
→ Bilateral sever to profound 
sensorineural loss requiring 
hearing aids 2 109 1.83% 1.83% 1.83% 1.83%
→ Unilateral sever to 
profound sensorineural loss 2 109 1.83% 1.83% 1.83% 1.83%
→ Unilateral moderate 
sensorineural loss 1 109 0.92% 0.92% 0.92% 0.92%
→ Unilateral high frequency 
losses (mild-moderate) 8 109 7.34% 5.52% 5.52% 5.52%
→ Conductive hearing loss 6 109 5.50% 1.87% 1.87% 1.87%
→ Profound bilateral 
sensorineural hearing loss 
(wears cochlear implant or 
HL≥90db) 6 245 2.45% 2.45% 2.45% 2.45%
→ Moderately severe 
bilateral sensorineural 
hearing loss (≥40db) 5 232 2.16% 1.21% 2.16% 2.16%
→Sensorineural hearing loss 
(unilateral or bilateral;  
hearing loss 20-40db) 4 232 1.72% 1.41% 1.72% 1.72%
→Any sensorineural hearing 
loss (unilateral or bilateral;  
hearing loss≥20db) 15 232 6.47% 5.21% 6.47% 6.47%
Deafness 28 391 7.16% 14 159 8.81% 12 458 2.62% 2.62% 8.81%
→ Bilateral deafness 8 159 5.03% 5.03% 5.03%
→ Unilateral deafness 6 159 3.77% 3.77% 3.77%
→ Severe bilateral deafness 6 391 1.53% 1.53% 1.53%
→ Severe unilateral deafness 9 391 2.30% 2.30% 2.30%
Blindness 1 391 0.26% 173 1.00% 1 115 0.87% 0.87% 343 0.90% 1 239 0.42% 0.42% 0.26% 1.00%
Visual impairment 44 504 8.73% 7 763 0.92% 0.92% 8.73%
Visual disturbance 9 868 1.04% 1.04% 1.04%
Seizures & Epilepsy 2 115 1.74% 1.74% 3 541 0.55% 5 239 2.09% 1.78% 5 109 4.59% 0.55% 4.59%
Epilepsy 5.80% 33 2367 1.39% 343 7.00% 7 763 0.92% 0.92% 7.00%
Seizures 2.0% 13.90% 9 159 5.66% 343 11.70% 21 868 2.42% 8 150 5.33% 2.00% 13.90%
Seizures requiring 
anticonvulsant at discharge 10 391 2.56% 4 231 1.73% 1.73% 2.56%
Motor deficits/mobility 
problems/motor disability 5 391 1.28% 13.0% 25 868 2.88% 1 109 0.92% 0.92% 13.00%
Impaired muscle function 33 763 4.33% 4.33% 4.33%
Cognitive 
impairments/dysfunctions 5 391 1.28% 1 115 0.87% 0.87% 8 541 1.48% 5 868 0.58% 26 763 3.41% 0.58% 3.41%
Brain injuries 12 391 3.07% 3.07% 3.07%
Brain nerve damage 9 763 1.18% 1.18% 1.18%
Paresthesia/ reduced 
sensitivity 4 763 0.52% 0.52% 0.52%
Tinnitus 6 763 0.79% 0.79% 0.79%
Speech and communication 
problems/aphasia 13.0% 3 763 0.39% 10 239 4.18% 3.56% 3 109 2.75% 0.39% 13.00%
Chronic migraine 3 541 0.55% 5 109 4.59% 0.55% 4.59%
Any neurologic sequelae (incl 
developmental dealy, focal 
neuro deficits, and/or 
seizures, etc) 12 391 3.07% 2 115 1.74% 1.74% 18 407 4.42% 9 340 2.65% 23 458 5.02% 95 868 10.94% 14 251 5.58% 11 109 10.09% 1.74% 10.94%
Other neurological 
impairments 2 391 0.51% 16 868 1.84% 6 231 2.60% 0.51% 2.60%
Not stated
Case series
Retrospective case review 
from Dublin's two tertiary 
referral paediatric 
hospitals, Our Lady's 






Median age was 1.5 years 
No




1988-1990 1975-2004 1990-1999 1995-2000 1974–2007 2001-2005
8 years following conclusion of 
recruitment period
Point estimates (%)
Canada England, UK Barcelona, Spain
England and 
Wales, UK US Merseyside, UK Iceland
Stovall, 2002 Tsolia, 2009 Viner, 2012 Wang, 2001 Wang, 2014Nguyen, 2002
Rivero-Calle, 




cohort study only) Harrison, 2001 Healy, 2002 Howitz, 2009 Kaplan, 2006 Karve, 2011Bettinger, 2013
Athens, Greece England, UK Boston, US
Adelaide, 
Australia
2002-2011 1999-2000 1977-2010 1999-2001 1998-2008
Spain Canada Netherlands Arkansas, USMaryland, US Ireland Denmark US US US
2000-20111998-2008 1985-1996 2008-2013 2002-2011
> 2 weeks after 
discharge Not stated
2 months - 5 
years
1999-2011 1988-2000 1999-2003 2004-2006 1981 - 1996





Median times from 
the baseline study 
interview to the 
follow-up 
interview: 583 days 
(range: 359–1225 
days) Not stated Not stated 12 Months Not stated Not stated
Up to hospital 
discharge
At discharge or the 
year afterward
Up to hospital 
discharge Up to discharge ≥3 years after the disease
Within 31 days 
after disease
During or after 
hospitalisation
12 months post 
discharge 
Up to hospital 
discharge Up to discharge
Up to hospital 
discharge
18-36 months after 
disease
FU until the 




years after the 
clinical episode
12 months post 
1st admission
NA
Median: 3.75 (IQR: 2.86-4.04, 







matched-cohort Case series Case series
Longitudinal 
retrosepctive 
NA NA Not stated
Median length of 
hospital stay: 8 days 
(range: 2-190 days)Not stated Not stated Not stated Not stated Not stated NA
Case series
Longitudinal 




studyCase-control Case series Case series Case series Cohort Case series




















review of IMD 
cases in children 
from 2 tertiary 
referral centers 
and 2 regional 
centers in 
Ireland
Case series Case series Case series Case-control study Case series
Retrospective 
review of 
medical notes of 
children with 






medical notes of 
children with 















based hospital and 
laboratory data
Retrospective review 











Children with IMD recuited from 
UK National Meningococcal 
Registry
The study based 
on registry data 













review of all 
children with 























identified from a 
health plan 
claims database












CM] code 036.x 
<15yrs All All ≤21yrsAll <19yrs All ≤19yrs All <20yrs
Mean age (SD): 






and clinical cases of 
IMD
Laboratory 









for IMD with [ICD-9-

























Median age: 11.9 Mean age at follow- mean age 30 yrs, Mean age: 12 yrs Mean (SD) age: Median age at diagnosis in months Not stated
868 879 150 262 245
5924 (1974-
2007); 2286 





Yes (sequelae only 
reported in cases) No No No
Median Children (<18yrs): Not stated Median age: 30 For patients Age by Median age: 10 Age range: 16  Mean age (SD): Mean age in 
Yes No No No No No No No No
Median age: 51.5 Mean age at follow-up: 6.5 (SD: Median age 
No No No Yes No
Supplementary Table 2 Sequelae rates reported in the literature 
Paper
%* Minus in 
control group 
(numbers not 
shown here)Borg, 2009 Cabellos, 2012 Darton, 2009 Davis, 2011 Fellick, 2001 Maoldomhnaigh, 2016 Point estimates (%)Stovall, 2002 Tsolia, 2009 Viner, 2012 Wang, 2001 Wang, 2014Nguyen, 2002
Rivero-Calle, 




cohort study only) Harrison, 2001 Healy, 2002 Howitz, 2009 Kaplan, 2006 Karve, 2011Bettinger, 2013
Any psychologic disorder 61 235 25.96% 15.71% 25.96% 25.96%
Oppostional defiant 17 149 11.41% 6.15% 11.41% 11.41%
Conduct disorder 9 149 6.04% 5.60% 6.04% 6.04%
Phobic disorder 7 149 4.70% 3.39% 4.70% 4.70%
Generalised anxiety disorder 4 149 2.68% 2.25% 2.68% 2.68%
Separation anxiety disorder 10 146 6.85% 5.96% 6.85% 6.85%
Depression 1 391 0.26% 0.26% 0.26%
Amputation 15 391 3.84% 3.0% 1 407 0.25% 2 159 1.26% 6 340 1.76% 17 381 4.46% 10 458 2.18% 7 150 4.67% 2 251 0.80% 7 231 3.03% 2 109 1.83% 0.25% 4.67%
Amputation with sustantial 
disability 3 239 1.26% 1.26% 1.26% 1.26%
→ Digital amputation 10 391 2.56% 1 255 0.39% 1 159 0.63% 2 231 0.87% 0.39% 2.56%
→Limb amputation 1.70% 343 2.30% 5 231 2.16% 1.70% 2.30%
→ Single limb amputation 2 391 0.51% 1 255 0.39% 0.39% 0.51%
→ Multiple limb amputation 2 391 0.51% 2 255 0.78% 1 159 0.63% 0.51% 0.78%
Arthritis related to IMD acute 
infection 39 522 7.47% 31 541 5.73% 7 109 6.42% 5.73% 7.47%
Vasculitis 1 109 0.92% 0.92% 0.92%
Urinary retention 2 763 0.26% 0.26% 0.26%
Renal dysfunction 8 391 2.05% 8 458 1.75% 22 868 2.53% 1.75% 2.53%
Renal failure 15 541 2.77% 2 407 0.49% 0.49% 2.77%
→ Acute RF 7 251 2.79% 2.79% 2.79%
→ Chronic RF 8.70% 343 4.40% 1 251 0.40% 0.40% 8.70%
→ Chronic RF requiring 
dialysis/renal transplantation 1 391 0.26% 0.26% 0.26%
Renal insufficiency/ dialysis 4 763 0.52% 0.52% 0.52%
Adrenal gland insufficiency 2 763 0.26% 0.26% 0.26%
Deteriorated lung function 1 763 0.13% 0.13% 0.13%
Skin necrosis/grafting 1.70% 343 2.00% 1.70% 2.00%
Skin necrosis 13 541 2.40% 14 159 8.81% 11 251 4.38% 2.40% 8.81%
Skin graft 4 159 2.52% 12 458 2.62% 8 150 5.33% 5 231 2.16% 2.16% 5.33%
Skin scarring 25 391 6.39% 18.0% 16 407 3.93% 17 340 5.00% 46 868 5.30% 26 763 3.41% 3.41% 18.00%
Scars/ skin lesions, no 
treatment 19 763 2.49% 2.49% 2.49%
Scars/ skin lesions requiring 
treatment 7 763 0.92% 0.92% 0.92%
Skin 
necrosis/grafting/scarring 11 109 10.09% 10.09% 10.09%
Necrosis requiring skin 
transplantation or 24 763 3.15% 3.15% 3.15%
Vertigo 17.0% 17.00% 17.00%
Impairment in upper-limb 
function 4.0% 4.00% 4.00%
Symptoms consistent with 
Raynaud phenomenon 28.0% 28.00% 28.00%
Limb loss or skin graft 23 504 4.56% 4.56% 4.56%
Stroke 12.10% 343 14.30% 12.10% 14.30%
Anoxic brain damage 4.10% 343 1.20% 1.20% 4.10%
Quadriparesis 1.70% 343 0.90% 0.90% 1.70%
Obstructive hydrocephalus 1.20% 343 3.20% 1.20% 3.20%
Ataxia 1.00% 4 159 2.52% 343 1.50% 1 763 0.13% 0.13% 2.52%
Learning disabilities/learning-
academic difficulties 1.00% 1 115 0.87% 0.87% 343 0.30% 0.30% 1.00%
PTSD 1 109 0.92% 0.92% 0.92%
Eating disorder 1 148 0.68% 0.68% 0.68% 0.68%
ADHD 3 115 2.61% 0.79% 17 149 11.41% 9.66% 0.79% 11.41%
Autistic spectrum disorder 2 149 1.34% 1.34% 1 109 0.92% 0.92% 1.34%
Hemorrhage 13 541 2.40% 2.40% 2.40%
Pericarditis 3 541 0.55% 0.55% 0.55%
Cerebral palsy and plegias 7 2367 0.31% 343 0.30% 0.30% 0.31%
Peripheral paralysis/-esis 10 763 1.31% 1.31% 1.31%
Hemiplegia 3 159 1.89% 1.89% 1.89%
Mental retardation 343 0.30% 4 763 0.52% 0.30% 0.52%
Unsteady gait/gait 
disturbance 1 458 0.22% 0.22% 0.22%
Skin lesions (ulcers, cellulitis) 7 458 1.53% 1.53% 1.53%
Mild pulmonary hypertension 2 458 0.44% 0.44% 0.44%
Muscle/tendon injuries 2 458 0.44% 0.44% 0.44%
Venous thrombosis 1 458 0.22% 0.22% 0.22%
Joint problems 11 868 1.27% 1.27% 1.27%
Bone & joint problems 9 109 8.26% 8.26% 8.26%
Haenatology (anaemia 
and/or thromobytosis) 7 763 0.92% 2 109 1.83% 0.92% 1.83%
Fatigue/ deteriorated 
condition/headeache/ 
myalgia/ arthralgia 48 763 6.29% 6.29% 6.29%
Lethargy 5 109 4.59% 4.59% 4.59%
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Supplementary Table 3 Epidemiological/clinical input parameters 




1.5 per 100,000 
population 
(variable by age) 
[1] 
Case fatality rate 




Proportion of patients requiring ambulance 
transfer (%) 
48.0 [2] 
Proportion of sequelae (%) 
Hearing loss requiring cochlear 
implantation  
2.45 [3] 
Hearing loss requiring hearing aids 2.16 [3] 
Hearing loss requiring adaptive listening 
strategies only 
1.72 [3] 
Blindness 0.42 [3] 
Epilepsy 2.56 [4] 
Brain injuries including cognitive 
impairments 
3.07 [4] 
Severe speech and communication 
problems 
4.18 [3] 
Chronic migraine 0.55 [5] 
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Parameter Base case 
Reference/ 
source  
Depression 0.26 [4] 
Digit amputation 2.56 [4] 
Single limb amputation 0.51 [4] 
Multiple limb amputation 0.51 [4] 
Arthritis 7.47 [6] 
Chronic renal failure requiring 
dialysis/renal transplantation 
0.26 [4] 
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Supplementary Table 4 Cost input parameters (US$) 
Parameter Base case 
Reference/ 
source  
Direct healthcare costs associated with acute admissions 
Acute admission cost One-off cost 










Follow-up care for 
patients without 
sequelae 





One-off cost $521.10 [9] 
Direct healthcare costs associated with sequelae 
Hearing loss requiring 
cochlear implantation  
One-off cost $40,721.38 [10] 
Hearing loss requiring 
hearing aids  
One-off cost $4,792.08 [10] 
Annual cost $1,146.66 [10] 
Hearing loss requiring 
adaptive listening 
strategies  
One-off cost $274.23 [10] 
Blindness  Annual cost $13,958.99 (first year) [11] 
 
~ 212 ~ 
 






Epilepsy Annual cost $10,312.82 [12] 
Brain injuries Annual cost  
$31,213.12 (within the first 
6 years) 
[13] 
$2,366.40 (after first 6 
years) 
[13] 
Severe speech and 
communication 
problems  
Annual cost  




$2,348.07 (after the first 2 
years) 
[14] 
Chronic migraine Annual cost $5,710.41 [15] 
Generalised anxiety 
disorder 
Annual cost $1,971.37 [16] 
Depression Annual cost $3,934.53 [17] 
Digital amputation  
One-off cost  $16,253.83 AR-DRG fee 
Annual cost  $3,396.73 
Expert 
opinion 
Single limb amputation One-off cost 
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Parameter Base case 
Reference/ 
source  
$63,059.76 (>18 years) [18], AR-DRG 
fee, expert 
opinion 
Annual cost  
$19,701.05 (0-18 years) Expert 
opinion 





$69,354.05 (0-18 years) [18], AR-DRG 
fee, expert 
opinion 
$76,646.69 (>18 years) [18], AR-DRG 
fee, expert 
opinion 
Annual cost  
$33,287.98 (0-18 years) Expert 
opinion 
$27,173.86 (>18 years) Expert 
opinion 
Stump revision One-off cost $36,745.42 AR-DRG fee 
Arthritis One-off cost $957.86 [19] 
Chronic renal failure 
requiring dialysis/renal 
transplantation 
One-off cost $40,857.76 [20-22] 
Annual cost $38,873.59 [20-22] 
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Parameter Base case 
Reference/ 
source  
Skin necrosis and 
grafting 
One-off cost $7,227.14 AR-DRG fee 
Direct non-healthcare costs 





Hearing loss requiring 
cochlear implantation 




intervention for children 





$2,560.43 (informal care) [10] 




$2,312.19 (informal care, 
out-of-pocket and other 
costs) 
[24] 
Brain injuries Annual cost  
$11475.27 (long term care, 
equipment and home 
modification costs within 
the first 6 years) 
[13]  
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Parameter Base case 
Reference/ 
source  
$10388.37 (long term care, 
equipment and home 
modification costs after 





Severe speech and 
communication 
problems 








costs and others) 
[16] 
Chronic renal failure 
requiring dialysis/renal 
transplantation  
One-off cost $1,507.49 (out-of-pocket 




costs and others) 
[20-22] 
Indirect costs (HC method) 
Acute admission  One-off cost  
Productivity loss: 6.91 





Productivity loss: 11.84 
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caused by IMD 
Annual cost 
Productivity value of life 
years lost during working 
age  
[25,26] 
Hearing loss requiring 
cochlear implantation 
or hearing aids  
Annual cost $2,422.55  [10] 
Blindness  Annual cost $5,034.67  [27] 
Epilepsy  Annual cost 
Productivity loss: 49.0 
days  
[25,26,28] 
Severe speech and 
communication 
problems 




Productivity loss: 38.7 
days  
[16,25,26] 
Chronic Migraine  Annual cost 
Productivity loss: 8.99 
weeks  
[25,26,29] 
Limb amputation  Annual cost  $6,699.69  [30] 
Chronic renal failure 
requiring dialysis/renal 
transplantation 
Annual cost $9,289.85 [31] 
Skin necrosis and 
grafting 
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Parameter Base case 
Reference/ 
source  
Total direct and indirect costs (HC method) 
Brain injuries Annual cost $72,348.09 [13] 
Depression Annual cost $12,690.96 [17] 
Indirect costs (FC method) 
Premature death caused by IMD  Productivity loss: 3 months [25,32] 
Brain injuries, chronic renal failure 
requiring dialysis/renal 
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Supplementary Table 5 Sensitivity analysis results (US$) 
 Parameter range Low value High value 
Discounting rate 0, 3.5%, 5% $13,968.40   $65,035.49  
IMD incidence 
Historically low & 
high records 
$7,250.78   $39,952.48  
Acute admission cost for patients 
with sequelae 
± 25% $13,360.87   $14,575.94  
Acute admission cost for patients 
without sequelae 
± 25% $13,367.37   $14,569.44  
Sequelae rate of brain injuries ± 25% $13,441.07   $14,495.74  
Annual cost of brain injuries ± 25% $13,452.75   $14,484.06  
Sequelae rate of epilepsy ± 25% $13,515.01   $14,421.79  
Annual cost of epilepsy ± 25% $13,524.74   $14,412.06  
Sequelae rate of multiple limb 
amputation 
± 25% $13,671.91   $14,264.90  
Annual cost of multiple limb 
amputation 
± 25% $13,813.95   $14,387.22  
Sequelae rate of severe speech 
problems 
± 25% $13,766.81   $14,169.99  
Sequelae rate of digit amputation ± 25% $13,777.27   $14,159.53  
Annual cost of severe speech 
problems 
± 25% $13,782.73   $14,154.08  
Annual cost of single limb 
amputation 
± 25% $13,930.95   $14,270.23  
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 Parameter range Low value High value 
Sequelae rate of chronic renal 
failure  
± 25% $13,803.60   $14,133.21  
Sequelae rate of single limb 
amputation 
± 25% $13,804.87   $14,131.94  
Annual cost of chronic renal failure  ± 25% $13,813.44   $14,123.36  
Annual cost of digit amputation ± 25% $13,822.28   $14,114.53  
Sequelae rate of hearing loss 
requiring cochlear implantation 
± 25% $13,874.49   $14,062.32  
One-off cost of hearing loss 
requiring cochlear implantation 
± 25% $13,883.80   $14,053.00  
Sequelae rate of depression ± 25% $13,962.66   $14,113.16  
Sequelae rate of hearing loss 
requiring hearing aids 
± 25% $13,909.89   $14,026.92  
Sequelae rate of chronic migraine ± 25% $13,912.99   $14,023.82  
Annual cost of chronic migraine ± 25% $13,915.10   $14,021.70  
Cost of public health management ± 25% $13,924.20   $14,012.61  
Annual cost of hearing loss requiring 
hearing aids 
± 25% $13,926.85   $14,009.96  
Sequelae rate of generalised 
anxiety disorder 
± 25% $13,926.85   $14,009.96  
Sequelae rate of blindness ± 25% $13,929.97   $14,006.83  
Case fatality rates 
95% confidence 
intervals 
$13,930.98   $14,005.83  
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 Parameter range Low value High value 
Annual cost of generalised anxiety 
disorder 
± 25%  $13,931.28   $14,005.53  
One-off cost of digit amputation ± 25% $13,933.13   $14,003.67  
Sequelae rate of arthritis ± 25% $13,933.91   $14,002.90  
Annual cost (after 1st year) of 
blindness 
± 25% $13,936.51   $14,000.29  
One-off cost of multiple amputation ± 25% $13,935.21   $13,995.46  
Sequelae rate of skin necrosis and 
grafting 
± 25% $13,942.37   $13,994.43  
One-off cost of single amputation ± 25% $13,941.11   $13,989.56  
Cost of skin necrosis and grafting ± 25% $13,952.34   $13,984.47  
One-off cost of chronic renal failure  ± 25% $13,958.34   $13,978.47  
One-off cost of hearing loss 
requiring hearing aids 
± 25% $13,959.64   $13,977.16  
Sequelae rate of hearing loss 
requiring adaptive listening 
strategies  
± 25% $13,961.44   $13,975.36  
One-off cost of arthritis ± 25% $13,962.33   $13,974.47  
Annual cost of depression ± 25% $13,962.99   $13,973.82  
Annual cost (1st year) of blindness ± 25% $13,963.45   $13,973.35  
Cost of follow-up visit ± 25% $13,965.57   $13,971.24  
One-off of hearing loss requiring 
adaptive listening strategies  
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CHAPTER 4: KNOWLEDGE TRANSLATION, GAPS AND FUTURE 
RESEARCH 
Two online surveys have provided a valuable contribution to the literature because 
understanding drivers for vaccination in adolescent populations is key to designing 
effective public health programs. Previous work has only focused on particular vaccines 
rather than the broad approach to adolescent views taken in this PhD project. The survey 
results can assist in developing new strategies to improve vaccine uptake in adolescents. 
Although the school-based immunisation programs have been considered as an efficient 
way of delivering publicly funded vaccines to adolescents [122], stronger preferences 
were given to vaccines administered at GP clinics than schools. Adolescents showed 
willingness to have an active role in the vaccine decision-making process. Without active 
adolescent engagement with vaccination, ensuring that written information about 
vaccination reaches parents could be challenging [123]. Only 10% of adolescents 
considered schools as the most important sources of information about immunisation. 
However, adolescents were less likely to seek information from health professionals but 
more likely to source information from school networks in comparison with adults. 
Educating adolescents, but not their parents, may be a novel approach to improve 
vaccine uptake. Differences in gender and socioeconomic status should be considered 
when developing school-based educational programs. Convincing the education sector 
to include the science of vaccination in an already crowded curriculum could be 
challenging. Effectiveness and feasibility of school vaccination educational programs 
needs to be further investigated. 
 
The results derived from the IMD systematic review can help researchers and policy 
makers understand the clinical and financial burden of the disease and inform future cost-
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effectiveness analyses. The review has provided precise estimates for CFR by age and 
serogroup. Accurate and generalisable data for CFR are essential for economic analyses 
of new vaccine programs and for interpretation of clinical studies and intervention trials 
aiming to impact on fatality. The review findings have provided concrete evidence to 
support government policy making and inform cost-effectiveness evaluations for new 
meningococcal vaccine programs. The results were provided to the Australian Technical 
Advisory Group on Immunisation and Pharmaceutical Benefits Advisory Committee 
(PBAC) to inform the government funding decisions for new meningococcal ACWY 
vaccine programs. Meningococcal ACWY vaccines replaced meningococcal C vaccines 
on the NIP for infants in July 2018 and will be NIP-funded for adolescents from April 2019. 
The review results were used to inform the state government funding decision in South 
Australia to launch a world first meningococcal B (MenB) vaccine program. The new 
MenB vaccine program commenced in October 2018 in South Australia. Investigating the 
burden of IMD has not only provided new evidence to cost-effectiveness analyses, but 
also improved knowledge and understanding of IMD. The systematic review found the 
clinical and financial burden associated with long-term disabilities caused by IMD has not 
been well documented. The difficulty in recruitment may limit the ability to conduct 
prospective follow-up studies. Retrospective case review study design may be a better 
option. For a study with a large sample size, searching ICD codes without reviewing 
medical notes may be an efficient way to identify IMD cases and complications/sequelae. 
However, coding errors could be an issue. In a previous retrospective case review study 
[96], 23 out of 132 cases who had a hospital separation code A39.0- A39.9, were not 
eligible after checking their hospital notes [unpublished data].  
 
The IMD costing study provides data for future modelling evaluation including model 
conceptualisation, data identification and model validation. The Markov model presented 
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in the thesis is different to previous modelling studies [74,124-134], as the best available 
evidence was used to input into the model and the most recent modelling guidelines were 
followed [135-139]. For example, clinical inputs were identified through a systematic 
review and selected based on the quality of studies. The conceptualisation process of 
model structures was not described in prior studies. The quantitative or qualitative 
process of eliciting expert opinions is not often used. Methods for searching and choosing 
the best evidence were not justified in those studies. It was found that wide-ranging 
parameter values were extracted from the published literature to populate the models. 
Without systematic identification and appropriate selection of parameter values, the 
quality of modelling studies might be compromised. For example, a cost-effectiveness 
study estimated the sequelae rate in adults at 20% which was extracted from one college 
study [126]. Only 28 college students infected with IMD were enrolled in this observational 
study [140]. Studies with small sample sizes might yield low quality results with wide 
variance [99]. The PBAC recommended to publicly fund MenACWY vaccines in 
adolescents and infants in Australia. The health economic model, which was presented 
in the PBAC submission, only included three health states following the meningococcal 
infection - ‘alive without long-term complications’, ‘alive with long-term complications’ and 
‘dead’. Annual costs for IMD cases with long-term sequelae were sourced from a 
Canadian study estimating healthcare costs for children with medical complexity over a 
two-year period [141]. Even, the PBAC questioned the relevance of these costing results 
to the long-term costs of IMD [78]. The IMD costing model developed in this PhD project 
may provide a framework for selecting health state and incorporating disease surveillance, 
clinical epidemiology and health economic data in future cost-effectiveness evaluations.   
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CHAPTER 5: CONCLUSIONS 
This thesis comprises two phrases of enquiry into adolescent immunisation: adolescent 
vaccine attitudes and the burden of IMD. Adolescents preferred vaccination against a life-
threatening illness. IMD is a serious vaccine-preventable disease with high mortality and 
morbidity rates. The MenACWY vaccine has recently been added to the NIP for 
adolescents due to a rapid increase of MenW cases. MenB vaccines have not been 
included on the NIP but are publicly funded for adolescents in South Australia. The 
disease severity influences vaccine acceptance in adolescents. Therefore, those two 
interrelated areas of research were investigated together in this thesis. The burden of 
IMD was evaluated as a case study to demonstrate the severity of the disease and 
significant healthcare and societal costs resulted from IMD.  
 
Research question one: What are adolescent views about immunisation and how do they 
differ from adult views? 
 
By using three survey questions in regard to vaccine benefits and safety to predict vaccine 
hesitancy, a higher level of vaccine hesitancy was demonstrated in adolescent than adults. 
Adolescents were more concerned about vaccine side effects than adults. Unlike adults, 
adolescents were less likely to consider health professionals as a main source of vaccine 
information. Although social media is an essential part of adolescent life, adolescents 
were less likely to choose the media (e.g. internet) as important sources of information, 
and were more likely to seek information from social networks including families and 
schools. Adolescents were more likely to prefer a joint decision with parents or by 
themselves compared with adults. Adolescents showed eagerness to be involved in the 
vaccine decision-making process.  
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Research question two: What are adolescent preferences for vaccination programs and 
what are the most important factors influencing their decisions? 
 
Stronger preferences were observed for vaccination against a life-threatening illness with 
a lower price, mild but common side effects and delivery via a skin patch. Although school 
immunisation programs have been implemented for many years, adolescents prefer 
receiving vaccines at GP clinics. Willingness to pay results were in line with their 
preferences. 
 
Research question three: What is known about the disease burden and consequences of 
IMD? 
 
A systematic review and meta-analysis showed the pooled overall CFR was 8.3% with 
the highest pooled CFR in serogroup W cases. Although, the disease incidence peaks in 
children aged less than five, the predicted CFR was higher in adolescents compared with 
young children. The systematic review also found most commonly reported sequelae 
were arthritis, neurocognitive sequelae, hearing loss, seizures, speech/communication 
problems, and amputation. The mean costs of acute admission ranged from I$1,629 to 
I$50,796. Presence of sequelae (complications) was associated with significantly higher 
hospitalisation costs. The direct and societal costs associated with long-term sequelae 
are essential component of the financial burden of IMD. However, costing data on long-
term follow-up and productivity loss are lacking.  
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Research question four: What is the mean lifetime cost of IMD per patient taking 
healthcare system and societal perspectives? 
 
To estimate the lifetime costs of IMD, a cohort-based state-transition model (Markov) was 
developed using results obtained from the systematic review and best available costing 
data to populate the model. The undiscounted lifetime societal cost per IMD case is 
estimated at US$319,897 including the direct healthcare cost of US$65,035. Given a 5% 
discount rate, the costs are USD$54,279 and USD$13,968 respectively. The sensitivity 
analysis shows the discount rate and IMD incidence had a significant impact on costing 
results.  
 
In conclusion, higher vaccine hesitancy and concerns were demonstrated in adolescents, 
which may be addressed through a school-based educational program. IMD can impose 
a substantial burden on patients, their families, the healthcare system and society. New 
meningococcal vaccine programs are being considered or have already been added to 
adolescent immunisation schedules. Effectively communicating with adolescents and 
actively engaging them in vaccination may improve vaccine coverage rates in the future.   
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Systematic Literature Review of the Clinical and 
Economic Burden of IMD  
 
Primary reviewer: Bing Wang (bing.wang@adelaide.edu.au)  
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Review Question and Objectives 
This review aims to identify, review and synthesise the evidence on clinical outcomes and 
economic costs of invasive meningococcal disease. 
The primary objective of this review is to describe the clinical and economic burden of 
meningococcal B infections in adolescents, including incidences, outcomes of the 
disease and any costs relevant to the disease. Given that there may be limited data in 
the published literature on meningococcal B infections in adolescent patients, the review 
will include all meningococcal infections in all age groups; however, information for 




The search strategy will include searches of the following electronic databases: 
 PubMed  
 Embase  
 The Cochrane Library, including the following: 
 The Cochrane Database of Systematic Reviews 
 The Cochrane Central Register of Controlled Trials 
 Database of Abstracts of Reviews of Effectiveness 
Specific search terms suitable to the individual databases will be developed. These 
search terms will include combinations of Medical Subject Headings (MeSH)/Emtree 
and text words contained in the title and abstract. Appendix 1 presents full listings of the 
search terms. 
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Health economic databases will be searched, including the following: 
 Health Economic Evaluation Database (HEED) 
 Cost-effectiveness Analysis (CEA) Registry 
 Health Technology Assessment (HTA) database 
 Paediatric Economic Database Evaluation (PEDE) 
Grey literature available online will be searched for relevant abstracts and/or posters 
from the following organizations: 
 Meningitis Research Foundation (MRF) 
 Infectious Diseases Society of America (IDSA) 
 International Pathogenic Neisseria Conference (IPNC) 
 European Society for Paediatric Infectious Diseases (ESPID) 
 International Congress on Infectious Diseases (ICID) 
 World Society for Pediatric Infectious Diseases (WSPID) 
 Australian Society for Infectious Diseases (ASID) 
Studies published in English will only be considered for inclusion in this review. The 
reference list of articles will be searched for additional studies. 
Keywords 
Keywords to be used will be:  
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Burden, costs, cost analysis, fees, hospital charges, economic model, economics, , 
expenditure, utilisation, case fatality, complications, sequelae, morbidity, mortality, 
death rates, incidence, survival analysis, health status. 
Search Process 
The article selection process will occur in the following two phases (Figure 1): 
 Level 1 screen: Titles and abstracts of articles identified from the electronic 
databases and from Internet searches will be reviewed. 
 Level 2 screen: The full text of articles selected at level 1 will be obtained and 
reviewed for eligibility using the level 2 inclusion and exclusion criteria. 
The reference list of all identified reports and articles will also be searched for additional 
studies.  
The inclusion and exclusion processes will be documented, including completion of a 
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow 
chart (Figure 1). This documentation will detail the volume of articles included and 
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PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-analyses. 



































Number of articles 
identified through database 
searching 
Number of additional 
articles identified through 
other sources 
Number of articles after duplicates removed 
Level 1 - Number of titles 
and abstracts screened 
Level 1- Number of 
articles excluded 
Level 2 - Number of full-
text articles assessed for 
eligibility 
Level 2 - Number of full-
text articles excluded, with 
reasons 
Number of articles included in 
quantitative synthesis 
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Selection Criteria 
Table 1 presents the inclusion and exclusion criteria that will be used at the level 1 
screening. Table 2 presents the inclusion and exclusion criteria that will be used at the 
level 2 screening. 
Table 1 List of Criteria for the Inclusion and Exclusion of Articles During the Level 1 
Screening Process 
Criteria Included Excluded 
Study 
design 
All clinical trials 
Observational studies 
International comparisons 
Health economic studies 
Comments and editorials 
(publication type) 
Consensus reports 
Case reports (<10 IMD patients) 
Qualitative studies 
Studies in animals but not in 
humans 
Population Meningococcal infection (age: all) Studies that include patients with 
meningococcal infection as part 
of a larger population but do not 
present outcomes for the 
meningococcal infection group 
separately 
Outcomes No limitsa Nonea 
Publication 
date 
From 01 January 2000 inclusive Before 01 January 2000 
Language Studies published in English  
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Table 2 List of Criteria for the Inclusion and Exclusion of Articles During the Level 2 
Screening Process 
Criteria Included Excluded 
Study design Same as level 1 Same as level 1 
Population Same as level 1 Same as level 1 
Outcomes - Clinical burden 
o Mortality: case fatality rates only 
(population based or national 
surveillance based CFRs; CFRs 
not grouped by diagnosis or 
syndrome) 
o Long-term sequelae (e.g., 
deafness, neurological deficits, 
seizures) 
- Economic burden for acute disease and 
long-term sequelae 
o Direct costs for acute disease 
(e.g., invasive meningococcal 
disease treatments, containment 
strategies)  
o Indirect costs for acute disease 
(e.g., school days loss, 
absenteeism for the patient or 
caregiver) 
Studies that do not 




~ 239 ~ 
 
Criteria Included Excluded 
o Direct and indirect costs 




The JBI Critical Appraisal Tools will be used to assess case controls, case series, cohort 
studies, quasi-experimental studies (non-randomised experimental studies), and 
randomised controlled trials (Appendices 2 – 6).  
The quality of the economic or costing studies will be assessed using a checklist 
(Appendix 7), which was created specifically for this systematic review on the basis of the 
Drummond 10-point Checklist (Drummond 2015) and ISPOR checklist for retrospective 
database studies.  
Two independent reviewers will assess the quality of studies by using the JBI Critical 
Appraisal Tools or BMJ Drummond Checklist where appropriate, and any divergences 
between them will be resolved by discussion.  
Data Extraction Methods 
Data will be independently extracted by two reviewers using an Excel spreadsheet. The 
following characteristics of each study will be collected: type of study including study 
design, multisite or single site and study period, population including sample size and age 
at illness, country, follow-up duration, perspective, outcome measure, model type (for 
economic studies only), time horizon (for economic studies only), discount rates (for 
economic studies only), results, sensitivity analysis (for economic studies only) and 
funding. 
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Data Synthesis Methods 
Data may be pooled in statistical meta-analysis using STATA software. Effect sizes 
expressed as odds ratio (for categorical data) and weighted mean differences (for 
continuous data) and their 95% confidence intervals will be calculated if meta-analysis is 
performed. Heterogeneity will be assessed statistically using the I2 statistic and also 
explored using subgroup analyses based on the different study designs included in this 
review. PRISMA 2009 checklist will be used for the meta-analysis. 
If statistical pooling is not possible due to clinical and methodological heterogeneity, the 
findings will be presented in narrative form including tables and figures to aid in data 
presentation where appropriate. 
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[mh:noexp] OR  
Neisseria meningitidis [tiab] 
OR 
Meningococc* [tiab] 






Death rate* [tiab] OR 
Incidence*[tiab] OR 
Morbidity[mh] OR 
Morbidit*[tiab] OR  
Health status[mh] OR  
Health status[tiab]  
Costs and cost 
analysis[mh] OR  
Economics, Medical [mh] 
OR 
Fees, Medical[mh] OR 
Fees, Pharmaceutical[mh] 
OR 
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models, economic[mh] OR 
Economic*[tiab] OR  
Cost[tiab] OR 
Costs[tiab] OR 







Invasive Meningococcal Disease 
Clinical and Economic 
Burden (537) 
(128) 
‘Meningococcosis’/syn  OR 
Meningococc*:ab,ti  OR 
‘Neisseria meningitidis’/syn 
'Case fatality':ti,ab OR  
Complication*:ti,ab OR 
Sequela*:ti,ab OR  
'Treatment outcome'/syn 
OR 




Incidence:ti,ab OR  
'Morbidity'/de OR  











'Health status':ti,ab,de OR 
‘Economic evaluation’/syn 
Cost*:ab,ti  OR 
Economic* NEAR/5 




Utilization:ab,ti  OR 




Invasive Meningococcal Disease  Clinical and Economic Burden (220) 
MeSH descriptor: [Meningococcal 
Infections] explode all trees  OR 
MeSH descriptor: [Neisseria 
meningitidis] explode all trees OR 
MeSH descriptor: [[Meningitis, 
Meningococcal]] explode all trees OR 
Meningococcal:ti,ab,kw  (Word 
variations have been searched)   
MeSH descriptor: [Disease Progression] 
explode all trees OR 
MeSH descriptor: [Morbidity] explode all 
trees OR 
MeSH descriptor: [Treatment Outcome] 
explode all trees OR 
MeSH descriptor: [Mortality] explode all 
trees OR 
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 “case fatality” OR “morbidity” OR 
“incidence” OR “sequelae” OR “clinical 
course " OR “complication*” OR 
“neurological” OR “deafness” or 
“seizure*” OR “outcome*”:ti,ab,kw  
(Word variations have been searched)  
MeSH descriptor: [Costs and Cost 
Analysis] explode all trees  OR 
MeSH descriptor: [Models, Economic] 
explode all trees  OR 
MeSH descriptor: [Economics, Hospital] 
explode all trees OR 
MeSH descriptor: [Economics, Medical] 
explode all trees OR 
MeSH descriptor: [Economics, Nursing] 
explode all trees OR 
MeSH descriptor: [Fees and Charges] 
explode all trees OR 
MeSH descriptor: [Health Resources] 
explode all trees and with qualifier(s): 
[Utilization - UT] OR 
“cost*” or “economic*” or "resource use" 
or "resource utilization" or "resource 
utilisation" or "direct and indirect 
cost":ti,ab,kw  (Word variations have 
been searched)  
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Yes No Unclear 
Not 
applicable 
1. Were the groups comparable other than 
the presence of disease in cases or the 
absence of disease in controls? 
□ □ □ □ 
2. Were cases and controls matched 
appropriately? 
□ □ □ □ 
3. Were the same criteria used for 
identification of cases and controls? 
□ □ □ □ 
4. Was exposure measured in a standard, 
valid and reliable way? 
□ □ □ □ 
5. Was exposure measured in the same 
way for cases and controls? 
□ □ □ □ 
6. Were confounding factors identified?  □ □ □ □ 
7. Were strategies to deal with confounding 
factors stated? 
□ □ □ □ 
8. Were outcomes assessed in a standard, 
valid and reliable way for cases? 
□ □ □ □ 
9. Was the exposure period of interest long 
enough to be meaningful? 
□ □ □ □ 
10. Was appropriate statistical analysis 
used? 
□ □ □ □ 
 
Overall appraisal:  Include   □ Exclude   □ Seek further info  □ 
Comments (Including reason for exclusion) 
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Appendix 3 The JBI Checklist for Case Series 
 Yes No Unclear Not 
applicable 
1. Were there clear criteria for inclusion in 
the case series?  □ □ □ □ 
2. Was the condition measured in a 
standard, reliable way for all participants 
included in the case series? 
□ □ □ □ 
3. Were valid methods used for 
identification of the condition for all 
participants included in the case series? 
□ □ □ □ 
4. Did the case series have consecutive 
inclusion of participants?  □ □ □ □ 
5. Did the case series have complete 
inclusion of participants? □ □ □ □ 
6. Was there clear reporting of the 
demographics of the participants in the 
study? 
□ □ □ □ 
7. Was there clear reporting of clinical 
information of the participants? □ □ □ □ 
8. Were the outcomes or follow up results 
of cases clearly reported?  □ □ □ □ 
9. Was there clear reporting of the 
presenting site(s)/clinic(s) demographic 
information? 
□ □ □ □ 
10. Was statistical analysis appropriate?  □ □ □ □ 
 
Overall appraisal:  Include   □ Exclude   □ Seek further info  □ 
Comments (Including reason for exclusion) 
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Appendix 4 The JBI Checklist for Cohort Studies 
 
 Yes No Unclear Not 
applicable 
1. Were the groups similar and recruited from 
the same population? □ □ □ □ 
2. Were the exposures measured similarly to 
assign people  
to both exposed and unexposed groups? 
□ □ □ □ 
3. Was the exposure measured in a valid and 
reliable way? □ □ □ □ 
4. Were confounding factors identified? □ □ □ □ 
5. Were strategies to deal with confounding 
factors stated? □ □ □ □ 
6. Were the groups/participants free of the 
outcome at the start of the study (or at the 
moment of exposure)? 
□ □ □ □ 
7. Were the outcomes measured in a valid 
and reliable way? □ □ □ □ 
8. Was the follow up time reported and 
sufficient to belong enough for outcomes to 
occur? 
□ □ □ □ 
9. Was follow-up complete, and if not, were 
the reasons to loss to follow-up described 
and explored? 
□ □ □ □ 
10. Were strategies to address incomplete 
follow-up utilized? □ □ □ □ 
11. Was appropriate statistical analysis used? □ □ □ □ 
 
Overall appraisal:  Include   □ Exclude   □ Seek further info  □ 
Comments (Including reason for exclusion) 
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Appendix 5 The JBI Checklist for Quasi-Experimental Studies (non-randomized 
experimental studies) 
 
 Yes No Unclear Not 
applicable 
1. Is it clear in the study what is the ‘cause’ and 
what is the ‘effect’ (i.e. there is no confusion 
about which variable comes first)? 
□ □ □ □ 
2. Were the participants included in any 
comparisons similar?  □ □ □ □ 
3. Were the participants included in any 
comparisons receiving similar treatment/care, 
other than the exposure or intervention of 
interest? 
□ □ □ □ 
4. Was there a control group? □ □ □ □ 
5. Were there multiple measurements of the 
outcome both pre and post the 
intervention/exposure? 
□ □ □ □ 
6. Was follow-up complete, and if not, was follow-
up adequately reported and strategies to deal 
with loss to follow-up employed? 
□ □ □ □ 
7. Were the outcomes of participants included in 
any comparisons measured in the same way?  □ □ □ □ 
8. Were outcomes measured in a reliable way? □ □ □ □ 
9. Was appropriate statistical analysis used? □ □ □ □ 
 
Overall appraisal:  Include   □ Exclude   □ Seek further info  □ 
Comments (Including reason for exclusion) 
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Appendix 6 The JBI Checklist for Randomized Controlled Trials 
 Yes No Unclear NA 
1. Was true randomization used for assignment of 
participants to treatment groups? □ □ □ □ 
2. Was allocation to treatment groups concealed? □ □ □ □ 
3. Were treatment groups similar at the baseline? □ □ □ □ 
4. Were participants blind to treatment assignment? □ □ □ □ 
5. Were those delivering treatment blind to treatment 
assignment?  □ □ □ □ 
6. Were outcomes assessors blind to treatment 
assignment? □ □ □ □ 
7. Were treatments groups treated identically other 
than the intervention of interest? □ □ □ □ 
8. Was follow-up complete, and if not, were 
strategies to address incomplete follow-up 
utilized? 
□ □ □ □ 
9. Wer  participants analysed in the groups to which 
they were randomized? □ □ □ □ 
10. Were outcomes measured in the same way for 
treatment groups? □ □ □ □ 
11. Were outcomes measured in a reliable way? □ □ □ □ 
12. Was appropriate statistical analysis used? □ □ □ □ 
13. Was the trial design appropriate, and any 
deviations from the standard RCT design 
(individual randomization, parallel groups) 
accounted for in the conduct and analysis of the 
trial? 
□ □ □ □ 
 
Overall appraisal:  Include   □ Exclude   □ Seek further info  □ 
Comments (Including reason for exclusion) 
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Appendix 7 The Critical Appraisal Checklist for Economic or Costing Studies 
  
Critical Appraisal Criterion  




Was (were) the objective(s) and research question(s) 
of the study described clearly? 
 
Time horizon 
Did the study examine costs or utilisation of the 
services over an appropriate time horizon? 
 




Were all the important and relevant costs identified?  
Did it cover all relevant perspective? (Possible 
perspectives include those of patients and third-party 
payers; other perspectives may also be relevant 
depending on the particular analysis.) 
 
Were costs measured accurately in appropriate 
physical units prior to valuation (e.g. hours of nursing 
time, number of physician visits, lost work-days)? 
 
Were the costs generated by the disease of interest or 
incremental costs (using a disease-free population as a 
comparison) calculated?  
 
If data were collected from or estimated for a period 
longer than one year, were costs adjusted for 
differential timing? Was the inflation rate/discount rate 
mentioned? 
 
Was the method of cost calculation clearly 
documented? 
 
Were all costs were valued at the price level of a stated 
base year? 
 




Have the data attributes been described in sufficient 
details to determine whether there was a good 
rationale for using the data source, the data source’s 
overall generalizability, and how the findings can be 
interpreted in the context of their own organisation? 
 
Have the reliability and validity of the data been 
described, including any data quality checks and data 
cleaning procedures? 
 
Have the necessary linkages among data sources 
and/or different care sites been carried out 
appropriately, taking into account differences in coding 




Have the inclusion and exclusion criteria and the steps 
used to derive the final sample from the initial 
population been described? (At least the objective 
diagnostic criteria (e.g., ICD code and DSM-IV) used to 
identify eligible patients were reported.) 
 
Was the study population clearly defined, including the 
source of patient recruitment and the 
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Critical Appraisal Criterion  
(Y, N, Not 
Applicable, 
Unclear) 
sociodemographic and disease characteristics, so as 
to facilitate the comparison among studies? 
Has the study included a control group in order to 
calculate excess costs or, if no control group was 
involved, were the costs due to the disease of interest 
(e.g., by diagnostic codes)? 
 
If comparison groups were used: a) were they 
matched, at least in terms of age and/or gender, to 
allow a direct comparison between equally dispersed 
groups with regard to their characteristics? or b) was 




What methods have been used to control for other 
variables that may affect the outcome of interest? 
 
Have the authors explained the rationale for the 
model/statistical method used? 
 
Have the authors examined the sensitivity of the 
results to influential cases? (For example, an individual 
who is depressed and attempts to commit suicide 
might have extremely high medical costs that could 
dramatically change conclusions about the costs of 
treating a patient with a particular antidepressant 
therapy. Such “outliers” can be particularly problematic 
if the sample is small.) 
 
Have the authors identified all variables hypothesized 
to influence the outcome of interest and included all 
available variables in their model? 
 
Uncertainty 
If a sensitivity analysis was employed, was justification 
provided for the form(s) of sensitivity analysis 
employed and the ranges or distributions of values (for 
key study parameters)? 
 
Was heterogeneity in the patient population 




Were the results compared with those of others who 
have investigated the same question? If so, were 
allowances made for potential differences in study 
methodology? 
 
Did the study discuss the generalisability of the results 
to tother settings and patient groups? 
 
Were limitations regarding the calculation of costs and 
the representativeness of the study population, in 
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